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Abstract 
 
Prion diseases are a group of fatal neurodegenerative diseases, including CJD and 
scrapie, which are thought to be caused by a protein termed a prion (PrP). As 
manganese has previously been suggested to be involved in prion disease we have 
investigated manganese binding to PrP and its role in the toxicity of the protein. We 
have shown that manganese bound PrP (MnPrP) has several of the characteristics of 
the disease form of PrP, including protease resistance and toxicity that is dependent 
on cellular PrP expression. Further investigation into the mechanism of toxicity 
revealed that MnPrP is significantly more toxic to neuronal cells than non-
manganese bound PrP and that toxicity requires the presence of known metal binding 
residues within the protein. We have demonstrated that treatment of neuronal cells 
with MnPrP causes caspase 3 activation and apoptosis, as demonstrated by DNA 
laddering, and we hypothesise that caspase 3 is activated by a p38 pathway. 
Treatment of neurones with MnPrP also caused a significant increase in cellular ROS 
production, although this did not appear to be a major cause of cell death as 
antioxidants were unable to save cells from cell death. We also investigated 
mechanisms by which cells can survive scrapie infection and MnPrP toxicity. We 
have shown that cells infected with scrapie have increased ERK activation which 
was important for their survival. Cells that survived MnPrP treatment were also 
found to have increased ERK activation. This suggests that ERK may have a 
protective role in prion diseases and may be a potential therapeutic target.  
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1. Introduction 
 
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, 
are a group of diseases that affect mammals. The diseases lead to pathology within 
the central nervous system (CNS), characterised by the formation of protein deposits 
and the spongy appearance of the CNS tissue. This causes a wide variety of 
symptoms, including a lack of coordination leading to paralysis. TSEs are invariably 
fatal. 
 
TSEs can occur spontaneously, through transmission and be inherited. One of the 
most recent transmissible TSEs to emerge is variant Creutzfeld Jacob Disease 
(vCJD). The first confirmed case of vCJD was reported in 1996 (Will et al., 1996). 
vCJD has an earlier onset than CJD and a longer illness duration (Will and Ward, 
2004). It has been linked to bovine spongiform encephalopathy (BSE), another new 
TSE affecting cattle, through strain typing and it has been widely postulated that 
vCJD has been transmitted to the population through the consumption of cattle 
infected with BSE (Bruce et al., 1997). However no direct link between BSE and 
vCJD has been demonstrated. As well as the possibility that vCJD may be 
transmitted from BSE infected cattle, several cases of human to human transmissions 
have been reported (Hewitt et al., 2006). The fear that there may be a large number 
of people with subclinical vCJD has led to intensive research into TSEs.  
 
There are also several inheritable prion diseases, due to mutations in the prion 
protein. These include Gerstmann-Sträussler-Scheinker (GSS) disease and fatal 
familial insomnia (FFI). GSS is caused by mutations of the prnp gene and follows a 
pattern of autosomal dominant inheritance. As with other TSEs, it is classified by the 
presence of amyloid plaques leading to neurodegeneration. FFI is also the result of 
mutations within the prnp gene and shows an autosomal dominant inheritance 
pattern, though with incomplete penetrance. As the name suggests patients suffer 
sleep disturbance in the earlier stages of the disease, which get progressively worse 
throughout the disease (for review see (Collins et al., 2001) ). 
 
- 12 - 
 
In humans 80% of TSEs are sporadic. The most common TSE is sCJD which has an 
incidence of approximately 1 in a million (1996). Unlike vCJD, sCJD has a late 
onset, and a shorter duration. There are several other TSEs that occur sporadically, 
including scrapie which is endemic in sheep in most European countries including 
the UK. This is, perhaps, the earliest reported TSE, with reports of scrapie dating 
back to the eighteenth century (Brown and Bradley, 1998). Whilst scrapie occurs 
sporadically, work has shown that certain sheep genotypes are much more 
susceptible to scrapie than others, this has led to national breeding programme in the 
UK which aims to increase the number of resistant sheep in the UK flock to prevent 
outbreaks.  
 
TSEs are thought to be caused by a protein termed the prion protein. This protein 
was first discovered in 1982 by Prusiner and is still unique, as it is the only protein 
thought to be a transmissible disease causing protein. The prion protein is a 30-
39kDa protein that is expressed in most tissues, however the highest expression 
levels are found in neural and lymphoid tissue. In prion disease the protein becomes 
misfolded. There is an increase in β- sheet content and a corresponding decrease in 
α- helices (Pan et al., 1993). This structural change may lead to a loss of function 
and, perhaps most importantly for disease, protease resistance and an ability to 
aggregate (Prusiner et al., 1983). 
 
The misfolded form of PrP is thought to be responsible for neurodegeneration in the 
TSE’s although the mechanism underlying nuerodegeneration is still unclear. 
Current research focuses on finding possible therapies for the TSE’s as there is 
currently no known cure. 
1.1 PrP Structure and Expression 
1.1.1 Genetic regulation of PrP 
 
The prion protein is encoded by the Prnp gene which has been well characterised in 
several species. The gene consists of three exons and two introns, with the third exon 
encompassing the entire open reading frame. The exceptions to this structure are in 
humans and hamsters where the second exon may not be spliced into the final 
mRNA sequence (Lee et al., 1998; Li and Bolton, 1997). Studies of the mice and 
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bovine gene have shown the importance of intron 1 in the modulation of gene 
expression as well as exon 1 which can act as an inhibitor of PrP expression (Haigh 
et al., 2007). Interestingly a TATA box has been found in intron 1 of both the mouse 
and bovine gene (Haigh et al., 2007), this is in contrast to the prion promoters 
studied so far, which lack a TATA box. However various binding sites have been 
found within the promoter that enhance and inhibit promoter activity. These include 
Sp-1 binding sites and AP-1 and AP-2 binding sites, which can inhibit and enhance 
promoter activity depending on which transcription factors bind to them (Saeki et al., 
1996b). Heat shock elements have been found in the rat promoter (Shyu et al., 2002), 
and heat shock proteins have also been shown to up-regulate prion protein 
expression in humans cells (Shyu et al., 2000). 
 
A variety of other factors have also been shown to regulate PrP expression either at 
the protein or gene level. The prion protein has been hypothesised to have a role in 
copper homeostasis in the brain (for review see (Brown, 2001) ) so it is perhaps 
unsurprising that copper has been shown to regulate PrP promoter expression in 
PC12 cells, a neuronal cell line. Deletion of parts of the promoter showed that a 
region of the promoter containing a putative MRE was essential for the upregulation 
of promoter activity in response to copper (Varela-Nallar et al., 2006). Copper has 
also been shown to up-regulate PrP expression at the protein level (Brown et al., 
1997b). However another study has shown that copper can down regulate PrP gene 
expression in GN11 cells, another neuronal cell line (Toni et al., 2005). Studies 
looking at other metals have shown that manganese and zinc are unable to regulate 
the prion promoter (Varela-Nallar et al., 2006), suggesting that the response to 
copper by the prion promoter is a specific specialised response. 
 
As the loss of the prion protein has been connected with oxidative stress, several 
studies have investigated the effect of hypoxia and ischemic brain injury on PrP 
expression. A study has shown that PrP expression is up-regulated in mice after 
severe focal ischemic brain injury, and that this increase in expression occurs shortly 
after brain injury. They hypothesise that given the known neuroprotective roles of 
PrPc up-regulation of PrPc may be protective (Weise et al., 2006). This is supported 
by a study demonstrating that PrP null mice show greater injury after ischemic injury 
when compared to WT mice (McLennan et al., 2004). Another study used hyperbaric 
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oxygen treatment to induce oxidative stress in N18 cells, a mouse neuroblastoma cell 
line. Treatment was shown to up-regulate PrP expression at both mRNA and protein 
levels. It was also shown to upregulate HSP70 expression, the upregulation of both 
these protein was shown to be regulated via JNK activation (Shyu et al., 2004). 
Overall there is strong evidence for a role for PrPc in the prevention of oxidative 
stress in the brain and expression of PrPc may be modulated by oxidative stress.  
 
As PrP expression is important for disease progression studies have investigated 
compounds that can regulate PrP expression. All-trans retinoic acid (ATRA) is a 
powerful antioxidant that is currently licensed for the treatment of skin conditions 
such as acne and it is also used in the treatment of acute promyelocytic leukemia, 
due to its ability to differentiate leukemic promyelocytics into mature granulocytes 
(Huang et al., 1988). Interestingly, ATRA has also been shown to down-regulate 
prion expression in granulocytes, independently of granulocyte maturation, this has 
led to the suggestion that it may be useful therapeutically (Rybner et al., 2002). 
1.1.2 Primary Structure 
 
PrP is relatively small protein varying in size between 30-39kDa depending on 
species, it is highly conserved in mammalian species. In mice the prnp gene is found 
on chromosome 2 and encodes for a 254 amino acid sequence (figure 1.1).  
 
 
 
Figure 1.1: The major features of the primary structure of PrP.  
 
A region spanning amino acids 1-23 directs the protein to the endoplasmic reticulum 
(ER) for processing and is cleaved shortly after translation. A short region at the end 
of the C-terminus is also cleaved during processing, prior to the addition of 
glycosylphosphatidylinositol (GPI) anchor. The GPI anchor tethers the protein to the 
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outside of the cell (Stahl et al., 1987). There are several important features in the 
primary structure of PrP. Perhaps most importantly for any possible function it has 
four octarepeats (PHGGGWGQ) in the N-terminal region of the protein, which have 
been shown to bind several transition metals including copper (Hornshaw et al., 
1995) and manganese, although with a much lower affinity (Brazier et al., 2008; 
Brown et al., 2000). There is also a fifth metal binding site at amino acids 95 and 
110 which binds both copper and manganese (Brazier et al., 2008; Thompsett et al., 
2005). Amino acids 112-145 form a hydrophobic region that is thought to be 
involved in the pathogenesis of prion disease, as proteins missing residues 114-121 
cannot be converted into PrPsc when over-expressed in N2A cells infected with 
scrapie (Holscher et al., 1998). Parts of the hydrophobic region have also been 
shown to form B-sheets spontaneously as in the case of the 106-126 peptide (Forloni 
et al., 1993) or be amyloidogenic such as residues 112-119 (Jobling et al., 1999). 
1.1.3 Secondary Structure 
 
The structure several species of prion protein has been determined by NMR 
including mouse PrP (Lopez Garcia et al., 2000; Riek et al., 1996; Zahn et al., 2000). 
The C-terminus of PrP has been found to be highly structured (figure 1.2). The PrPc 
form consists of three α- helices at amino acids 114-154, 170-193 and 200-217 with 
a disulphide bond linking helix 2 to helix 1. There are also two short strands of β-
sheet structure at amino acids 128-131 and 161-193 (Riek et al., 1996). The structure 
of the N-terminus of PrP is much less clear, when it is not bound to metals. Studies 
using a variety of techniques including nuclear magnetic resonance (NMR) and 
circular dichroism (CD) have shown it is highly flexible (Hornemann et al., 1997), 
however it has been postulated that on binding to copper the N-terminus may 
become more structured (Jones et al., 2004; Miura et al., 1996). The sequence of 
mammalian prion protein is highly conserved especially the unstructured N-terminus 
indicating its importance in function (Wopfner et al., 1999). 
 
Upon conversion to PrPsc the secondary structure changes significantly. PrPc has 
been shown to contain ~ 40% α-helical structure and ~ 3% β-sheet structure (Pan et 
al., 1993), whilst PrPsc has been shown to contain ~ 30% α-helical structure and ~ 
40% β-sheet structure (Pan et al., 1993) (figure 1.2). However, due to the tendency 
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of PrPsc to aggregate, the actual structure of PrPsc has not been determined, although 
recent developments have provided some details of the structure. Lu et al studied the 
structure of D178N huPrP90-231, which undergoes an autocatalytic conversion to 
the amyloid state, using hydrogen/deuterium exchange. They demonstrated the 
location of the β-sheet core was in the C-terminus of the protein (Lu et al., 2007). 
Higher resolution work using site-directed spin labelling and electron paramagnetic 
resonance (EPR) spectroscopy has shown the amyloid region to encompass residues 
~160-220. The structure was found to be parallel in-register β–sheet (Cobb et al., 
2007). This is in contrast with earlier modelling studies (DeMarco and Daggett, 
2004; Govaerts et al., 2004) but the structure described is common motif for many 
amyloids including Aβ (Torok et al., 2002) and alpha synuclein (Chen et al., 2007). 
 
 
Figure 1.2: The secondary structural features of the prion protein. The normal conformer 
(PrPc) of the prion protein is high in α-helical structure. The abnormal conformer (PrPsc) has a 
much higher level of β-sheet content. 
 
The prion protein sequence is highly conserved throughout mammalian species, but 
in non-mammalian species the sequence is much less well conserved. Prion 
homologues exist in many species, perhaps the best characterised of the non-
mammalian prions are the prion proteins of chickens (Gallus Gallus), turtle 
(Trachemys scripta) and frog (Xenopus laevis). Using NMR the structure of these 
proteins has been identified, they show only about 30% homology to mammalian 
prion proteins but do retain the structured C-terminus and relatively unstructured N-
terminus. The globular domain in chicken and turtle PrP consists of three α-helices 
and a short anti-parallel β-sheet. Xenopus PrP also contains three α-helices but has a 
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longer β-sheet region. Despite the low homology the structure of the globular C-
terminus is remarkably similar to that of mammals suggesting that key amino acids 
are involved in structure (Calzolai et al., 2005). 
 
Several regions of the N-terminus are also conserved between huPrP and the non-
mammalian prion proteins, this includes amino acids 15–20 which are involved in 
the cleavage of the amino acids 1-22. However interestingly the octarepeat region is 
not highly conserved, in turtles and chickens the region consists of hexarepeats and 
in Xenopus no repeat region is present suggesting that this protein is not able to bind 
metal (Calzolai et al., 2005). 
1.2 PrP conversion 
 
The conversion of the prion proteins results in a dramatic change in both the 
properties of the protein and its structure. PrPsc has a protease resistant core and is 
thought to be infectious.  
 
Conversion of PrP can be explained as follows: PrPc is thought to exist in 
equilibration with another intermediary termed PrP*, with PrPc dominating the 
equilibrium (Cohen et al., 1994). PrPsc is thought to bind to PrP* and convert it to 
PrPsc, assembly of PrPsc then continues until a stable seed is formed, the seed can 
continue to grow by accretion and can divide by breakage into smaller, infectious 
units. In transmitted disease this PrPsc would come from exogenous sources (Figure 
1.3). In inherited disease there may be a preference for the PrP* that can then be 
converted into PrPsc. Once this process begins the amount of PrPsc will increase 
exponentially (Cohen and Prusiner, 1998). Several studies have implicated another 
protein in this conversion process termed protein X (Kaneko et al., 1997; Telling et 
al., 1995). 
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PrP*PrPc PrPsc PrP* PrPsc
PrPscPrPsc
Exogenous PrPsc
 
Figure 1.3: PrP conversion. PrP exists in two forms in PrPc and PrP*. When exogenous PrPsc 
binds to the much rarer form PrP* it is able to convert PrP* in to PrPsc. This then begins an 
exponential increase in PrPsc. 
 
Protien X was first hypothesised to exist after experiments on transgenic mice 
expressing a chimeric form of PrP containing part of the mouse and human 
sequences. These mice were susceptible to human prions, unlike mice expressing 
both mouse and human prions which were resistant to human prions (Telling et al., 
1994). This led to the theory that protein X bound to a specific part of PrPc and 
assisted in its conversion. As mice expressing the mouse and human prions were 
resistant to human prion protein, protein X must bind more strongly to the mouse 
PrP. Further experiments elucidated the binding site of protein X, at the C-terminal 
end of the protein (Telling et al., 1995), however protein X has never been isolated. 
1.3 PrP Function 
 
Understanding the function of the prion protein may be essential in understanding its 
role in disease as the disease might result from a change in function of the prion 
protein, this could either be a gain of toxic function, a subversion of function for 
instance the ability to transduce pro-apoptotic signals rather than anti-apoptotic 
signals or a loss of function (for review see (Westergard et al., 2007)).  
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1.3.1 PrP in copper transport 
 
Several studies have suggested that PrP may have a role in controlling synaptic 
copper fluctuations. PrPc is predominantly located in the synapse (Herms et al., 
1999) and is rapidly internalised in response to copper treatment in vitro (Brown and 
Harris, 2003; Pauly and Harris, 1998). PrP expression is also linked to copper release 
on depolarisation of the synapse (Brown, 1999). In PrP-null mice there is evidence 
of a reduction of copper in synaptosomal preparations (Brown et al., 1997a) and in 
the disease state there is evidence of a change in metal balance in the brains of mice 
infected with scrapie (Thackray et al., 2002), this may be due to the loss of the prion 
protein’s ability to bind copper. The loss of the function of prion protein as a copper 
transporter protein, in the disease state, may result in copper imbalance in the brain. 
Both an increase or decrease of copper in the brain can lead to brain damage, this is 
demonstrated in two inheritable diseases, both due to mutations in copper 
transporters. Wilson’s disease involves mutations in the ATP7A gene, ATP7A is a 
copper transporter and mutations result in an increase of copper in the brain and the 
liver, symptoms include liver disease and neurodegeneration. Menke’s disease is also 
due to a mutation in the ATP7A gene and results in poor distribution of copper in the 
body, with low levels of copper in the brain, this also results in neurodegeneration 
(Ala et al., 2007; Menkes et al., 1962). 
1.3.2 PrP as an antioxidant 
 
PrPc has been shown have superoxide dismutase (SOD) like activity. Studies have 
shown that recombinant PrP and PrP extracted from brain tissue has copper 
dependent SOD-like activity (Brown et al., 1999), this has led to the hypothesis that 
it may have an antioxidant role in the brain. However other studies have not been 
able to detect SOD like activity in recombinant protein (Jones et al., 2005b) and 
suggest any antioxidant activity may be due to indirect action.  
 
Whilst the mechanism behind PrPc antioxidant activity is unclear, it is clear that PrPc 
plays a role in reducing oxidative stress in the brain. It has been shown that PrP 
knockouts have compromised antioxidant function (Klamt et al., 2001). Research has 
also shown that cultured neurones from mice deficient in PrPc were more sensitive to 
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oxidative stress (Brown et al., 1997c). In the normal state PrPc expression is 
increased in cells exposed to oxidative stress (Brown et al., 1997b).  
 
In the disease state immunohistochemistry of brain slices of mice infected with 
scrapie have revealed several markers of oxidative stress including nitrotyrosine, a 
marker of peroxynitrite generation (Guentchev et al., 2000) and lipid oxidation 
markers (Wong et al., 2001c). In vitro experiments are in agreement with these 
results, oxidative stress was induced in cells treated with the 106-126 fragment of 
PrP (Pietri et al., 2006). The increase in oxidative stress markers in the disease state 
may be due to the conversion of PrPc to PrPsc. 
1.3.3 Other Functions 
 
As PrPc is mainly found at the cell surface it has been suggested that PrP may have a 
role in signal transduction. In lymphocytes PrPc has been shown to be incorporated 
into lipid rafts within the cell membrane, these rafts contain accumulated cross-
linked proteins. It is hypothesised that PrPc may become cross-linked in these rafts. 
PrPc cross-linking has been shown to cause the activation of several signalling 
pathways including MAPK pathways (Stuermer et al., 2004). Several 
neuroprotective molecules have also been shown to be activated by a PrPc binding 
partner including ERK and protein kinase A in mouse retinal cells, this activation 
was not seen in PrP null cells (Chiarini et al., 2002). 
 
Some studies have suggested that PrPc may have a role in regulating sleep patterns as 
patients suffering from FFI have disrupted sleep patterns. PrP null mice have also 
been shown to have altered sleep regulation when compared to WT mice (Tobler et 
al., 1997; Tobler et al., 1996). Recent work has shown that neuronal but not non-
neuronal PrPc expression is involved in sleep homeostasis and that PrPc may play a 
role in the hormonal regulation of the hypothalamic–pituitary–adrenal axis (Sanchez-
Alavez et al., 2007). 
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1.4 PrP and Metals 
1.4.1 Copper 
 
PrP has been shown to bind several transition metals with varying affinity. PrP has 
been shown to have the highest affinity for copper and has been shown to bind up to 
6 copper atoms at physiological conditions. Copper is thought to bind at two sites, 
the octarepeat region and the so-called fifth site at 95 and 110. PrP has also been 
shown to bind several other metals including nickel, zinc and manganese. However 
the interactions between these metals are at a much lower affinity. 
 
The prion protein has been demonstrated to bind copper at the octarepeat region both 
in vitro and in vivo (Brown et al., 1997a), although binding to the fifth site has only 
been demonstrated in vitro (Jones et al., 2004; Jones et al., 2005a). The affinity of 
copper for PrP is still widely debated with some studies suggesting affinity values as 
low as micromolar affinity (Stockel et al., 1998) and some as high as femtomolar 
affinity (Jackson et al., 2001). Most agree that there is at least one nanomolar-
binding event (Treiber et al., 2007; Walter et al., 2006). In the octarepeat region 
copper the histidine is thought to be the primary residue coordinating binding, with 
the full complex consisting of residues HGGGW (Aronoff-Spencer et al., 2000; 
Burns et al., 2003), however the exact coordination is dependent on copper loading, 
with differing coordination patterns when less than two copper molecules are bound 
(Chattopadhyay et al., 2005). 
 
The fifth site is now widely accepted to bind copper and there has been a significant 
amount of research into the coordination of this binding. Binding requires that at 
least amino acids 92-96 and 107-111 (in humans) are present (Jones et al., 2005a). 
They also showed that both pH and chain length effected the relative affinities of 
each histidine with the binding at low pH being coordinated whilst at higher pH the 
histidines bind independently (Klewpatinond and Viles, 2007). The affinity of 
copper for the 5th site is also under debate however it has been shown that it has a 
higher affinity for copper than the octarepeat region (Jones et al., 2005a; Treiber et 
al., 2007). 
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Once converted to PrPsc there is no evidence that copper can still bind to the protein 
however copper is still able to modulate prion disease. It has been shown that the 
copper chelator, D-(-)-penicillamine can delay the onset of prion disease in mice 
(Sigurdsson et al., 2003) and that brain homogenates incubated with CuCl2 showed 
increased PK resistance. Conversely other studies have shown that treatment of 
scrapie infected cells with copper increases PrPc expression but decreases PrPsc 
accumulation, hamsters infected with scrapie also showed delayed onset of prion 
disease when treated with copper. This was hypothesised to be due to the increase in 
internalised PrPc, which would hinder its interaction with PrPsc (Hijazi et al., 2003).   
 
Copper has been shown to be able to convert recombinant PrP into a PrPsc-like 
protein (Qin et al., 2000), as well as being able to convert PrPc from mice brains into 
a PK resistant form, although this was shown to be structurally distinct from PrPsc 
(Quaglio et al., 2001). Further work has shown that copper is able to inhibit 
conversion of full length recombinant PrP by stabilising a PK resistant non-
amyloidgenic form of PrP (Baskakov et al., 2002). However when copper was added 
to fibrils of PrP it increased PK resistance and induced further aggregation 
(Bocharova et al., 2005). The complexity of coppers involvement in the disease state 
in highlighted by the differing results obtained by groups and more research will 
need to be done to elucidate the role of copper and PrP both in health and disease. 
1.4.2 Manganese 
 
PrP has been shown to bind several transition metals as well as copper. Perhaps the 
most extensively researched of these is manganese. Early work suggested that the 
prion protein bound manganese in the octarepeat region of the prion protein and was 
able to bind up to 4 manganese atoms (Brown et al., 2000), however this was in 
contrast to other reports that suggested that manganese was unable to bind in the 
octarepeat region (Garnett and Viles, 2003; Treiber et al., 2007). Further work 
suggested that another binding site at histidines 95 and 110 (the so-called fifth site) 
was able to bind manganese however it was suggested that this site was a low 
affinity site when compared to the octarepeat region (Jackson et al., 2001). More 
recent work has used isothermal titration calorimetry to identify the manganese 
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binding sites in wild-type mouse PrP. This revealed that PrP has two manganese 
binding sites with affinities that would bind manganese at concentrations of 63 and 
200 µM at pH 5.5, interestingly this affinity is similar to other known manganese 
binding proteins. In contrast to earlier work they concluded that the highest affinity 
manganese-binding site was associated with His-95 in the so-called "fifth site". They 
also established that manganese could bind at the fifth site in the presence of copper 
suggesting that copper displacement would not be required for manganese binding 
(Brazier et al., 2008). 
 
The interest in manganese binding PrP is due to several lines of evidence that 
suggest that manganese may have a role in prion disease. Elevated manganese levels 
have been observed in the CNS and blood of the patients suffering from prion 
disease, suggesting that manganese may play role in disease (Hesketh et al., 2008). 
This phenomenon has also been observed in scrapie and BSE (Hesketh et al., 2007), 
and as the increase in manganese occurs prior to the onset of clinical signs of disease 
it has been suggested as a possible diagnostic tool (Hesketh et al., 2007; Thackray et 
al., 2002). 
 
Levels of manganese have also been shown to be significantly higher in the brain 
tissue of patients with sCJD. The metal occupancy of PrP in sCJD patients also 
differed from PrP purified from normal brains. There was an elevation of manganese 
and, to a lesser extent, of zinc accompanied by significant reduction of copper bound 
to the purified PrP (Wong et al., 2001b). The reason for the change in metal balance 
in the brains of TSE sufferers remains unclear. It was hypothesised that high dietary 
manganese may result in changes in manganese concentration in the brain and 
therefore manganese binding to PrP. However research into this hypothesis has 
shown high dietary manganese does not result in increased susceptibility to prion 
disease (Legleiter et al., 2007a; Legleiter et al., 2007b). Work investigating a link 
between high levels of soil manganese and scrapie ‘hotspots’ has shown no 
correlation between the two (Chihota et al., 2004). It is likely that the reason for the 
metal imbalance observed in prion disease is more complex than a simple dietary 
imbalance. 
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Manganese binding has been shown to convert the prion protein into a structure 
more like that of PrPsc. Investigation has shown that initially manganese binding 
resulted in a protein similar to copper bound PrP, however after ageing the protein 
became protease resistant and lost function. The protein also underwent structural 
changes resulting in an increased β-sheet content, manganese binding also resulted in 
increased toxicity to astrocytes (Brown et al., 2000). More recent work has shown 
that initial manganese binding to PrP results in an increase in α- helical content 
suggesting that ageing is required for conversion to a more PrPsc-like protein (Zhu et 
al., 2008). It has also been shown that manganese binding to PrP does not protect 
manganese from water interactions, unlike copper binding, which protects copper 
from water interactions. A real-time study of the protein alloforms showed that 
copper bound PrP remained stable in solution, but that manganese bound PrP 
underwent different changes that led to fibril formation (Tsenkova et al., 2004). 
 
In vitro work has shown that, in common with several other transition metals 
manganese influences PrP aggregation. Work in yeast has shown that manganese 
supplemented media induced PrPres formation (Treiber et al., 2006). Manganese has 
also been shown to have pro-aggregatory effect on PrP in cell-free systems, which 
could be blocked by copper (Giese et al., 2004). Further work using the protein-
misfolding cyclic amplification (PMCA) cycle, a technique that has been shown to 
drive the amplification of misfolded prion protein of PrPSc seeds, showed that 
treating normal hamster brain homogenate with manganese was able to efficiently 
drive PrP conversion. This suggests that manganese could be involved in conversion 
in vivo (Kim et al., 2005). In contrast other work using cell free systems has shown 
that manganese has no effect on PrP conversion or aggregation (Bocharova et al., 
2005).  
 
Work investigating the mechanism of aggregation of PrP in cells treated with 
manganese has suggested that it is due to manganese inducing reversible 
intermolecular binding between PrP fibrils rather than manganese binding to the 
protein (Levin et al., 2005) suggesting that aggregation induced by manganese 
treatment occurs by a different route that of manganese loaded PrP, which appears to 
occur because of structural changes. 
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Unlike copper, manganese is unable to induce cellular prion protein expression 
(Varela-Nallar et al., 2006), suggesting that PrP is not involved in manganese 
metabolism. However the prion protein has been shown to protect against manganese 
toxicity; PrPc has been shown to reduce manganese accumulation in cells treated 
with manganese and to protect against manganese induced oxidative stress, as well 
as prevent manganese induced apoptosis (Choi et al., 2006). However work using a 
different cell line showed that PrPc did not protect against manganese toxicity 
(Rachidi et al., 2003). 
 
There is increasing evidence that manganese binding to the prion protein results in 
conversion of the prion protein to a PrPsc-like protein. Recent work has demonstrated 
the potential relevance of this in vivo, as manganese levels are heightened in patients 
suffering from CJD. Work demonstrating that the binding affinity of PrP for 
manganese is similar to that of other known manganese binding proteins, 
demonstrates the physiological relevance of manganese binding to PrP. 
1.4.3 Prion Protein and other Transition Metals 
 
As well as manganese binding to the prion protein, iron binding has also been 
hypothesised to be involved in the disease, as studies have shown higher levels of 
iron in scrapie infected hamsters (Kim et al., 2000). There is also evidence that iron 
can covert PrPc to PrPsc- like form and that when infected cells are iron depleted 
there is a decrease in the production of PrPsc (Basu et al., 2007).  
 
Metals have also been shown to modulate aggregation of the prion protein and 
studies using PrP 106-126 have shown that both copper and zinc could bind to the 
peptide leading to aggregation and neurotoxicity. This effect was reversed when the 
metals were removed (Jobling et al., 2001). The evidence that metal imbalance is a 
feature of several neurodegenerative diseases and that both iron and manganese have 
been shown to convert PrP to a PrPsc-like protein lead many to belief that metals may 
be involved in the pathogenesis of prion disease.  
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1.5 Prion Protein Toxicity  
 
Prion disease results in massive neuronal cell death, leading to the classic 
spongiform appearance in the brain. However, despite intensive research, there is no 
clear answer to the mechanism underlying the toxicity of the prion protein. 
Neurotoxicity is unlikely to be wholly due to the loss of function of the prion protein 
as PrP null mice have few abnormalities (Bueler et al., 1992). Although as 
conversion from PrPc to PrPsc is thought to result in loss of function it may play 
some role in toxicity (Hetz et al., 2003a).  
 
It is unclear whether PrPsc itself is toxic although in vitro studies have demonstrated 
that PrPsc is toxic (Hetz et al., 2003b). However some forms of prion disease have  
very low levels of PrPsc deposits in the brain (Collinge et al., 1995a; Hsiao et al., 
1990; Manetto et al., 1992) leading to suggestions that PrPsc is not toxic itself but 
simulates neurotoxic signalling pathways (Solforosi et al., 2004), or that only a 
subset of PrP, generated as an intermediate (PrP*) or as a side product during prion 
propagation, is toxic (Hill et al., 2000; Manuelidis et al., 1997). 
1.5.1 PrP Expression and Toxicity 
 
It is clear that toxicity requires cellular PrP expression as PrP-null neurons survive 
exposure to a fragment of the prion protein (Brown et al., 1994). Cellular prion 
expression has also been shown to be required in vivo for toxicity. PrP null mice that 
received neural grafts over-expressing PrPc were inoculated with mouse adapted 
scrapie and whilst the grafts became infected and developed the severe 
histopathological changes characteristic of scrapie the PrP-null tissue remained 
healthy (Brandner et al., 1996). The level of PrPc in the cell has also been shown to 
effect the incubation time of the disease with lower expression levels leading to a 
prolonged incubation time (Manson et al., 1994; Prusiner et al., 1993). PrPc is up-
regulated in disease (Voigtlander et al., 2001) suggesting that PrPsc itself may have 
and up-regulatory effect on the promoter region of prnp. Therefore gene expression, 
in particular the activity of the prnp promoter are thought to be important in disease 
pathogenesis. 
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1.5.2 Regions Required for Infection and Toxicity 
Investigation has revealed the requirement for certain regions of cellular prion 
protein for prion propagation. The hydrophobic region amino acids 112-119 is the 
most fibrillogenic region of the prion protein and has been shown to be required for 
prion infection in vitro (Norstrom and Mastrianni, 2005). Studies have also shown 
that PrPSc interacts with this region suggesting its importance in conversion (Brown, 
2000b).  
Numerous studies have also shown that amino acids 23-90 are not required for prion 
propagation (Fischer et al., 1996; Muramoto et al., 1997; Muramoto et al., 1996) 
suggesting that much of the N-terminal region is not required for infectivity. Further 
work using a fragment of PrP termed PrP106 or the mini prion, which is 106 amino 
acids long and contains the deletions ∆23-88 and ∆141-176, has shown that the 
octareapet region, which spans amino acids 51-90, is not required for toxicity or 
infection (Bonetto et al., 2002). As the octarepeat region is the major metal binding 
region, and hence thought to be important for normal function, it is perhaps 
surprising this region is not required for infectivity. 
 
The ablation of certain regions of the prion protein in transgenic mice are lethal 
which suggests that these regions may be involved in the toxicity of the protein, 
although the exact reason for the toxicity of the deletions remains unclear. Deletion 
of the N-terminus of the prion protein (amino acids 32-134) in transgenic mice 
results in a fatal pathology including ataxia, degeneration of cerebellar granule cells, 
and vacuolation of white matter in the brain. These symptoms are thought to be due 
to the up-regulation of Bax dependant pathways (Li et al., 2007a). Deletion of the 
region spanning 105-125, which encompasses the hydrophobic region, results in 
fatal neurodegeration in mice (Li et al., 2007b). Unlike N-terminal deletion, this 
deletion does not up-regulate Bax dependant pathways (Li et al., 2007a) but they 
hypothesise a model in which this protein has greatly enhanced affinity for a 
hypothetical receptor that serves to transduce the toxic signal (Li et al., 2007b). The 
deletion of amino acids 94-134 of the prion protein results myelin degeneration 
which led to the hypothesis that the prion protein is involved in maintaining myelin 
integrity (Baumann et al., 2007). 
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In summary the C-terminus of the prion protein appears to be important for 
infectivity, the hydrophobic region has been shown to be required for infectivity, as 
have amino acids 89-140 and 176-231. Deletion of regions of the prion protein, in 
transgenic mice, has shown that deletion of certain regions can be lethal, suggesting 
these regions may be important structurally. 
1.5.3 Species Barrier and Conversion 
 
A strong species barrier exists between most species, in most cases transmission 
from one species to another results in longer incubation time or is unsuccessful, 
however subsequent transmission resemble ‘within species’ transmission. Work 
using transgenic mice expressing hamster PrPc showed that they are highly 
susceptible to Sc237 hamster prions, unlike WT mice (Prusiner et al., 1990). Studies 
argued that the barrier was due to in differences in PrP primary structure between the 
donor and recipient species, making it difficult for the conversion to occur (Palmer et 
al., 1991; Prusiner et al., 1990). However the BSE prion strain is highly promiscuous 
and retains its biological characteristics on transmission to other species (Bruce et 
al., 1994). Also, unlike classical CJD, vCJD transmits easily to mice (Hill et al., 
1997), and as the CJD and vCJD variants have exactly the same structure it suggests 
be that the barrier is not species dependant. Recent work has also shown that, outside 
of the cell, mouse and hamster full-length recombinant PrPs are able to cross-seed 
polymerisation reactions furthering the suggestion that factors other than the PrP 
sequence may have an impact in regulating prion transmission between mammalian 
species (Makarava et al., 2007). However other studies have shown the maintenance 
of a species barrier in a cell-free environment, although this work used a fragment of 
PrP. This may suggest that this fragment contains the regions important in species 
barrier (Jones and Surewicz, 2005; Vanik et al., 2004). 
1.5.4 Disease Mutations and Toxicity 
 
Inheritable prion diseases result from a mutation in the prion protein genetic 
sequence that presumably makes the protein more likely to convert to PrPSc. The N-
terminus of the prion protein region includes mutations involved in inheritable prion 
diseases, suggesting that this region may play an important role in the conversion of 
the protein to the neurotoxic form although previous work has shown that much of 
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this region is not required for conversion to PrPsc (Muramoto et al., 1996). Perhaps 
the best described mutation is found in GSS patients at amino acid 102 where a 
proline is substituted for a leucine (Hsiao et al., 1989). The mutation has been 
reproduced in mice and upon challenge with scrapie results in prion disease (Hsiao et 
al., 1991). However high expression levels of PrP are required for disease to develop 
(Hsiao et al., 1991). In familial CJD, additional N-terminal mutations are observed 
which include multiple repeats of the octarepeat region. This highlights the 
importance of the metal binding regions in disease, even though this region is not 
generally thought to be required for infection (Flechsig et al., 2000). A mouse model 
containing insertions of extra octarepeats has been created. This model, Tg(PG14), 
contains an extra 9 repeats which corresponds to the largest number of extra repeats 
so far found in patients (Chiesa et al., 1998). These mice spontaneously develop 
prion disease.  
 
In addition, several mutations involved in inheritable disease are found in the C-
terminus of the prion protein, including E200K and F198S. It has been revealed that 
expression of certain parts of the C-terminus of PrP is intrinsically toxic to cells, and 
that this toxicity can be enhanced by mutations of the C-terminus of PrP  that are 
found in genetic prion disease (Daniels et al., 2001), and that this toxicity is 
hypothesised to be due to the generation of hydrogen peroxide (Turnbull et al., 
2003b). As with the C-terminal mutations described some other mutations have been 
directly linked to toxicity. Substitution of alanine for valine at amino acid 117 is a 
mutation observed in GSS and has been shown to increase the toxicity of PrP 106-
126 (Brown, 2000a). 
1.5.5 Recombinant Protein and Peptide Models of Toxicity 
 
Perhaps the best-studied model of prion toxicity is the 106-126 peptide, which 
encompasses the hydrophobic region of the protein (amino acids 112-119). The 106-
126 peptide has been shown to reproduce many of the properties of the prion protein, 
it is toxic to neuronal cells (Forloni et al., 1993), toxicity is mediated by cellular PrP 
expression (Brown et al., 1994) and requires the presence of mircoglial cells (Brown 
et al., 1996). Toxicity requires the presence of metals (Jobling et al., 2001) and the 
presence of copper results in the production of hydrogen peroxide, which may 
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explain the mechanism of toxicity of PrP 106-126 (Turnbull et al., 2003a). 
Furthermore, the 106-126 peptide induces neuronal apoptosis (Forloni et al., 1996), 
which is a feature of prion diseases in vivo. It is thought the hydrophobic core of the 
peptide mediates the toxicity and structure of the peptide, as substitution of the 
hydrophobic residues results in a decrease in toxicity as well as a decrease in β-sheet 
structure and alters the aggregation properties of the peptide (Jobling et al., 1999). 
 
Other peptides that have been used as a substitute for PrP include a peptide spanning 
amino acids 185-208 which has a structural motif homologous to a motif in 
Alzheimer’s disease-associated peptide Aβ (Klajnert et al., 2006). This fragment was 
shown to form amyloid fibrils in the presence of heparin and was also found to be 
cytotoxic (Cortijo-Arellano et al., 2008). A synthetic peptide spanning the sequence 
82-146, which spans a fragment of the protein commonly found in patients suffering 
from GSS, has also been shown to readily form aggregates that are partially resistant 
to protease digestion (Salmona et al., 2003). This peptide has also been shown to be 
toxic to primary neurones and this is primarily due to the oligomers that it forms 
(Fioriti et al., 2007).  
 
Longer fragments of the prion protein such as the mini prion have also been widely 
used to investigate prion toxicity. The mini prion is a soluble form of PrP that 
possesses several properties in common with PrPsc (Bonetto et al., 2002; Laws et al., 
2001). When expressed in scrapie infected cells, the mini prion can generate a 
protease-resistant polypeptide (Muramoto et al., 1996; Supattapone et al., 1999). In 
vivo PrP knockout mice expressing PrP106 are able to maintain scrapie infection 
(Supattapone et al., 1999). Work using recombinant mini prion has show that it is 
was highly toxic to primary neuronal cultures (Bonetto et al., 2002), thereby 
highlighting its usefulness as a model to study toxicity. 
 
Many studies use the 90-231 fragment of PrP, this region is equivalent to PrP 27-30, 
the N-terminally truncated form of PrP. Both PrP 27-30 and recombinant 90-231 PrP 
were found to be toxic in vitro (Post et al., 2000). More unusually transmembrane or 
cytosolic prion protein has been used to investigate prion protein toxicity. A peptide 
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spanning 118-135 of PrP has been used to mimic prion toxicity as it is part of the 
putative transmembrane region of PrP. This region which has been shown to be toxic 
to neurones both in vitro and in vivo although toxicity is independent of PrP 
expression, which suggests this may not be relevant in vivo (Chabry et al., 2003). 
Additionally, although cytosolic PrP has been shown to be toxic in vivo this toxicity 
is also independent of cellular PrP expression (Norstrom et al., 2007) and other 
reports have found it is not toxic (Fioriti et al., 2005).  As the toxicity of 
transmembrane and cytosolic PrP is independent of cellular PrP expression the value 
of these, as models of prion disease, is questionable. 
 
Previous studies using recombinant prion protein have often used protein that has 
been converted into agregatory mis-folded and protease resistant forms like PrPsc 
using metals (Kim et al., 2005) or SDS (Stohr et al., 2008). However SDS would not 
be found in tissue and as such does not represent a conversion that could take place 
in vivo. However studies using recombinant PrP have shown it to be a useful 
analogue of PrPsc. PMCA cycling is common method of creating large quantities of 
PrPres, a protease resistant form of PrP analogous to PrPsc. PMCA cycling uses large 
quantities of PrPc which are incubated with much lower concentrations of PrPres 
which acts as template for the conversion of the PrPc to PrPres. The protein is 
sonicated at intervals to generate multiple smaller units for the continued formation 
of new PrPres (Saborio et al., 2001). Protein generated in this manner has been shown 
to be selectively toxic to cells expressing PrP (Novitskaya et al., 2006) suggesting 
that recombinant PrP represents a realistic model of prion toxicity, whilst peptides 
often do not replicate a fragment of the peptide that would be found in the disease 
state. 
 
Studies using recombinant prion protein have highlighted the link between 
aggregation, structure and toxicity. Emerging theories are centralised around the idea 
that prion toxicity is linked to prion structure, and the conversion of the prion protein 
to PrPsc results in an increased tendency to form aggregates. There is increasing 
evidence that larger aggregates of PrPsc are not toxic, as originally believed, but that 
the smaller soluble oligomers are the toxic species (Kazlauskaite et al., 2005; 
Simoneau et al., 2007). Small aggregates of other non-disease associated protein 
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have also been shown to be toxic suggesting that there may be a general mechanism 
of toxicity and avoidance of protein aggregation is crucial for the preservation of 
biological function (Bucciantini et al., 2002). Investigations using an antibody 
developed specifically against Aβ oligomers found the antibody was able and 
prevent their toxicity in vitro which demonstrates there is a common structure for 
soluble amyloid oligomers and also implies there is a common toxic mechanism 
(Kayed et al., 2003). This mechanism has since been suggested to involve increased 
membrane permeability and calcium dysregulation (Demuro et al., 2005). However, 
some argue that whilst oligomers are toxic to cells, they are not the sole toxic 
species, as mature fibrils have also been demonstrated to be toxic to cultured and 
primary cells  (Novitskaya et al., 2006; Novitskaya et al., 2007).  
There is increasing evidence that structure plays an important role in toxicity and 
studies have shown that amyloid proteins have similar structural features (Kayed et 
al., 2003). The toxicity of 90-231 is dependent on structure: α-helical 90-231 PrP is 
not toxic to cells but once converted to a β-sheet form the protein becomes more 
prone to aggregation and is toxic to cells (Corsaro et al., 2006). Further study has 
shown that denatured monomeric PrP 90-231 is toxic to cells, and that this is 
probably due to exposure of the hydrophobic region and increased internalisation 
(Chiovitti et al., 2007). The toxicity of full-length recombinant PrP also requires high 
β-sheet content (Novitskaya et al., 2006). 
1.6 Cell death in Prion disease. 
 
All TSEs result in a spongiform appearance in the brain due to the loss of neurones. 
Neuronal cell death in prion disease is widely accepted to be caused by apoptosis. 
This has been demonstrated both in vitro and in vivo in a variety of animals and in 
humans (Fairbairn et al., 1994; Forloni et al., 1993; Giese et al., 1995; Gray et al., 
1999). The cause of apoptosis is still unknown, it may be due to a variety factors 
including a loss of function of PrP, aggregation of PrP or endoplasmic reticulum 
stress due to a build up of misfolded protein. 
 
It is unclear how apoptosis in prion disease is initiated; PrPsc may bind to receptors 
to initiate apoptosis as PrP has been shown to bind several receptors. Perhaps the 
most widely studied is the laminin receptor which has a role in PrPc internalisation 
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(Gauczynski et al., 2001) and may have a role in PrPsc propagation (Leucht et al., 
2003). However no receptor has been shown to bind PrPsc and initiate apoptosis. PrPc 
may itself be involved in signalling, it has been shown to bind Fyn, a tyrosine kinase 
(Mouillet-Richard et al., 2000), PrPsc may cause deregulation of this signalling 
leading to apoptosis (Pietri et al., 2006). However apoptosis may also be initiated 
internally by the endoplasmic reticulum and the mitochondria. 
 
Studies have detected active caspase 12 in N2a cells treated with purified scrapie 
from mouse brain (Hetz et al., 2003b). As caspase 12 is localised to the endoplasmic 
reticulum (ER) and is associated with apoptosis induced by ER stress it suggests that 
the ER may play a role in apoptosis in prion disease. However more recent work has 
shown that ER stress may not have a prominent role in human prion diseases in vivo 
(Unterberger et al., 2006). Further research has shown that BiP a chaperone known 
to bind PrP is up-regulated in early prion disease, inhibition of BiP in N2A led to 
increased PrPsc toxicity (Hetz et al., 2005) suggesting BiP may have a protective 
role. Other studies have shown that neurons treated with the 106-126 peptide release 
calcium through ER ryanodine (RyR) and inositol 1,4,5-trisphosphate (IP(3)R) 
receptors leading to ER stress and subsequent apoptosis via mitochondrial 
cytochrome C release (Ferreiro et al., 2008a).  
 
p53 is a transcription factor involved in the regulation of cell cycle. PrPc has been 
shown to regulate p53 induced caspase 3 apoptosis, in neuronal cells, leading to 
knock-out cells showing increased resistance to staurosporine induced apoptosis 
(Paitel et al., 2004). This has been shown to be regulated by C-terminal fragment of 
PrP (Sunyach et al., 2007). In the disease state, p53 has been shown to induce 
caspase 3 mediated cell death. Inhibition of p53 reduced caspase 3 expression, in 
hamster brains but had no effect on the incubation time of the disease (Engelstein et 
al., 2005), suggesting that this pathway is not required for cell death in prion disease. 
 
The Bcl-2 family proteins comprise both anti-apoptotic and pro-apoptotic signalling 
molecules; they regulate apoptosis via the release of factors such as cytochrome-C 
from the mitochondria. Bcl-2 an anti-apoptotic signalling molecule and Bax a pro-
apoptotic signalling molecule have both been implicated in prion toxicity. Over-
expression of Bcl-2 in GT1 cells protects against the neurotoxic effects of the 106-
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126 peptide (Ferreiro et al., 2007). In vivo Bcl-2 over-expression has been shown to 
protect mice expressing a lethal N-terminal truncated form of PrP (PrP∆32-134), 
leading to an increase in life expectancy (Nicolas et al., 2007). Other studies have 
investigated the role of Bax, a pro-apoptotic member of the Bcl-2 family in prion 
disease. In the normal state there is evidence that PrPc can protect against Bax 
induced apoptosis in a variety of cell including breast carcinoma and primary 
neuronal cells (Roucou et al., 2005). Bax deletion delayed cell loss in one mouse cell 
line expressing the lethal N-terminally truncated PrP∆32-134 in contrast Bax 
deletion did not affect cell loss in another mouse cell line expressing the deletion 
mutant PrP∆105-125 . Work using mice infected with the Rocky Mountain 
Laboratory  (RML) strain of scrapie has also shown that deletion of Bax has little 
effect on disease progression and that over-expression of Bcl-2 also had little effect 
of disease progression (Li et al., 2007a). This suggests that the Bcl-2 family is not an 
appropriate target for therapy. 
 
Several other pathways have been implicated in neurodegeneration in prion disease. 
pJNK is up-regulated in cells treated with the toxic peptide, 106-126 (Carimalo et al., 
2005), in vivo pJNK is up-regulated in the brains of hamsters infected with scrapie. 
pERK (phosphorylated ERK) is also up-regulated in hamsters infected with scrapie 
(Lee et al., 2005). p38 activation has also been demonstrated in several models 
(Corsaro et al., 2006; Corsaro et al., 2003; Lee et al., 2005; Thellung et al., 2002). 
The activation of p38 may lead to caspase 3 activation and apoptosis as inhibition of 
p38 has been shown to prevent cell death in cells treated with PrP106-126 (Corsaro 
et al., 2003). 
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Figure 1.4: Cell signalling pathways thought to be involved in apoptosis in prion disease. The 
red circle represents PrPsc and the green circles PrPc.  
 
 
1.7 Aims and Objectives 
 
Despite extensive research into the toxicity of the protein the mechanism underlying 
the toxicity and conversion of the prion protein still remain a mystery. We have 
investigated the use of manganese bound PrP as model of prion toxicity. This model 
has allowed us to investigate the toxicity of the prion protein and gain a better 
understanding of the mechanism of prion toxicity. Initially we characterised 
manganese bound PrP and confirmed it replicated several properties of the prion 
protein, including protease resistance. 
 
We investigated the regions of the prion protein required for MnPrP (manganese 
bound PrP) toxicity to try and further understand the effect of manganese binding on 
the prion protein. We established that metal binding to known metal binding residues 
was required for MnPrP toxicity. We also established that the octarepeat region had a 
protective effect on MnPrP and its removal resulted in increased toxicity.  
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We also wanted to establish the signaling mechanisms involved in cell death in 
MnPrP treated cells as well as using chronically infected cells to investigate pathway 
that may be involved in neuronal survival in scrapie infection, we hoped this might 
provide better understanding and possible therapies. We found that MnPrP caused 
apoptosis and the cell survival signal ERK was involved in cell survival in cells 
chronically infected with scrapie. 
 
The final part of the study has investigated possible mechanisms for the prevention 
of manganese bound PrP toxicity, investigating the whether the promoter is up-
regulated by MnPrP and whether this results in toxicity. We have also investigated 
whether antioxidant can protect against prion disease. Finally we have investigated 
whether the expression of non-mammalian prion proteins was protective against 
manganese PrP toxicity. 
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2. Materials and methods 
 
2.1 Protein Production 
2.1.1 Materials 
 
LB Broth high salt purchased from Melford (Ipswich UK) 
Qiagen Miniprep Kit from Qiagen (Crawley, UK) 
Chelating Sepherose, Fast Flow from Amersham Biosciences (Buckinghamshire, 
UK) 
Bio-Rad protein assay from Bio-Rad (Herts, UK) 
Bovine serum albumin purchased from Fisher Scientific (Loughborough, UK)  
Manganese Sulphate purchased from Fisher Scientific (Loughborough, UK)
 
Imidazole purchased from Fisher Scientific (Loughborough, UK) 
Vivaspin concentrator purchased from Fisher Scientific (Loughborough, UK) 
Triton X-100 purchased from Sigma-Aldrich (Poole, UK) 
Igepal CA-630 purchased from Sigma-Aldrich (Poole, UK) 
Nickel Sulphate purchased from Fisher Scientific (Loughborough, UK) 
Copper Sulphate purchased from Fisher Scientific (Loughborough, UK) 
Tris-HCl purchased from Sigma-Aldrich (Poole, UK) 
EDTA purchased from Sigma-Aldrich (Poole, UK) 
NaCl purchased from Fisher Scientific (Loughborough, UK) 
PMSF purchased from Sigma-Aldrich (Poole, UK) 
Lysozyme purchased from Sigma-Aldrich (Poole, UK) 
Urea purchased from Melford (Ipswich UK) 
Deoxycholic acid purchased from Sigma-Aldrich (Poole, UK) 
DNase purchased from Sigma-Aldrich (Poole, UK) 
BL21 cells purchased from Invitrogen (Paisley, UK) 
XL-2 Blue ultra competent cells purchased from Stratagene (Amsterdam, 
Netherlands) 
Carbenicillin purchased from Melford (Ipswich UK) 
Kanamycin sulphate purchased from Melford (Ipswich UK) 
IPTG purchased from Apollo Scientific (Stockport, UK) 
Agarose purchased from Melford (Ipswich UK) 
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TEMED purchased from Sigma-Aldrich (Poole, UK) 
SDS purchased from Fisher Scientific (Loughborough, UK) 
Acrylamide purchased from National Diagnostics (Hessle, UK) 
Dialysis Tubing purchased from Visking (UK) 
Ethanol purchased from Fisher Scientific (Loughborough, UK) 
 
2.1.2 Protein expression 
2.1.2.1 Minipreps 
 
Transformed XL-2 Blue ultra competent cells from a glycerol stock were spread onto 
an agar plate containing the appropriate selection antibiotic (either carbenicillin for 
pET23a plasmids or kanamycin for pEGFP-C1 and pd2-EGFP-N1 plasmids) and 
incubated overnight at 37oC. A single colony was picked and incubated overnight in 
3.5 ml of LB containing appropriate antibiotic, with shaking. The cells were spun 
down at 4000rpm for 10 minutes. Plasmid DNA was obtained using a Qiagen 
Miniprep Kit. The manufacturer’s instructions were followed and the DNA was 
resuspended in 50µl of water. The product was run on a 1% agarose gel to check 
purity and determine quantity. 
 
2.1.2.2 Protein Expression 
 
Constructs had previously been created and inserted into a pET23a plasmid. DNA 
was transformed into BL21 cells as follows; cells were defrosted on ice then 1-2µg 
of plasmid DNA was added to the cells, the cells were then left on ice for 5 minutes. 
The cells were heated for 1 minute at 42oC then placed on ice for 5 minutes. Cells 
were grown in 5mls LB for 1hr at 37oC, 200 rpm. The culture was transferred into 
20mls of LB broth and incubated overnight at 37oC, 200rpm. The LB was 
supplemented with 50µg/ml carbenecillum. The next day the 20mls was added to a 
litre of LB supplemented with 50µg/ml carbenecillum and incubated at 37oC, 
200rpm until the cells reached and optical density of 0.6 (at 600nm). The cells were 
then supplemented with 1mM IPTG to induce protein expression. The cells were 
incubated for a further 4-5h and then spun down at 6000rpm for 15 minutes and 
stored at –20oC prior to lysis. 
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2.1.3 Protein Purification 
2.1.3.1 Cell Lysis 
 
The transformed BL-21 cells were lysed to release protein as follows, the cells were 
resuspended in cell lysis buffer (50mM TrisHCl, 1mM EDTA, 100mM NaCl) with 
0.4µM/ml PMSF, 10mg/ml lysozyme was then added to the lysis buffer and the cells 
were left at room temperature for 20 minutes. Deoxycholic acid was added at 
2mg/ml and the cells were incubated at 37oC, with shaking, until viscous. 20µg/ml 
DNase was then added to degrade any DNA present. The lysate was then spun at 
12000rpm for 20 minutes. The supernantant was discarded and the pellet 
resuspended in lysis buffer, the lysate was then spun as before. The pellet was 
resuspended in binding buffer (8M urea, 200mM NaCl, 50mM Tris at pH 7.8) and 
stored at –20oC. 
2.1.3.2 Purification of His tagged Proteins 
 
Protein was purified using immobilised metal ion affinity chromatography (IMAC) 
as previously described (Cui et al., 2003). A column was prepared as follows: it was 
packed with a bed of 6mls of chelating sepharose and washed with 5 volumes of 
water to remove the storage buffer. The column was then washed with 0.3M nickel 
sulphate which bound to the sepharose, it was then washed with MilliQ water to 
remove any excess nickel. It was then saturated with binding buffer prior to the 
addition of the lysate. The lysate was loaded onto the column and any his-tagged 
protein bound to the nickel loaded speharose. After the lysate had been loaded the 
column was washed with 8 volumes of binding buffer then 100mls of low imidazole 
buffer (20mM imidazole in binding buffer). The protein was eluted in high imidazole 
buffer (300mM imdiazole in binding buffer), which interferes with the binding of 
histidine with the sepharose causing the protein to be released from the column. The 
eluates and column washes were run on a 12% SDS-page gel and stained in 
Coomassie stain for 1hr at RT. The gel was then destained using Coomassie destain 
overnight and the eluate was checked for purity. 
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2.1.3.3 Purification of Non His-tagged Proteins 
 
Protein was purified using immobilised metal ion affinity chromatography (IMAC) 
as previously described (Jones et al., 2004). As the prion protein has a high affinity 
for copper it can be purified using its metal binding site by loading chelating 
sepharose with copper, the prion protein will then bind to the sepharose and can be 
purified in this way. The IMAC column was packed with a bed of 6ml of chelating 
sepharose washed with 5 volumes of water, 0.3M copper sulphate and water. It was 
then saturated with binding buffer. After the lysate had been loaded the column was 
washed with binding buffer until protein was no longer coming off the column. The 
protein was eluted in high imidazole buffer (300mM imdazole in binding buffer). 
The eluate and column washes were run on a 12% SDS-page gel and stained in 
Coomassie stain for 1hr at RT. The gel was then destained using Coomassie destain 
overnight and the eluate was checked for purity. 
2.1.3.4 Purification of the null mutants 
 
A series of mutants were generated in our laboratories that had the histidines thought 
to bind metals replaced with alanines. These mutants included one that has all of its 
histidines removed (Zhu et al., 2008), the others had either the fifth site mutated or 
the octarepeat region histidines mutated into alanines (Klewpatinond et al., 2008). 
Mutants that did not contain the octarepeat region could not be purified by a column 
method and so were purified as previously described (Zhu et al., 2008). Briefly the 
proteins were lysed as previously described, however the pellet was not resuspended 
in binding buffer but underwent a series of washes as follows: The cell pellet was 
resuspended in a solution of lysis buffer containing 1% Igepal and 0.5% Triton X-
100 by sonication at 30% for 1 minute. Protein was repelleted at 10,000 xg for 5 
minutes, this step was repeated a further 5 times. The pellet was then resuspended, as 
before, in a further was solution containing 1% Triton X-100 and spun as before, this 
step was repeated 6 times. Finally the pellet was resuspended in a lysis buffer and 
spun as before, this was repeated 4 times to remove any detergent. The pellet was 
then resuspended in binding buffer, by sonication at 70% max power for 3x1 minute. 
Purity was confirmed by Coomassie stained SDS-PAGE gel. 
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2.1.3.5 Protein Refolding 
 
Protein was bound to manganese as follows, protein was diluted in binding buffer to 
1.5mg/ml, 1ml of this was then made up to 5mls with binding buffer, this was then 
concentrated to 1ml using a Vivaspin concentrator (15kDa cut-off), this removed the 
imidazole. The protein was then made up to 5mls using 5mM MnSO4 in binding 
buffer; this was then concentrated back down to 1ml. The protein was then made up 
to 5mls with 5mM MnSO4, this was added drop wise with stirring to prevent the 
protein precipitating out. This was spun down for 10 minutes at 4000rpm prior to 
concentrating to 1ml. This was then dialysed in MilliQ water to a 1 in 10,000 
dilution in 12,000kDa cut-off dialysis tubing, which had previously been soaked in 
MilliQ water to ensure it was free of storage buffer (20% ETOH). The protein was 
then aged at –20Co for 2 weeks prior to use. 
 
Protein was refolded with water as follows, protein was diluted in binding buffer to 
1.5mg/ml. The protein was then made up to 5ml with Milli Q water, this was added 
slowly with stirring to prevent precipitation. This was then centrifuged for 10 
minutes at 4000rpm. This was then dialysed in Milli Q water to a 1 in 10,000 
dilution in 12,000kDa cut-off dialysis tubing, which had previously been soaked in 
MilliQ water to ensure it was free of storage buffer (20% ETOH). The protein was 
then aged at –20Co for 2 week prior to use. 
2.1.4 Determination of Protein concentration 
2.1.4.1 Bio-Rad protein assay. 
 
The Bio-Rad protein assay is based on the Bradford assay, a colorimetric assay to 
quantify protein concentration. A series of standards were prepared using bovine 
serum albumin. The standards ranged in concentration from 0-1µg/ml. 1µl of each 
standard was added in triplicate to a 96 well plate. 1µl of each test sample was also 
added in triplicate with dilutions of sample, if necessary, to ensure the concentration 
fell within the standard curve. The dye concentrate was diluted 1:5 in Milli-Q water 
and 200µl was added to each well. The plate was incubated at room temperature for 
5 minutes and then measured at 595nm in a plate reader. The resulting readings were 
plotted and the sample concentrations calculated. 
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2.1.4.2 Protein measurement by spectroscopy. 
 
Protein was diluted 1:30 in the appropriate dilutant and the spectrophotometer was 
blanked using the dilutant. The sample was then measured from 200-900 nm so any 
contamination by DNA could be observed. The protein concentration was calculated 
using the OD280 this was multiplied by the dilution factor and divided by the 
extinction coefficient. All protein samples were measured using both methods to 
ensure an accurate reading. 
 
2.2 Cell culture 
2.2.1 Materials 
 
All plastics were purchased from Fisher Scientific (Loughborough, UK) 
Media was purchased from Lonza (Slough, UK)  
OptiMeM serum free, phenol red free media (Invitrogen, Paisley, UK) 
Penicillin purchased from Sigma-Aldrich (Poole, UK) 
Streptomycin purchased from Sigma-Aldrich (Poole, UK) 
Geneticin purchased from Gibco (Paisley, UK) 
L-Glutamine purchased from Gibco (Paisley, UK) 
Foetal Bovine Serum purchased from BioSera (East Sussex, UK)  
Newborn calf serum purchased from Sigma-Aldrich (Poole, UK) 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) from Promega (Wisconsin, USA) 
Phenazine methosulfate (PMS) from MP Biomedicals (California, USA) 
Optimem media purchased from Gibco (Paisley, UK) 
Fugene 6 from Roche diagnostics (Lewes, UK) 
PD98059 from Promega (Wisconsin, USA) 
DMSO purchased from Fisher Scientific (Loughborough, UK) 
CM-H2DCDFDA from Molecular Probes (Paisley, UK) 
Bovine Serum Albumin purchased from Fisher Scientific (Loughborough, UK) 
PMSF purchased from Sigma-Aldrich (Poole, UK)  
Tris-HCl purchased from Sigma-Aldrich (Poole, UK) 
Tris base purchased from Melford (Ipswich UK) 
NaCl purchased from Fisher Scientific (Loughborough, UK) 
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Igepal CA-630 purchased from Sigma-Aldrich (Poole, UK) 
SDS purchased from Fisher Scientific (Loughborough, UK) 
EDTA purchased from Sigma-Aldrich (Poole, UK) 
β-Mercaptoethanol purchased from Sigma-Aldrich (Poole, UK) 
Complete Tablets purchased from Promega (Wisconsin, USA) 
Sodium orthovanadate purchased from Sigma-Aldrich (Poole, UK) 
Tween purchased from Sigma-Aldrich (Poole, UK) 
PBS tablets purchased from Oxoid Ltd (Basingstoke, UK) 
Glycine purchased from Fisher Scientific (Loughborough, UK) 
HCl purchased from Fisher Scientific (Loughborough, UK) 
Non-Fat dry milk powder (Marvel, UK) 
Dulbeccos phosphate buffered saline purchased from Sigma-Aldrich (Poole, UK) 
Poly-L-lysine purchased from Sigma-Aldrich (Poole, UK) 
Multi-well borosilicate slides purchased from Fisher Scientific (Loughborough, UK) 
2.2.2 Cell Maintenance 
 
SMB cells are mesodermal cell line taken from a mouse clinically infected with the 
Chandler scrapie isolate, this cell line is capable of maintaining scrapie infection. 
SMB-PS cells are cells from the SMB cell line that have been successfully cured of 
scrapie using pentosan polysulphate (Birkett et al., 2001).  
 
SMB and SMB-PS cells were maintained in 199 Medium of composition 1 g/L 
glucose, 2.2 g/L sodium bicarbonate, supplemented with 2mM L-Glutamine, 10% 
Foetal Bovine Serum (FBS) and 5% Newborn Calf Serum (NCS), with penicillin and 
streptomycin at final concentrations of 1U/ml and 0.5mg/ml respectively. Growth 
conditions were maintained at 37oC, 5% CO2 prior to any experiment. 
 
F14 (PrPc knockout mouse cerebellar-neuroblastoma fusion cells) and F21 ((PrPc 
wild type mouse cerebellar-neuroblastoma fusion cells) were created in our 
laboratory by a fusion of cerebellar suspension from PrP null mice or WT mice with 
N18TG2 mouse neuroblastoma cells (Holme et al., 2003). F14 and F21 cells were 
maintained in Dulbeccos Modified Eagles Media (DMEM) comprised of 4.5 g/L 
glucose, 1.5 g/L sodium bicarbonate without sodium pyruvate and glutamine. This 
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was supplemented with 10% FBS and penicillin and streptomycin at final 
concentrations of 1U/ml and 0.5mg/ml respectively. Growth conditions were 
maintained at 37oC, 5% CO2 prior to any experiment. All transfections were 
maintained using 0.5mg/ml geneticin.  
 
N2a cells were established by from a spontaneous tumour of a strain A albino mouse 
(Klebe et al., 1970) and are a mouse neuroblastoma cell line. N2a cells were 
maintained in Earle’s Minimal Essential Medium with Earle’s BSS and adjusted to 
contain 1 g/L glucose, 2.2 g/L sodium bicarbonate, 2mM L-glutamine without 
sodium pyruvate. This was supplemented with 10% FBS, 0.1mM non essential 
amino acids and penicillin and streptomycin at final concentrations of 1U/ml and 
0.5mg/ml respectively. Growth conditions were maintained at 37oC, 5% CO2 prior to 
any experiment. 
2.2.3 Transfection 
2.2.3.1 PrP Constructs 
 
A green fluorescent protein (GFP) fusion construct made using mouse PrPc 
(accession number M13695), called pEGFP-C1-PrP(m) was donated to the lab by 
Marco Prado. Xenopus and turtle constructs were then created using mouse 
signalling sequences to ensure the correct expression of the proteins. The mouse 
construct contained the GFP sequence inserted at amino acid 42, the full mouse 
sequence is included in it. The Xenopus and turtle constructs contained the mouse 
sequence from amino acid 1 to 42, then the GFP and then the turtle or Xenopus 
sequence, the mouse sequence was also included at the C-terminus end of the protein 
from amino acid 231, again to allow correct processing of the protein. The construct 
was inserted into pEGFP-C1 vector (figure 2.1). 
G FP
1 42 41
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231 255
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1 42 43 255
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Figure 2.1: A schematic diagram of the chimeric constructs of PrP developed. 
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2.2.3.2 Promoter Constructs 
 
The mouse PrP promoter construct was made by Lark Technologies on behalf of Dr 
Cathryn Haigh. The promoter construct was created using the mouse long incubation 
prion gene (accession number U29187). The construct was made in pd2-EGFP-1, a 
promoter-less vector containing destabilised GFP with a half-life of two hours. A 
construct containing the cytomegalovirus (CMV) promoter was also created. As the 
vector is CMV driven GFP expression was constitutive and could be used as a 
control for non-specific changes in fluorescence. The PrP promoter can be seen 
below (figure 2.2). 
 
 
 
Figure 2.2: A schematic diagram of the mouse prion promoter construct used.  
2.2.3.3 Stable Transfection 
 
PrP-GFP constructs were stably transfected into F14 cells prior to toxicity assays. 
All transfections were performed using Fugene transfection reagent following the 
manufacturer’s protocol. Briefly, cells were plated out at 50% confluence in 40mm 
dishes and left overnight to adhere prior to transfection. 3µl Fugene and 1-2 µg 
plasmid DNA were incubated at RT in 100µl serum free media for 20 minutes prior 
to transfection. The reagent was then added dropwise to the cells and the cells were 
incubated for 24h prior to selection. Transfected cells were selected using 100µg/ml 
of geneticin, once selection was complete the cells were maintained with 50µg/ml of 
geneticin. No stably transfected cells were used beyond passage ten. 
2.2.3.4 Transient Transfection 
 
F14 cells were transiently transfected with promoter constructs prior to promoter 
expression assessment using confocal microscopy. Chambered coverslips were 
coated in poly-L-lysine in order to ensure cell adhesion. Cells were plated out at 40-
50% confluency and maintained at 37oC, 5% CO2 overnight, to allow cells to adhere. 
To 20µl of serum free DMEM, 0.6µl of Fugene was added and the tubes were tapped 
to mix, then 0.2ug of DNA was added. The mixture was incubated at room 
-4329 0
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temperature for 20 minutes and then added to the cells. The cells were not used for at 
least the first 24h after transfection to ensure a proper turnover of plasmid product. 
2.2.4 Toxicity Assays 
 
Toxicity assays were carried out to assess the toxicity of manganese refolded PrP 
and variety of manganese refolded PrP mutants. The toxicity of ApoPrP and the 
ApoPrP mutants was also investigated concurrently. These assays were carried out 
on F21 cells. The F21 cells were plated out at 75% confluency in DMEM and 
maintained at 37oC, 5% CO2 overnight, to allow the cells to adhere. The medium 
was then replaced with OptiMeM, a serum free medium without phenol red. The 
appropriate treatment was added to cells in triplicate and the cells were incubated for 
48h prior to the MTS assay. Several assays investigating toxicity over time and the 
ability of anti-oxidants and non-mammalian prion proteins to rescue cells from 
MnPrP were also carried out. These used the method described above but used time-
points ranging from 6h-72h. 
 
The toxicity of MnPrP and ApoPrP to SMB and SMB-PS cells was also investigated. 
SMB and SMB-PS cells were plated out in media 199 at 90% confluency and 
maintained at 37oC, 5% CO2 overnight, to allow cells to adhere. The medium was 
then replaced with Optimem, a serum free medium without phenol red. The 
appropriate treatment was added to cells in triplicate and the cells were incubated for 
48h prior to the MTS assay. 
 
The toxicity of MnPrP to N2a cells was also investigated. N2a and cells were plated 
out in EMEM at 50% confluency and maintained at 37oC, 5% CO2 overnight, to 
allow cells to adhere. The medium was then replaced with Optimem, a serum free 
medium without phenol red. The appropriate treatment was added to cells in 
triplicate and the cells were incubated for 48h prior to the MTS assay. 
 
The toxicity of the 106-126 peptide and a control peptide was also assessed in F21 
cells and SMB cells. SMB cells were plated out in media 199 at 90% confluency and 
maintained at 37oC, 5% CO2 overnight, to allow cells to adhere. The F21 cells were 
plated out at 75% confluency in DMEM and maintained at 37oC, 5% CO2 overnight, 
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to allow the cells to adhere. In both cell lines the medium was then replaced with 
OptiMeM, a serum free medium without phenol red. The appropriate treatment was 
added to cells in triplicate to both cell lines concurrently and the cells were incubated 
for 48h prior to the MTS assay. The differing initial confluency that the cells were 
plated out at ensured that density at the start of the assay is comparable for each cell 
line. 
2.2.5 MTS Assay 
 
The MTS assay is a colorimetric method for determining viability. The assay is 
composed of MTS a tetrazolium salt and an electron coupling reagent PMS 
(phenazine methosulfate). MTS is reduced by cells into a formazan product. The 
MTS is converted into formazan by dehydrogenase enzymes only found in 
metabolically active cells. The quantity of formazan product as measured by the 
amount of 490nm absorbance is therefore directly proportional to the number of 
living cells in culture.  
 
All MTS assays were performed in 96 well plates with cell free wells to act as 
blanks, the assay was performed following the manufacturer’s instructions. Cells 
(F21, SMB, SMB-PS or N2a) were plated and treated as described above. MTS was 
made up at 2 mg/ml in Dulbeccos phosphate buffered saline (DPBS) and PMS was 
made up at 0.96mg/ml in DPBS. 2mls of MTS and 100µl of PMS were mixed 
immediately prior to addition to cells, 20µl was added to each well and the cells were 
incubated in the dark at 37oC for 1-4h and then read at 490nm on a 
spectrophotometer in order to determine cell viability. 
2.2.6 Measurement of Reactive Oxygen Species (ROS) 
 
Direct measurement of cellular reactive oxygen species was made using a 96 well 
plate assay using a fluorescent probe, CM-H2DCDFDA. This probe is non-
fluorescent until the acetate groups are removed by intercellular esterases and 
oxidation occurs within the cell when it emits a florescence that can be measured at 
excitation and emission of 488 and 534nm. As CM-H2DCDFDA is cell permeable 
until oxidised it allows measurement of cellular production of ROS. Oxidation can 
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be induced by H2O2 (in the presence of endogenous metal ions), peroxynitrite, 
organic hydroperoxides and nitric oxide (Martin et al., 1998). 
 
F21 or SMB cells were plated at 90-95% confluency and maintained at 37oC, 5% 
CO2 overnight, to allow the cells to adhere. Cells were then treated with the PrP prior 
to the addition of the probe or the media removed and replaced by 50µl of 5µM 
probe in PBS (phosphate buffered saline). The cells were then incubated in the dark 
for 20 minutes. The probe was then removed from the cells and replaced by 
OptiMeM. If the cells had not already been treated the test reagent was added to 3 
wells per experiment at this point. Fluorescence intensity was measured using a 
microplate reader with excitation and emission of 488 and 534nm respectively at 
time 0, 1h and 2h. 
2.2.7 Confocal Analysis 
 
F14 cells were plated out onto poly-L-lysine coated multi-well borosilicate slides at 
50% confluency and left overnight to adhere. Cells were then transfected as 
previously described and left for 48h. Cells were treated as appropriate then 
incubated for 4h. Images of the cells were taken using the Zeiss LS 550 confocal 
microscope. 
2.3 Cell signalling studies 
2.3.1 Protein Extraction 
 
In order to investigate cell signalling protein was extracted from SMB, SMB-PS and 
F21 cells for Western blotting. Cells from the appropriate cell line were plated out in 
order to achieve full confluency the following day in 24 well plates. Cells maintained 
at 37oC, 5% CO2 overnight, to allow the cells to adhere. The cells were the then 
treated as appropriate prior to extraction. The extraction buffer was made up using 
RadioImmunoPrecipitation Assay (RIPA) buffer consisting of 50mM Tris HCl (pH 
8), 150mM NaCl, 1% Igepal CA-630, 0.1% SDS and 1mM EDTA. A Complete 
tablet was added to the solution to provide inhibitors, 2µM sodium orthovandate and 
1µM PMSF were also added. 
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30µl of extraction buffer was added to each well and incubated at 4oC for 20 minutes 
to allow the cells to lyse. The protein was stored at –80oC prior to use. 
2.3.2 Western Blotting 
 
Protein was denatured by boiling for 5 minutes in Laemmli’s loading buffer 
(Laemmli, 1970), 20µg of protein was loaded on each well of a 12% SDS gel. The 
gel was run for 50 minutes at 35mA. The protein was transferred onto a 
nitrocellulose membrane using a Biorad semi-dry transfer apparatus. 
 
The membrane was blocked for 1 hour using either 5% malted milk (MM) or 5% 
bovine serum albumin (BSA) in Tris Buffered Saline (40mM Tris base and 0.15M 
NaCl) with 1% Tween (TBST). The membrane was then incubated overnight, with 
rocking, in primary antibody at the appropriate concentration (see table 2.1). The 
membrane was then washed for 15 minutes, on the rocker, with three changes of 
TBST and incubated in secondary antibody for 1 hour, with rocking, at the 
appropriate concentration (table 2.1) and washed as described previously. 
 
The membrane was then incubated with Millipore detection reagent for 5 minutes, 
any excess was then removed and the signal was visualised on X ray paper. Band 
intensity was quantified using Image J. Membranes were then stripped using a low 
pH stripping buffer (25mM glycine, 1%(w/v) SDS pH to 2 with concentrated HCl) 
as follows; the membranes were incubated in stripping buffer for 30 minutes with 
rocking. The membranes were then washed for 5 minutes in TBST with rocking. The 
membranes could then be re-probed with another antibody. 
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Primary Antibody Concentration Secondary Antibody Concentration Antibody dilutant 
Tubulin 1:15000 Anti-Mouse 1:10000 1% MM in TBST 
Actin 1:1000 Anti-Goat 1:2500 1% MM in TBST 
Caspase 3 1:500 Anti-Rabbit 1:2500 5% MM in TBST 
Caspase 9 1:1000 Anti-Rabbit 1:2500 5% MM in TBST 
ERK 1:500 Anti-Rabbit 1:2500 1% MM in TBST 
PERK 1:5000 Anti-Rabbit 1:2500 1% MM in TBST 
p-p38 1:500 Anti-Mouse 1:2500 1% MM in TBST 
p38 1:1000 Anti-Rabbit 1:2500 1% MM in TBST 
BiP 1:1000 Anti-Mouse 1:2500 1% MM in TBST 
p53 1:1000 Anti-Mouse 1:2500 1% MM in TBST 
ICSM-18 1:10000 Anti-Mouse 1:10000 1% BSA in TBST 
Caspase 12 1:1000 Anti-Rabbit 1:5000 1% MM in TBST 
pAKT 1:1000 Anti-Rabbit 1:2500 1% MM in TBST 
AKT 1:1000 Anti-Rabbit 1:2500 1% MM in TBST 
14-3-3 1:1000 Anti-Rabbit 1:5000 1% MM in TBST 
 
Table 2.1: A table showing all the primary antibodies used for western blotting. The 
concentration used the secondary used are also included. The antibody dilutant refers to the 
dilutant used for both the primary and secondary antibody. 
2.3.3 Inhibitor Studies. 
 
For inhibitor toxicity studies SMB and SMB-PS cells were plated out in a 96 well 
plate and maintained at 37oC, 5% CO2 overnight, to allow cells to adhere. The ERK 
inhibitor PD98059 was dissolved in DMSO prior to addition to the cells. Cells were 
treated with varying concentrations of PD98059 for 16h. Viability was assessed 
using an MTS assay. For the protein studies SMB and SMB-PS cells were plated out 
in a 24 well plate and maintained at 37oC, 5% CO2 overnight, to allow cells to 
adhere. The PD98059 was dissolved in DMSO prior to addition to the cells. Cells 
were treated with varying concentrations of PD98059 for 1h and pERK expression 
was assessed by western blotting. 
 
For inhibitor toxicity studies, using a PKA inhibitor, SMB and SMB-PS cells were 
plated out in a 96 well plate and maintained at 37oC, 5% CO2 overnight, to allow 
cells to adhere. Cells were treated with varying concentrations of H89, PKA inhibitor 
for 24h. Viability was assessed using an MTS assay. For the protein studies SMB 
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and SMB-PS cells were plated out in a 24 well plate and maintained at 37oC, 5% 
CO2 overnight, to allow cells to adhere. Cells were treated with varying 
concentrations of H89 for 4h and pERK expression was assessed by western 
blotting. 
2.4 Data Analysis 
 
Intensity of measurements of live cell images was made using the Zeiss LSM 
software. Band intensity measurements for Western blots were made using Image J 
software, for all intensity reading a background measurement was subtracted from 
the values to eliminate any interference. All toxicity data was analysed using 
Microsoft Excel. One-way ANOVA was used for determining point differences on 
data points were considered to be significant once P<0.05 and F>1. A Students T-test 
was used for comparison of single points. A two tailed test assuming unequal 
variances was used. There was considered to be a significant difference once P<0.05.  
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3. Manganese and PrP Toxicity 
 
Previous studies assessing the toxicity of PrP have used a variety of different models 
to investigate the mechanism of neuronal loss in prion disease. Some studies use PrP 
either purified from infected tissue or recombinant protein that has been misfolded or 
aggregated using a variety of methods including using SDS (Post et al., 2000; Stohr 
et al., 2008). More unusually transmembrane (Hegde et al., 1998) or cytosolic forms 
(Norstrom et al., 2007) of PrP have been used. Due to the difficulties in purifying 
large quantities of PrPsc, many studies use synthetic peptides such as the well 
researched 106-126 peptide (Forloni et al., 1993) (Brown et al., 1994). However, it 
has been suggested that, as this peptide would not be found in vivo its use may not be 
an accurate representation of prion toxicity. Several studies have also used truncated 
forms of the prion protein, including C-terminus fragments with disease related 
mutations (Daniels et al., 2001).  
 
Manganese has been hypothesized to be an important factor in prion disease, as  
studies have shown a perturbation of metal levels in sheep with scrapie and cows 
with BSE (Hesketh et al., 2007) and humans with CJD (Hesketh et al., 2008). The 
most striking result in these studies was an increase in manganese in certain areas of 
the brain and in the blood. Moreover, PrP can bind manganese, although the affinity 
of manganese was reported to be much lower than that of copper (Jackson et al., 
2001). However recent work has shown that manganese binds to PrP with an affinity 
similar to that of several manganese binding proteins suggesting that the prion 
protein may be able to bind manganese in vivo (Brazier et al., 2008). 
 
There is evidence that PrP bound to manganese displays PrPsc-like qualities, 
including an increase in β-sheet content, increased PK (proteinase K) resistance and 
a tendency to aggregate (Brown et al., 2000). This has led to the hypothesis that PrP 
bound to manganese may be important in the disease pathogenesis. However, so far 
there has been no comprehensive study on the effect of manganese bound PrP on 
neuronal cells. Given the shared characteristics between MnPrP and PrPsc, 
investigating MnPrP may further our understanding of prion disease. It has been 
established that prion disease leads to neuronal cell death, which is thought to be 
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caused by the toxicity of PrPsc. Therefore the first part of this study intends to 
characterise the toxicity of the protein to neuronal-like cells. We intended to 
investigate the toxicity of MnPrP using neuronal cell lines. The cell lines used were 
the F21 cell line, a neuroblastoma fusion cell line and the N2a cell line, a well 
characterised neuroblastoma cell line that has previously been shown to be 
susceptible to PrPsc toxicity and infection. We showed MnPrP was toxic to both 
these cell lines. The results also confirmed the use of MnPrP as a suitable model of 
toxicity for use in further studies. 
 
One of the puzzles of prion research is the ability of cells infected with scrapie to 
carry infection through repeated passages without any loss of cell viability. This is in 
contrast to animal models of mice and sheep infected with scrapie, where the animals 
suffer massive neuronal loss after infection (Fairbairn et al., 1994; Giese et al., 
1995). We investigated toxicity in SMB and SMB-PS cell lines. These cell lines 
were originally derived from a mouse infected with the Chandler strain of scrapie 
(Clarke and Haig, 1970), the SMB-PS cell line has been successfully cured of 
scrapie using pentosan sulphate (Birkett et al., 2001). The results demonstrated that 
MnPrP is toxic to both SMB and SMB-PS cells and that, as in the case of PrPsc, this 
cell death is due to apoptosis. We hypothesise that cells infected with scrapie may be 
able to survive as the levels of PrPsc produced by the cells may not be sufficient to 
cause toxicity. 
3.1 Purification of PrP 
 
Full-length mouse PrP (amino acids 23-231) was cloned into a pET23a vector with a 
6 histidine tag on the C-terminal end of the protein to allow purification. The protein 
was transformed into E Coli and expression was induced using IPTG. The protein 
was purified using nickel chelating sepharose IMAC column. The resulting protein 
was then separated on a SDS-PAGE gel and stained with coomassie to establish 
purity (figure 3.1a) and Western blotting was used to confirm it was mouse PrP 
(figure 3.1b) 
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Figure 3.1: Representative blots of purified WT recombinant PrP. A: A representative gel of 
column washes and protein eluate, 20µl was loaded into each lane of a 12% SDS gel. The gel 
was then stained and the purity of the eluate was assessed. B: A representative western blot 
using the PrP specific antibody ICSM-18 showing washes and an elution  
 
PrP without a 6 his-tag was also used for certain experiments. This construct was 
purified using one of two methods, either using a copper chelating sepharose column 
(figure 3.2) or using a wash method. With both methods, the purity of the protein 
was assessed by comassie staining. 
 
 
 
 
 
 
 
 
 
Figure 3.2: Representative gel of purified non-his-tagged PrP. A: A representative gel of column 
washes and protein eluate from a copper column, 20µl was loaded into each lane of a 12% SDS 
gel. The gel was then stained and the purity of the eluate was assessed. 
 
The purified protein was  refolded in the presence of manganese as previously  
described in (Brown et al., 2000) prior to extensive dialysis to remove any excess 
manganese. Mass spectrometry  analysis revealed that the full length protein was 
able to bind two atoms of manganese (Uppington and Brown, 2008). 
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3.2 Toxicity of Manganese bound PrP (MnPrP) 
 
Work had assessed the toxicity of MnPrP on primary neuronal cultures (Uppington 
and Brown, 2008), as primary neurones expressing PrPc have been shown to be 
susceptible to PrPsc. In order to test MnPrP toxicity, cultures of cerebellar granule 
neurons (CGNs) from wild-type and PrP knockout mice were prepared and treated 
with either MnPrP or apoPrP (water refolded PrP) for 48h. Viability was then 
assessed using a MTT cell proliferation assay. The MTS assay is a colorimetric 
method for determining viability. 
 
The MnPrP was significantly more toxic to CGNs than apoPrP, however there was 
no difference in toxicity between MnPrP and apoPrP in PrP-knockout cultures 
(figures 3.3). When the toxicity of MnPrP in knockout cell lines was compared to the 
toxicity of MnPrP in WT cells there was a significant increase in toxicity in WT 
cells. This suggests that cellular PrP expression is required for MnPrP induced 
toxicity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:Toxicity of MnPrP to primary CGNs. Primary cultures of WT (squares) or KO-PrP 
(circles) CGNs were treated for 48h with varying concentrations of MnPrP (Black symbols) or 
apoPrP (open symbols). Survival was assessed using an MTT assay. MnPrP was significantly 
toxic to cells at dosages above 1µg/ml as assessed by students T-test. Error bars are SEM each 
point represents at least 4 repeats. 
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To exclude the possibility that the toxicity observed was due to the manganese 
present in the protein we tested the toxicity of MnSO4 to cells. Cells were treated for 
48h with varying concentrations of MnSO4 and cell viability was assessed by an 
MTS assay, MTS is soluble and in the presence of mitochondrial activity it 
undergoes a colour change, allowing a quantitative analysis of cell viability. 
Significant cell death was observed at doses above 10µM. Mass spectroscopy 
analysis revealed that MnPrP binds two manganese atoms per molecule, implying 
that treatment of cells with up 125µg/ml MnPrP would not result in manganese 
toxicity in cells treated for 48h (figure 3.4). Further experiments have revealed that 
doses up to 175µg/ml were not toxic to F21 cells (Uppington and Brown, 2008). 
 
Figure 3.4: Manganese toxicity to F21 cells. F21 cells were treated for 48h with increasing 
concentrations of MnSO4. Cell viability was then assessed using an MTS assay, a cell 
proliferation assay. MnSO4 was found not to be toxic to cells up to a concentration of 10µM 
(p=0.55 as tested by students T test). Graph depicts cell viability compared to control. N=6 
(Error bars are SEM) * Shows significant points. 
 
In order to further develop a model of toxicity we choose to use neuroblastoma cell 
lines. We investigated MnPrP toxicity in F21 cells a fusion neuroblastoma cell line 
that has been shown to express the neuronal marker including Neu-N, and express 
PrP. Toxicity was also investigated in the well characterised N2A cell line, a 
neuroblastoma cell line that has been shown to express PrP. 
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We treated F21 cells with a variety of concentrations of MnPrP, and assessed 
toxicity over a range of time points. In order to assess viability we used an MTS 
assay. No significant cell death was seen at 6h, however by 24h significant cell death 
was seen at a dose of 40µg/ml and this was repeated at 48h. A significant increase in 
death between 24 and 48h was also observed when comparing the 40µg/ml dose. By 
72h, there appeared to be a slight decrease in cell death, although this was not 
significant (figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Toxicity of MnPrP over time.  F21 cells were treated with increasing concentrations 
of MnPrP for either 6h (A), 24h (B), 48h (C) or 72h (D). Cell viability was then assessed using 
an MTS assay. N=4 (Error bars are SEM). * Significant points were assessed by Students T-test. 
 
Having established the toxicity of MnPrP in F21 cells we tested the toxicity of both 
MnPrP and apoPrP (water refolded PrP) to F21 cells. F21 cells were treated with 
MnPrP or apoPrP for 48h and cell viability was assessed by MTS assay. MnPrP was 
found to be significantly more toxic to F21 cells than apoPrP, leading us to the 
conclusion manganese binding to PrP is important in toxicity, although unlike the 
results observed in primary neuronal cultures apoPrP was toxic to F21 cells (figure 
3.6) 
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Figure 3.6: Toxicity of MnPrP and apoPrP to F21 cells. F21 cells were treated for 48h with 
increasing concentrations of either MnPrP (red line) or apoPrP (Green line). Cell viability was 
then assessed using an MTS assay. Graph depicts cell viability compared to control. N=10 
(Error bars are SEM). Significance was assessed using a one-way ANOVA p<0.05. 
 
To ensure the toxicity observed in F21 cells was reproducible in other cell lines we 
investigated the toxicity of MnPrP in N2A cells. The N2a cell line is a well 
established neuronal cell line that has been shown to be susceptible to both infection 
(Butler et al., 1988) and PrP toxicity (Hetz et al., 2003b). F21 and N2a cells were 
treated for 48h with MnPrP, and viability was assessed using a MTS assay. Both F21 
and N2a cells were shown to respond in a similar dose dependant manner to MnPrP 
(figure 3.7). The levels of manganese added to the N2a cells were are not 
significantly toxic to the cells (data not shown).  
 
We also investigated the effect of MnPrP on a knockout cell line. F14 cells were 
treated for 48h with MnPrP and viability was assessed using an MTS assay. There 
was significant increase in cell death observed in WT cells when compared to knock-
out cells (figure 3.8).  
 
We have shown that MnPrP is toxic to cell lines, although a higher concentration is 
required to induce cell death than observed in primary cultures, we were also able to 
show that cell lines that do not express PrP are not susceptible to MnPrP toxicity. 
Finally we demonstrated that apoPrP was less toxic than MnPrP. 
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Figure 3.7: Toxicity of MnPrP to N2a cells. F21 (red line) and N2a (Green line) cells were 
treated for 48h with increasing concentrations of MnPrP. Cell viability was then assessed using 
an MTS assay, N=6 (Error bars are SEM). No points were significant as determined by one-way 
ANOVA.  
 
Figure 3.8: The toxicity of MnPrP to PrP null cells.  F14 and F21 cells were treated for 48h with 
80µg/ml of MnPrP. Cell viability was then assessed using an MTS assay, N=3(Error bars are 
SEM). P<0.05 as tested by Students T-Test. 
 
Previous reports have suggested that when PrP is initially bound to manganese, it 
displays characteristics similar to PrP bound to copper, however, if the protein is 
aged for 2 weeks it becomes more protease resistant and there is an increase in β-
sheet structure (Brown et al., 2000). In order to investigate whether aging was 
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important in the toxicity of the protein we treated cells with aged or un-aged protein. 
Protein was bound to manganese as previously described and then allowed to age at 
–20oC for two weeks. This was compared to fresh MnPrP made immediately prior to 
the experiment. F21 cells were incubated with 40 µg/ml of MnPrP for 48h and 
toxicity was assessed using an MTS assay. We found that aged MnPrP was 
significantly more toxic to F21 cells than fresh PrP (figure 3. 9) this suggests that the 
ageing process not only changes the physical properties of MnPrP but increases its 
toxicity to cells. 
 
Figure 3.9: The toxicity of aged and un-aged MnPrP. The toxicity of manganese PrP either 
fresh or aged for 2 weeks at –20oC was assessed using an MTS assay. Prior to the assay cells 
were treated with 40µg/ml MnPrP for 48h. Error bars are SEM. Each bar represents at least 5 
repeats. P<0.01 as assessed by students T-Test. 
 
In order to ensure that MnPrP was a sound model of PrP toxicity we wanted to 
ensure all excess manganese was removed from the protein, as the excess manganese 
could be toxic to the cells. We also wanted to investigate the survival of the protein 
in culture, as survival in culture may play a role in toxicity, and finally we wanted to 
investigate whether the his-tag played any role in MnPrP toxicity. 
 
Extensive dialysis is used to remove any excess manganese from MnPrP prior to its 
addition to cells. Previous work by (Brown et al., 2000) had used MnPrP that had 
been aged and then dialysed, however we decided to perform dialyse before aging, in 
order to ensure the complete removal of any excess manganese. F21 cells were 
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treated for 48h with 80 µg/ml MnPrP. We found that there was a significant increase 
in toxicity in cells treated with PrP that had been dialysed before aging however this 
difference was small (figure 3.10). 
 
Figure 3.10: The effect of dialysis on the toxicity of MnPrP. Viability of F21 cells incubated for 
48h with 80µg/ml MnPrP either, dialysed and aged for 2 weeks (manganese dialysed) or aged 
for 2 weeks and then dialysed (manganese aged), as assessed by MTS assay. Graphs show 
viability compared to control. (Error bars are SEM) Each bar represents at least 6 repeats. 
P<0.01 as assessed by students T-Test. 
 
To exclude differences in toxicity observed between apoPrP and MnPrP being due to 
apoPrP degrading more quickly in culture, the ability of MnPrP and apoPrP to 
survive in culture was tested. MnPrP or apoPrP was incubated at 37oC in media with 
or without cells for at least four days. We found that apoPrP was able to survive in 
culture for 4 days. Interestingly, we found that apoPrP was cleaved in the presence of 
F21 cells giving a product of about 16kDa (figure 3.11). MnPrP was also able to 
survive in culture for up to 4 days and was also cleaved in the presence of cells (data 
not shown). 
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Figure 3.11: The ability of apoPrP to survive in culture. 80µg/ml apoPrP was incubated at 370C 
either media alone or with F21 cells and the media was removed for analysis. 20µl of media was 
separated on a 12% SDS-PAGE gel. The gel was transferred onto nitrocellulose and western 
blotted with ICMS-18 a monoclonal antibody against PrP. 
 
As the protein we were using was his-tagged we investigated whether the his-tag had 
any influence on the toxicity of the MnPrP. There was no significant difference in 
toxicity between the tagged and untagged protein suggesting that the his-tag plays no 
part in MnPrP toxicity (figure 3.12a). The toxicity of recombinant untagged PrP was 
also investigated was found to be significantly less toxic than MnPrP (figure 3.12b). 
 
 
Figure 3.12: The toxicity of non-his-tagged PrP. A: F21 cells were treated for 48h with either 
untagged WT MnPrP (red line) or tagged MnPrP (green line). Cell viability was then assessed 
using an MTS assay (error bars are SEM.) B: F21 cells were treated for 48h with either 
untagged apoPrP (blue line) or untagged MnPrP (green line). Cell viability was then assessed 
using an MTS assay. (Error bars are SEM.) Significant points were assessed using a one-way 
ANOVA p<0.05. Each point represents at least 4 repeats. 
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3.3 Properties of MnPrP. 
 
We have also shown that aged MnPrP is partially resistant to proteinase K. MnPrP 
was incubated with varying concentrations of PK for 30 minutes. MnPrP showed 
some level of PK resistance at all concentrations tested, which is in direct contrast to 
apoPrP which was fully digested by all but the lowest concentration of PK (figure 
3.13). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: The PK resistance of MnPrP and apoPrP. MnPrP and apoPrP were treated for 30 
minutes with varying concentrations of PK. The protein was then separated on a 12% SDS-
PAGE gel and Western blotted using ICMS-18, a specific monoclonal PrP antibody. 
3.4 Cell death induced by MnPrP in infected cells 
 
The toxicity of MnPrP was also investigated in infected cells. The SMB cell line, a 
cell line persistently infected with scrapie and SMB-PS cells, a cell line cured using 
pentosan sulphate, were used. The SMB cell line, like several other scrapie infected 
cell lines has been shown to survive with the infection. Cells were treated for 48h 
with varying concentration of his-tagged MnPrP and viability was assessed using an 
MTS assay. His-tagged PrP was used for the remainder of experiments in this thesis 
unless otherwise stated. 
0         80               8            4           0.8 µg/ml PK 
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- 64 - 
 
0
20
40
60
80
100
120
140
20 70 120 170
%
 
Ce
ll v
ia
bi
lity
 
co
m
pa
re
d 
to
un
tre
at
ed
 
co
nt
ro
l
µg/ml MnPrP
 
Figure 3.14: Toxicity of MnPrP to scrapie infected and cured cells. SMB (red line) or SMB-PS 
(blue line) cells were treated for 48h with increasing concentrations of MnPrP. Cell viability was 
then assessed using an MTS assay, a cell proliferation assay. Graph depicts cell viability 
compared to control. N=3 (Error bars are SEM) 
 
Cells died in similar manner to F21 and N2A cells suggesting resistance to scrapie 
infection did not prevent cell death mediated by MnPrP (figure 3.14).  
 
In order to understand the mechanism of cell death we investigated whether 
apoptotic signals were activated in response to MnPrP. To confirm that MnPrP 
caused apoptosis, we investigated whether MnPrP caused caspase 3 cleavage in 
SMB cells. Several previous reports have shown caspase 3 activation both in cells 
treated with the 106-126 peptide (Thellung et al., 2002) and in the brains of mice 
infected with scrapie (Jamieson et al., 2001). Caspase 3 activation is one of the final 
steps in the induction in apoptosis. Cells were treated for 4, 8, 16 and 24h with 
80µg/ml MnPrP and caspase 3 cleavage was assessed using Western blotting. 
Caspase 3 cleavage was seen after 16h of treatment with MnPrP (figure 3.15). 
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Figure 3.15: Caspase 3 cleavage in infected cells treated with MnPrP. SMB cells were treated 
with 80µg/ml PrP for varying lengths of time. Cellular protein was extracted using RIPA buffer 
and proteins were separated on an SDS-PAGE gel. Caspase 3 expression and activation was 
assessed using western blotting. Lane 1: 0h, Lane 2: 4h, Lane 3: 8h, Lane 5: 16h, Lane 6: 24h. 
 
To investigate this phenomenon further we treated both SMB and F21 cells with the 
106-126 peptide and the octarepeat peptide (amino acids 51-90). Both F21 cells and 
SMB cells were sensitive to treatment with the peptide (figure 3.16) confirming that 
SMB cells are sensitive to PrP toxicity despite resistance to scrapie infection. 
 
 
Figure 3.16: Toxicity of 106-126 to both F21 cells and scrapie infected cells. Cells were treated 
for 48h with increasing concentrations either 100 µM control peptide (green) or 106-126 (red). 
Cell viability was then assessed using an MTS. Graph depicts cell viability compared to control. 
(Error bars are SEM) n=4. Significant cell death was seen in cells treated with 106-126 peptide 
when compared to cells treated with the control peptide in both F21 and SMB cells as tested by 
students T-Test p>0.01. 
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We hypothesised that the infection in SMB cells might produce low levels of PrPsc 
that allow the cells to survive infection. To investigate this we treated the both F21 
and SMB cells with PK digested SMB lysate for 24h prior to the addition of MTS, 
no evidence of cell death was observed even at the highest concentration of lysate. 
This may be due to the low levels of PrPsc expressed by SMB cells. Previous work 
has shown that infected cultures may only contain as few as 1% infected cells 
although in certain cells lines this can increase to 13% (Nishida et al., 2000; Race et 
al., 1987). Work in our lab has also shown that over expression of PrP in SMBs by 
stable transfection is not possible for more than a few passages suggesting cells with 
more PrPc available to convert to PrPsc either divide slower or are unable to survive 
(unpublished data) (figure 3.17). 
 
Figure 3.17: Toxicity of SMB cell lysate. A: SMB cell lysates were extracted and digested with 
PK the resulting digest was then concentrated and Western blotted using a PrP specific 
antibody ICSM-18 an un-concentrated un-digested sample was also run. B: SMB cells (blue) or 
F21 cells (red) were treated for 48h with increasing concentrations of PK digested SMB lysate. 
Cell viability was then assessed using an MTS assay, a cell proliferation assay. Graph depicts 
cell viability compared to control. N=4 (Error bars are SEM). 
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3.5 Discussion 
 
There has been extensive research into prion diseases, most of it using models. Work 
using mouse models has revealed that the disease is caused by a novel infectious 
protein termed a prion (Prusiner, 1982). Work in mouse models also demonstrated 
that the propagation of PrPsc and hence the disease requires cellular PrP expression 
(Brandner et al., 1996; Bueler et al., 1993; Prusiner et al., 1993; Weissmann et al., 
1994). The level of expression of PrPc can affect the incubation time of the disease, 
but not the final pathology. Over-expression results in a shorter disease incubation 
time (Fischer et al., 1996) and lower PrPc expression results in a longer incubation 
period (Bueler et al., 1994). 
 
It has been demonstrated that the massive neuronal loss observed in prion disease is 
due to neuronal apoptosis (Fairbairn et al., 1994; Giese et al., 1995), although the 
signalling pathway leading to apoptosis remains unclear. Work on animal models 
also revealed a species barrier, transmission of classical CJD to mice is difficult and 
often fails, however transmission to transgenic mice expressing only the human 
prion protein lacks a species barrier (Collinge et al., 1995b). Mouse models also 
provided the first evidence that PrPsc assembles into filaments within the brain and 
that these filaments accumulate in extracellular spaces to form amyloid plaques 
(DeArmond et al., 1985). Animal models can provide a wealth of information on 
prion diseases however, they are expensive and cell culture models often provide 
more information at the cellular level. 
 
Cell culture models using PrPsc purified from infected brains replicate many of the 
properties of prion diseases observed in vivo. PrPsc is toxic to neuronal cells in vitro 
(Post et al., 2000), and cell death is due to apoptosis (Hetz et al., 2003b). However 
the difficulty of purifying large quantities of PrPsc has meant that alternate models 
of prion disease have been developed.  
 
Much early work used peptides, and they are still widely used as a model of prion 
toxicity today. Perhaps the most widely used is a short peptide sequence of human 
PrP encompassing the amino acids 106-126. This region has several of the properties 
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associated with PrPsc including the tendency to aggregate (Forloni et al., 1993) and a 
high level of β-sheet structure (Selvaggini et al., 1993). The 106-126 peptide is 
selectively toxic to PrP expressing neurones (Brown et al., 1994), however the 
validity of using the peptide has been called into question as although this sequence 
is present in several longer peptides isolated from cerebral amyloid plaques of 
patients suffering from GSS (Ghetti et al., 1996), the PrP 106–126 peptide has never 
been found in vivo. 
 
There have been increasing numbers of studies that use recombinant PrP that has 
been converted into misfolded, aggregated, and protease resistant forms like PrPsc 
using chemicals such as SDS (Stohr et al., 2008) or exposure to harsh denaturants 
and shaking (Novitskaya et al., 2006). These chemicals would not be found at these 
concentrations in tissue and as such do not represent a conversion that could take 
place in vivo. Several studies have used truncated versions of the prion protein, such 
as the 90-231 fragment rather than using the full-length protein (Corsaro et al., 2006; 
Thellung et al., 2007). 
 
Previous studies have demonstrated that amyloid fibrils of recombinant PrP are toxic 
to both primary neuronal cells and cell lines. Down-regulation of PrPc expression 
resulted in a decrease in toxicity (Novitskaya et al., 2006). This suggests that toxicity 
requires cellular PrP expression. Full-length recombinant PrP that has an α-helical 
structure and is not aggregated has been shown not to be toxic to neuronal cells 
(Novitskaya et al., 2006) suggesting structure is important for toxicity. Studies using 
a thermally denatured fragment of PrP have also shown that the conversion to a β-
sheet structure from a α-helical structure results in an increase in toxicity (Corsaro et 
al., 2006). 
 
Studies using recombinant PrP have demonstrated its usefulness as model of prion 
disease, as it replicates several of the hallmarks of prion disease, it causes neuronal 
apoptosis, once converted into an amyloid form and toxicity requires cellular prion 
expression. As recombinant PrP has been shown to be a suitable model of prion 
disease, we choose to use it in this study. PrP bound to manganese has been shown 
to demonstrate several of the properties of PrPsc (Brown et al., 2000), however there 
had been limited studies investigating the toxicity of MnPrP. 
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Our study has shown that MnPrP is toxic to neuronal cells and is selectively toxic to 
PrP-expressing cells. Toxicity was dependent on manganese binding to PrP in 
primary cultures and significantly increased its toxicity to F21 cells, suggesting that 
manganese binding plays an important role in prion toxicity in our model. We also 
showed that MnPrP was partially resistant to PK digestion. Previous work had 
shown that MnPrP contained increased levels of β-sheet structure, which has been 
shown to be important for toxicity, and an intact disulphide bridge (Brown et al., 
2000; Wong et al., 2001b). Thus MnPrP reproduces many of the characteristics of 
PrPsc and we suggest it can be used as a valid model of prion toxicity in vitro. 
3.5.1 The Prion Protein and Metal Binding 
 
Our model uses aberrant metal binding to covert the recombinant PrP to a more toxic 
form. Metal binding is thought to be important for the function of the prion protein 
and copper binding has been suggested to provide structure in the relatively 
unstructured N-terminal region of the prion protein (Jones et al., 2004) as well as 
effecting the structure of the C-terminal region (Zhu et al., 2008). The prion protein 
has been shown to bind copper in vivo (Brown et al., 1997a). It has also been shown 
to bind several other transition metals in vitro (Brazier et al., 2008; Jackson et al., 
2001). 
 
Several investigations using recombinant PrP and PrP peptides have shown that 
manganese can bind to PrP (Brown et al., 2000; Gaggelli et al., 2005; Jackson et al., 
2001; Treiber et al., 2007). Perhaps the most comprehensive study to date, by 
Brazier et al, has demonstrated that one manganese atom can bind to the octarepeat 
region, however the highest affinity binding occurs at the fifth site (amino acids 
95,110). The affinity of manganese to be PrP has been shown to be comparable to 
several other manganese binding proteins, suggesting that manganese binding to PrP 
is physiologically relevant (Brazier et al., 2008).  
 
MnPrP has been shown to have an increased β-sheet content (Brown et al., 2000) 
and further work has shed more light on the structural changes that occur when the 
prion protein binds manganese. Studies using near infrared spectroscopy have shown 
that while bound to copper PrP is stable in aqueous solution, manganese bound PrP 
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is not protected from interactions with water and forms fibrils in an aqueous solution 
(Tsenkova et al., 2004). Work using Raman Spectroscopy showed that the initial 
binding of manganese to PrP resulted in an increase in α-helical structure (Zhu et al., 
2008). As this is in contrast to work on aged protein that showed an increase in β-
sheet structure (Brown et al., 2000), this suggests that ageing of manganese bound 
PrP is required to produce a PrPsc-like structure. This correlates with our earlier work 
showing that aging is required to increase toxicity of MnPrP. 
 
Our model may also have some in vivo relevance; there is increasing evidence to 
suggest manganese may be involved in prion disease. It has been demonstrated that 
manganese levels are raised in both blood and the CNS of patients suffering from 
prion disease (Hesketh et al., 2008) as well as in cattle infected with BSE and sheep 
infected with scrapie (Hesketh et al., 2007). Manganese is also associated with PrP 
purified from infected brains and cultured cells (Brown et al., 2000; Thackray et al., 
2002; Wong et al., 2001b).  
 
The concentration of MnPrP required to induce cell death in both N2a and F21 cells 
was relatively high. However other studies using full-length recombinant PrP in a 
PrPsc like form have used concentrations of about 10 µg/ml to induce apoptosis in 
SH-SY5Y cells (Novitskaya et al., 2006), this is in the same concentration range 
required to induce toxicity in our model although much higher doses were required 
to produce a complete toxicity curve.  
 
Initial studies have demonstrated that MnPrP is a valid model of prion disease, 
however the mechanisms leading to cell death remain unclear. There are several 
studies that investigate manganese binding to the prion protein and its effect on 
structure (Brazier et al., 2008; Treiber et al., 2007; Zhu et al., 2008). However as yet, 
studies have not investigated the regions of PrP that are involved in the structural 
conversion that occurs when PrP binds manganese and the regions required for metal 
binding, leading to cellular toxicity. This work would help us to understand the 
regions important in MnPrP toxicity. 
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3.5.2 Manganese Toxicity 
 
As manganese is highly toxic to neurones it could be hypothesised that the cell death 
observed in our model is due to manganese toxicity. Our investigations have clearly 
shown that the levels of manganese added to the cultures, whilst approaching 
toxicity at the highest dose, do not cause the massive cell death observed when the 
cells are treated with MnPrP. Chronic manganese poisoning leads to symptoms 
resembling idiopathic parkinsonism (Calne et al., 1994). At the cellular level it has 
been demonstrated that manganese induces apoptotic cell death in PC12 cells, a rat 
pheochromocytoma cell line, however this cell death is not caspase dependant (Roth 
et al., 2000) unlike the cell death observed in our model which is due to caspase 3 
activation. Therefore we can exclude manganese toxicity as the cause of cell death in 
our model. 
3.5.3 Metal Imbalance and Other Neurodegenerative Diseases. 
 
As well as studies suggesting that aberrant metal binding may be involved in prion 
disease there is increasing evidence that metal imbalance maybe relevant in other 
neurodegenerative diseases. In Alzheimer's disease (AD) high levels of copper, zinc, 
and iron are found in and around amyloid plaques (Lovell et al., 1998). Previous 
studies have shown that amyloid beta (Aβ), the main constituent of amyloid plaques 
in the brains of AD patients, can bind copper and zinc (Talmard et al., 2007; Tougu 
et al., 2008). Copper binding to Aβ 25-35 has been shown to promote conversion to 
a more β-sheet structured peptide that is more toxic in vitro (Giuffrida et al., 2007). 
Interestingly it has also been suggested that zinc binding to Aβ can cause 
aggregation (Tougu et al., 2008), however the addition zinc to cells in culture can 
prevent Aβ induced apoptosis by preventing Aβ aggregation (Cardoso et al., 2005). 
 
Alpha-synuclein is a protein associated with Parkinson’s disease. It has been shown 
to bind copper (Rasia et al., 2005) and iron (Binolfi et al., 2006; Golts et al., 2002). 
Both copper (Rasia et al., 2005) and iron have been shown to increase alpha-
synuclein aggregation (Ostrerova-Golts et al., 2000). However there is no direct 
evidence that metal binding increases the toxicity of alpha-synuclein. 
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This suggests that out model using aberrant metal binding may also be useful to 
model other neurodegenerative diseases as there is increasing evidence that metals 
play a role in neurodegenerative diseases. 
3.5.4 Chronic Scrapie Infection 
 
Cell lines chronically infected with scrapie have been widely used as tools for prion 
research, especially for investigating possible compounds useful for prion 
therapeutics (Pankiewicz et al., 2006; Webb et al., 2007). Certain cell lines seem to 
be able to maintain scrapie infection without any detrimental effect to the cell line. 
One such cell line is the SMB cell line, which is infected with the Chandler strain of 
scrapie (Clarke and Haig, 1970). 
 
We investigated the toxicity of MnPrP on SMB cells, interestingly we found that 
scrapie infected cells were susceptible to MnPrP toxicity and cell death was 
apoptotic. Further investigation revealed that scrapie infected cells were also 
susceptible to the toxic peptide PrP 106-126, as were F21 cells. We hypothesised 
that scrapie infected cells were vulnerable to MnPrP toxicity as they are not resistant 
to PrP toxicity, as is often assumed, but that the levels of PrPsc produced by the 
scrapie infected cells are low enough to be tolerated by the cells. This fits with 
previous work which has demonstrated that whilst cells can be infected with scrapie 
the infection rate can be as low as 1% in N2a cells (Race et al., 1987) rising to 13% 
infection in N2a cells over expressing PrP (Nishida et al., 2000). It also fits with 
observations in our laboratory that the availability of more PrPc, which can be 
converted to PrPsc is detrimental to the cells. As over-expression of PrP by stable 
transfection is not possible as cells lose expression after a few passages either due to 
slowing of division or death of transfected cells. 
 
In order to investigate this hypothesis we treated both scrapie infected and F21 cells 
with PK digested lysate obtained from scrapie infected cells. This was shown not to 
be toxic to the cells, leading us to the conclusion that our hypothesis was correct and 
scrapie infected cells express levels of PrPsc that are low enough to be tolerated by 
the cells. However it may be useful, in future work, to confirm our hypothesis that 
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SMB cells have a low level of infection by investigating the percentage of cells that 
are producing PrPsc. 
 
This chapter has shown that MnPrP is a suitable model of PrPsc. It demonstrates 
many of the properties of PrPsc, including an increase in β-sheet structure (Brown et 
al., 2000) and increased protease resistance. As it the full-length prion protein it is 
relevant in vivo unlike some peptides. There is also increasing evidence that 
manganese binding to the prion protein could occur in vivo (Brazier et al., 2008), 
suggesting that this model could represent a real disease mechanism.  
 
Work treating SMB cells with MnPrP has demonstrated that cell death in infected 
cells is as a result of apoptosis. It would be useful to confirm that the cell death 
observed in F21 cells is due to apoptosis. Further investigation into the cell 
signalling mechanism that leads to apoptosis may provide possible therapeutic 
targets and work will also investigate the regions of MnPrP required for toxicity, this 
will help us to understand the regions important in the conversion of the prion 
protein into a toxic form. 
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4. PrP Toxicity 
 
Previous studies have demonstrated that once PrP is converted from the normal 
cellular form to PrPsc it is toxic to neurones. The toxicity of PrPsc has been replicated 
using a variety of models, including peptides (Chabry et al., 2003; Forloni et al., 
1993), recombinant protéine (Novitskaya et al., 2006) and expression of toxic 
mutants of PrP (Norstrom et al., 2007). The toxicity of the protein appears to be tied 
the increase in β-sheet that occurs when PrPc is converted to PrPsc. In vitro the 
increase in β-sheet content observed in PrPsc has been replicated using a variety of 
methods, including the addition of chemicals such as SDS (Xiong et al., 2001) or by 
the addition of metals, including manganese (Kim et al., 2005). 
 
PrP is able to bind manganese at two sites in the protein, these binding sites are in 
the octarepeat region (Jackson et al., 2001) and the so called fifth site (Brazier et al., 
2008). The fifth binding site consists of two histidines located at amino acids 95 and 
110 that have been shown to bind copper. A Met at residue 121 is also involved in 
this binding (Gaggelli et al., 2005). Manganese also binds at this site but in a 
differing manner, as it does not displace copper (Brazier et al., 2008). The octarepeat 
region also contains four potential binding sites located in the region stretching over 
amino acids 51-90. This region has been shown to bind manganese at low affinity. 
The octarepeat region also been hypothesised to be important in the disease, partly 
because an increase in the number of octarepeat regions from 5 up to 14 is one of the 
mutations observed in fatal familial insomnia, an inherited form of the disease 
(Collinge, 1997; Krasemann et al., 1995). Other investigations have also shown that 
mice expressing prion protein devoid of the octarepeat region have longer disease 
incubation times (Flechsig et al., 2000) leading to the belief that that this region has a 
role to play in the pathogenesis of the disease, although the octarepeat region is not 
thought be to be required for infection (Flechsig et al., 2000) suggesting a more 
complex picture. 
 
The C-terminus region has been shown to contain the only known histidine mutation 
involved in inherited forms of the disease, at amino acid 187 (Cervenakova et al., 
1999) as well as several other mutations involved in GSS. Cleaved fragments of the 
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C-Terminus have also been found in the brains of people suffering with CJD, and 
these fragments have been shown to be PK resistant (Zanuy et al., 2004). The C-
Terminus consists of three α-helices, one of which was been shown to be toxic to 
cells in the presence of copper, although why copper was required for toxicity was 
not clear (Thompson et al., 2000). Whilst there are three histidines in the C-Terminus 
it is not clear whether these can bind metals, the histidine at 140, has been shown not 
bind copper however the results for the other histidines remained much less clear due 
to aggregation of the peptides used (Cereghetti et al., 2001). Further work, using 
peptides has shown that histidine 187 may be able bind metals (Brown et al., 2004). 
 
Whilst there has been intensive study of the prion protein and the regions involved in 
toxicity the regions required for toxicity are still unclear. This study intends to 
investigate the effect of manganese on prion protein toxicity, as it has been 
hypothesised that manganese binding to the prion protein may be involved in the 
pathogenesis of prion disease. Any regions involved in the toxicity of MnPrP may 
also play a role in its conversion to a more β-sheet like protein. We have investigated 
a variety of mutants including mutants missing metal binding regions, the 
hydrophobic region and both N-terminal and C-terminal mutants. We have found 
that removal of all the metal binding regions significantly reduces the toxicity of 
MnPrP. We have also shown the importance of the presence of the octarepeat region, 
for the stability of the prion protein. 
4.1 Toxicity of prion protein mutants 
4.1.1 Metal Binding regions 
 
Initially we investigated whether the mutants we were investigating were 
intrinsically toxic, that is toxic even without manganese bound. We investigated the 
null mutant, which has the histidines at sites 66, 68, 76, 84, 96 and 111 mutated into 
alanines, these are all the histidines currently thought to be involved in metal binding 
in the prion protein. Previous work has demonstrated that the null mutant does not 
bind copper using Raman (Zhu et al., 2008). 
 
There are no histidines present in the octarepeat region, so the protein does not bind 
to a copper loaded IMAC column, therefore the protein was purified by the wash 
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method, as described in the materials and methods. F21 cells were treated for 48h 
with varying concentrations of null MnPrP or null apoPrP for 48h and viability 
assessed using an MTS assay. 
 
Figure 4.1: Toxicity of Null PrP. A: A schematic diagram showing the mutations in the null 
prion protein, the red bars represent the mutation of histidines to alanines in the regions 
thought to bind metals the top diagram shows the WT protein. B: F21 cells were treated for 48h 
with either recombinant Null apoPrP (blue line) or Null MnPrP (green line). Cell viability was 
then assessed using an MTS assay error bars are SEM. Significant points were assessed using a 
one-way ANOVA p<0.05. Each point represents at least 4 repeats. 
 
There was not a dose dependant difference between the null apoPrP and the 
manganese bound null PrP (figure 4.1) although there was a significant difference in 
toxicity at two doses, most notably the highest dose. The reason for this difference is 
unclear and requires further investigation As previous studies have shown that null 
does not bind copper (Zhu et al., 2008) and a recent study has also shown that the 
null mutant does not bind manganese (Brazier et al., 2008) it was expected that there 
would be no difference in toxicity whether refolded in the presence of manganese or 
not. 
 
Having investigated the toxicity of a mutant unable to bind manganese we 
investigated several mutants that had mutations in the octarepeat region. Initially we 
investigated the effect of the removal of the octarepeat region on toxicity using 
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deletion mutants. We first used a mutant that had had the entire octarepeat region 
removed, PrP ∆51-89. This protein was purified by nickel IMAC via a his-tag and 
F21 cells were treated for 48h with varying concentrations of MnPrP ∆51-89 or 
apoPrP ∆51-89 for 48h and viability assessed using an MTS assay. PrP ∆51-89 was 
found to be significantly less toxic than manganese bound ∆51-89 (figure 4.2b). This 
suggests that manganese binding does have an effect on the toxicity of PrP that is 
missing the octarepeat region, suggesting that manganese binding to the fifth site, 
which is the only site available to bind to, is able to modulate toxicity.  
 
Figure 4.2: Toxicity of PrP ∆51-89. A: A schematic diagram showing the mutations in the ∆51-
89, the removal of octarepeat can be seen the top diagram shows the WT protein. B: F21 cells 
were treated for 48h with either apoPrP ∆51-89 (blue line) or MnPrP ∆51-89 (green line). Cell 
viability was then assessed using an MTS assay error bars are SEM. Significant points were 
assessed using a one-way ANOVA p<0.05. Each point represents at least 4 repeats. 
 
We investigated whether partial removal of the octarepeat region had any effect on 
toxicity, to investigate this we used a mutant (∆67-89) that has had all but the first 
repeat removed leaving one copper binding site in the octarepeat region as well as 
the fifth site. This protein was purified by nickel IMAC via a his-tag, F21 cells were 
then treated with varying concentrations of MnPrP ∆67-89 or apoPrP ∆67-90 for 48h 
and toxicity was assessed using an MTS assay. The ∆67-90 apoPrP was significantly 
less toxic than the metal bound PrP (figure 4.3). 
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Figure 4.3: Toxicity of PrP ∆67-89. A: A schematic diagram showing the mutations in the ∆67-
89, the partial removal of octarepeat can be seen the top diagram shows the WT protein. B: F21 
cells were treated for 48h with either apoPrP ∆67-89 (blue line) or MnPrP ∆67-89 (green line). 
Cell viability was then assessed using an MTS assay error bars are SEM. Significant points 
were assessed using a one-way ANOVA p<0.05. Each point represents at least 3 repeats. 
 
The removal of such a large part of the protein may lead to structural changes in the 
prion protein. To further investigate the effect of metal binding on the toxicity of the 
prion protein we choose to use a series of mutants that had had the histidines 
involved in metal binding mutated to alanines. This allowed us to investigate the 
effect of metal binding without the possibility of dramatically changing the structure 
of the protein. 
 
We investigated the effect of mutating the histidines in the octarepeat region into 
alanines to prevent binding. This left only the fifth site available for binding. As with 
the null mutant this protein was purified by the wash method and F21 cells were 
treated as previously described, with MnPrP Fifth site only or apoPrP Fifth site only. 
As with the previous two mutants we observed an increase in toxicity when 
manganese was bound to the protein suggesting manganese binding to the fifth site 
increases toxicity (figure 4.4), however it is noticeable that the addition of 
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manganese appears to increase toxicity more than in the deletion mutants, as even at 
the highest dose used apoPrP fifth only shows very little toxicity. 
 
Figure 4.4: Toxicity of PrP Fifth only.  A: A schematic diagram showing the mutations in the 
fifth only prion protein, the red bar represents the mutation of histidines to alanines in the 
octarepeat region thought to bind metals, the top diagram shows the WT protein. B: F21 cells 
were treated for 48h with either recombinant Fifth only apoPrP (blue line) or Fifth Only 
MnPrP (green line). Cell viability was then assessed using an MTS assay error bars are SEM. 
Significant points were assessed using a one-way ANOVA p<0.05. Each point represents at least 
4 repeats. 
 
We also investigated the effect of the loss of the fifth site on toxicity. A mutant with 
the histidines at 95 and 110 mutated into alanines was purified using the wash 
method. F21 cells were treated for 48h with either no fifth apoPrP or no fifth MnPrP 
and viability was assessed using an MTS assay. The removal of the fifth site did not 
lead to a loss of toxicity, manganese bound PrP no fifth site was significantly more 
toxic then apoPrP no fifth site, suggesting that binding to the octarepeat region may 
have some effect on toxicity (figure 4.5). 
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Figure 4.5: Toxicity of PrP No Fifth. A: A schematic diagram showing the mutations in the no 
fifth prion protein, the red bar represents the mutation of histidines to alanines at the fifth site 
thought to bind metals, the top diagram shows the WT protein. B: F21 cells were treated for 
48h with either apoPrP no fifth (blue line) or MnPrP no fifth (green line). Cell viability was then 
assessed using an MTS assay error bars are SEM. Significant points were assessed using a one-
way ANOVA p<0.05. Each point represents at least 4 repeats. 
4.1.2 N-Terminal Region. 
 
The N-terminal region of the prion protein is defined as amino acids 23-112. We 
have investigated two mutants that cover the N-terminal region one spanning amino 
acids 23-112 and the other spanning amino acids 23-171. The N-terminal region of 
PrP is thought be unstructured (Donne et al., 1997), although it has been reported 
that metal binding may confer more structure on the region (Jones et al., 2004).  
 
Initially we investigated PrP 23-112, which is missing amino acids 112-231. F21 
cells were treated for 48h with varying concentrations of MnPrP 23-112 or apoPrP 
23-112 and viability was assessed using an MTS assay. MnPrP 23-112 showed an 
increase in toxicity when bound to manganese (figure 4.6), as this region still has all 
the metal binding histidines available to bind it is perhaps unsurprising that it is more 
toxic when bound to manganese. 
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Figure 4.6: Toxicity of PrP 23-112. A: A schematic diagram showing the 23-112 prion protein, 
the top diagram shows the WT protein. B: F21 cells were treated for 48h with either apoPrP 23-
112 (blue line) or MnPrP 23-112 (green line). Cell viability was then assessed using an MTS 
assay error bars are SEM. Significant points were assessed using a one-way ANOVA p<0.05. 
Each point represents at least 4 repeats. 
 
We also investigated a bigger fragment of the N-terminal end of the protein, amino 
acids 23-171, which is missing residues 172-231. As before cells were treated for 
48h with MnPrP 23-171 or apoPrP 23-171 and viability was assessed using an MTS 
assay. This fragment was shown to be toxic when bound to manganese, however it 
was also shown to be toxic without metal bound to it, leading us to believe that this 
is an intrinsically toxic fragment of the prion protein (figure 4.7). 
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Figure 4.7: Toxicity of PrP 23-171. A: A schematic diagram showing the 23-171 prion protein, 
the top diagram shows the WT protein. B: F21 cells were treated for 48h with either apoPrP 23-
171 (blue line) or MnPrP 23-171 (green line). Cell viability was then assessed using an MTS 
assay error bars are SEM. Significant points were assessed using a one-way ANOVA p<0.05. 
Each point represents at least 4 repeats. 
4.1.3 Palindromic Region. 
 
The palindromic region of the prion protein consists of 8 amino acids extending from 
amino acid 112 to 119. The sequence (AGAAAAGA) is also known as the 
hydrophobic core. Work has using the 106-126 peptide demonstrated the replacing 
hydrophobic amino acids in the palindromic region with hydrophilic amino acids 
resulted in a loss of toxicity and marked decrease in β-sheet structure (Jobling et al., 
1999). The absence of the palindromic region prevents the conversion to PrPsc 
(Norstrom and Mastrianni, 2005). 
 
Cell were treated for 48h with varying concentrations of MnPrP ∆112-119 or apoPrP 
∆112-119. Interestingly, although the protein bound to metal is significantly less 
toxic than the recombinant protein this difference in toxicity is strikingly less than 
seen in other mutants (figure 4.8), this may suggest that the fragment is, at 
intrinsically toxic although metal binding does confer a very slight increase in 
toxicity. 
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Figure 4.8: Toxicity of PrP ∆112-119.  A: A schematic diagram showing the ∆112-119 prion 
protein, the top diagram shows the WT protein. B: F21 cells were treated for 48h with either 
apoPrP ∆112-119 (blue line) or MnPrP ∆112-119 (green line). Cell viability was then assessed 
using an MTS assay error bars are SEM. Significant points were assessed using a one-way 
ANOVA p<0.05. Each point represents at least 4 repeats. 
4.1.4 112-231 
 
The C-terminus region of the prion protein comprises amino acids 112-231 and is 
highly structured. In the normal prion the structure consists of 3 α-helices and two 
short β-sheet strands. 
 
Our results have shown that the C-terminus is not intrinsically toxic to the cells 
(figure 4.9), in fact this protein, when not bound to metal, appears not to be toxic to 
cells at any concentration. This is in sharp contrast to most other mutants which 
show toxicity at high doses. Previous work has shown that cellular PrP expression 
protects cells from the toxicity of the C-terminal fragment of PrP (Daniels et al., 
2001).  
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Figure 4.9: Toxicity of PrP 112-231. A: A schematic diagram showing the 112-231 prion protein, 
the top diagram shows the WT protein. B: F21 cells were treated for 48h with either apoPrP 
112-231 (blue line) or MnPrP 112-231 (green line). Cell viability was then assessed using an 
MTS assay error bars are SEM. Significant points were assessed using a one-way ANOVA 
p<0.05. Each point represents at least 4 repeats. 
 
A mutant encompassing more of the protein, 45-231 was also investigated, this 
protein contains all of the metal binding regions and is missing just the first 22 
amino acids. This protein was not found to be intrinsically toxic (figure 4.10) 
however it was toxic once bound to manganese. 
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Figure 4.10: Toxicity of PrP 45-231. A: A schematic diagram showing the 45-231 prion protein, 
the top diagram shows the WT protein. B: F21 cells were treated for 48h with either apoPrP 45-
231 (blue line) or MnPrP 45-231 (green line). Cell viability was then assessed using an MTS 
assay error bars are SEM. Significant points were assessed using a one-way ANOVA p<0.05. 
Each point represents at least 4 repeats. 
 
Finally we also investigated the toxicity of ∆135-150 and ∆35-45. Neither of these 
deletions has had any reported effect on the proteins ability to bind metals and 
neither was intrinsically toxic to the cells (figures 4.11 & 4.12). However manganese 
binding significantly increased the toxicity of protein. 
 
- 86 - 
 
 
Figure 4.11: Toxicity of PrP ∆135-150. A: A schematic diagram showing the ∆135-150 prion 
protein, the top diagram shows the WT protein. B: F21 cells were treated for 48h with either 
apoPrP ∆135-150 (blue line) or MnPrP ∆135-150 (green line). Cell viability was then assessed 
using an MTS assay error bars are SEM. Significant points were assessed using a one-way 
ANOVA p<0.05. Each point represents at least 4 repeats. 
 
Figure 4.12: Toxicity of PrP ∆35-45. A: A schematic diagram showing the ∆35-45 prion protein, 
the top diagram shows the WT protein. B: F21 cells were treated for 48h with either apoPrP 
∆35-45 (blue line) or MnPrP ∆35-45 (green line). Cell viability was then assessed using an MTS 
assay error bars are SEM. Significant points were assessed using a one-way ANOVA p<0.05. 
Each point represents at least 4 repeats. 
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4.2 Comparison of MnPrP WT toxicity to the mutants. 
 
Having established the toxicity of each mutant when bound to manganese we wanted 
to investigate which regions of the protein were responsible for the increased toxicity 
of MnPrP when compared to apoPrP. F21 cells were treated for 48h with varying 
concentrations of WT PrP or mutant PrP bound to manganese, and an ED50 for each 
mutant was established as well as a dose response curve. The results are summarised 
in a table on page 92. 
 
We used both the wash method and his-tag to purify PrP, depending on the mutant 
used. The his-tagged protein was significantly less toxic than the protein purified by 
the wash method. The reasons for this are unclear, it may be due to slight differences 
in the protein produced by each method as they are very different methods for 
producing protein. However due to these differences in toxicity the mutants were 
compared back to the relevant wild type protein results.  
4.2.1 Metal binding Regions 
 
The null mutant was significantly less toxic than the wild type protein with an ED50 
of 3.28µM compared to WT, which had an ED50 of 1.96µM. It is not entirely 
surprising that the null mutant is less toxic than WT given that the null mutant is not 
thought to bind manganese. The graph shows that the difference was not as great at 
the highest dose (figure 4.13b) but this point may not be as relevant as the two lower 
doses, as this is approaching the concentration where the levels of manganese may 
become toxic to the cells and the large volumes of protein added to the cells may 
affect the cell culture media buffering. This result suggests that removal of the sites 
currently thought to bind manganese can reduce but not obliterate the toxicity of the 
prion protein. 
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Figure 4.13: Toxicity of Null MnPrP compared to WT MnPrP. A: F21 cells were treated for 48h 
with either WT MnPrP (red line) or Null MnPrP (green line) or WT MnPrP (column purified) 
(yellow line). Cell viability was then assessed using an MTS assay error bars are SEM. 
Significant points were assessed using a one-way ANOVA p<0.05. Each point represents at least 
4 repeats. 
 
We observed increases in toxicity in both the mutants that had had the octarepeat 
removed, even when the octarepeat was only partially removed. Full removal of the 
octarepeat region gave an ED50 value of 2.17µM and partial removal gave an ED50 of 
2.47µM these are both much lower than the wild type PrP value of 3.94µM. Dose 
response curves for both mutants also showed a significant increase toxicity when 
compared to the WT (figure 4.14). 
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Figure 4.14: Toxicity of ∆51-89 and ∆67-89 MnPrP compared to WT MnPrP. A: F21 cells were 
treated for 48h with either WT MnPrP (red line) or ∆51-89 MnPrP (green line). B: F21 cells 
were treated for 48h with either WT MnPrP (red line) or ∆67-89 MnPrP (green line). Cell 
viability was then assessed using an MTS assay error bars are SEM. Significant points were 
assessed using a one-way ANOVA p<0.05. Each point represents at least 4 repeats. 
 
As deletion of the octarepeat increased the toxicity of MnPrP we investigated the 
toxicity of a mutant that had all the histidines in the octarepeat region replaced with 
alanines (fifth site only mutant). This allowed us to assess whether the increase in 
toxicity was due to the metal binding sites or changes in structure induced by the 
removal of the octarepeat. We confirmed that the increase in toxicity was also 
observed in the fifth site only mutant (figure 4.15) indicating that when both the fifth 
site and the octarepeat have metal bound this may give a slight protective effect 
compared to the fifth is on its own. 
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Figure 4.15: Toxicity of fifth site only compared to WT MnPrP. A: F21 cells were treated for 
48h with either WT MnPrP (red line) or fifth site only (green line). Cell viability was then 
assessed using an MTS assay error bars are SEM. Significant points were assessed using a one-
way ANOVA p<0.05. Each point represents at least 4 repeats. 
 
We also investigated the effect of the removal of the fifth site leaving just the 
octarepeat region. Interestingly it was found that this mutant showed no significant 
difference in toxicity when compared to WT MnPrP and had a very similar ED50 
value to the WT value. Taken with the results using the null and fifth site only 
mutants this suggest that the fifth site bound to manganese can increase the toxicity 
of the prion protein and that the octarepeat region is not able to modulate the toxicity 
of the protein.  
4.2.2 N-Terminal Region. 
 
We investigated the effect of removal of the structured C-terminus of PrP on MnPrP 
toxicity using the 23-112 mutant. The other mutant that covered the N-terminus was 
found to be intrinsically toxic so was suitable for investigating the role of metal 
binding in PrP toxicity. The N-terminus of PrP was found to be highly toxic with an 
ED50 value of 1.18µM, almost four times lower than the value for WT MnPrP and 
the dose response curve showed a significant increase in toxicity compared to the 
WT (figure 4.16). This is despite the presence of the all the metal binding sites, 
suggesting that the presence of the C-terminus might be important in the prevention 
of toxicity. 
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Figure 4.16: Toxicity of 23-112 MnPrP compared to WT MnPrP. A: F21 cells were treated for 
48h with either WT MnPrP (red line) or N-terminal PrP (green line). Cell viability was then 
assessed using an MTS assay error bars are SEM. Significant points were assessed using a one-
way ANOVA p<0.05. Each point represents at least 4 repeats. 
4.2.3 Hydrophobic Region 
 
Cells were treated for 48h with varying concentrations of WT MnPrP or ∆112-119 
MnPrP. Our work has shown that there is no difference in toxicity between WT and 
the ∆112-119 mutant suggesting that whilst this region is highly fibrillogenic and 
involved in the toxicity of the protein, the binding of manganese is not involved in 
this toxicity. 
4.2.4 113-231 
 
Our results have shown that the 113-231 shows a slight decrease in toxicity when 
compared to the WT MnPrP with an ED50 value of 4.77µM compared to the EC50 
value of WT MnPrP which is 3.96µM. This is reflected in the dose response curve 
which shows a slight but significant decrease in toxicity (figure 4.17). 
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Figure 4.17: Toxicity of 113-231 MnPrP compared to WT MnPrP.  A: F21 cells were treated for 
48h with either WT MnPrP (red line) or 113-231 (green line). Cell viability was then assessed 
using an MTS assay error bars are SEM. Significant points were assessed using a one-way 
ANOVA p<0.05. Each point represents at least 4 repeats. 
 
 This decrease is toxicity may be due to the fact that no manganese is bound to the 
protein, although the difference in toxicity is not as great as observed in the Null 
mutant. Another mutant that has the N-terminus partially removed (45-231) showed 
no difference in toxicity compared to WT MnPrP. Interestingly the ∆35-45 mutant 
also had a much higher ED50 value than WT MnPrP, whilst the ∆135-150 mutant 
showed no difference. 
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A 
Mutant ED50 Compared to WT 
(µM) 
Change in toxicity 
compared to control 
WT His Overall 3.94 N/A 
∆112-119 3.16 No change 
∆51-90 2.17 Increase 
∆67-90 2.47 Increase 
23-112 1.18 Increase 
112-231 4.77 Decrease 
∆35-45 4.80 Decrease 
∆135-150  3.99 No change 
45-231 
 
3.71 
 
No change 
 
WT wash Overall 1.96 N/A 
Fifth Only 0.73 Increase 
Null 3.28 Decrease 
No fifth 1.70 No change 
 
B 
51 90 110 112 11923 231171
Octarepeat 
region
Fifth 
site
Hydrophobic 
region
GPI 
anchor
 
 
Table 4.1: A: Shows the ED50 values for each manganese bound mutant compared to the 
relevant manganese bound WT protein. Differences in toxicity are given when there was a 
significant increase or decrease apparent on the chart. B: A schematic diagram highlighting 
some of the important regions of the prion protein. 
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4.3 Discussion 
 
This study has highlighted the potential significance of manganese binding in the 
pathogenesis of prion disease. The results in the previous chapter showed that 
manganese binding increases the toxicity of the prion protein. In this chapter we 
have further investigated the role of manganese binding in prion toxicity. Our work 
has shown that if the histidines known to bind manganese are mutated the toxicity of 
the protein is significantly reduced suggesting binding of manganese is required for 
toxicity. We have also shown that removal of the octarepeat region increases the 
toxicity of MnPrP, suggesting that this region has a protective effect. In contrast 
removal of the fifth site has no effect on toxicity. However it might be that this is 
because manganese is bound to the octarepeat in this situation. 
4.3.1 Metal Binding 
 
As we had shown that manganese bound PrP was toxic to neuronal cells we 
investigated whether altering the metal binding ability of PrP affected the toxicity of 
the prion protein.  
 
We assessed the role of metal binding sites and their effect on MnPrP mediated 
toxicity. The Null mutant, which has all the histidines known to bind metal replaced 
with alanines and is unable to bind manganese (Brazier et al., 2008). The Null 
mutant was found to be significantly less toxic than the WT protein at lower doses. 
This suggests that the binding of manganese to the WT prion protein leads to an 
increase in toxicity and confirms our earlier work that showed an increase in toxicity 
when manganese is bound to WT PrP.  
 
Studies of a variety of neurodegenerative diseases have shown that metal ions can 
induce aggregation of proteins. Several studies have demonstrated that the prion 
protein aggregates in the presence of manganese (Giese et al., 2004; Kim et al., 
2005; Treiber et al., 2006) and it has been suggested that manganese causes 
aggregation by creating interactions between PrP molecules rather than binding to 
the protein (Levin et al., 2005). Our data suggest that the increase in toxicity we 
observed with manganese is due to binding of the metal to specific regions of the 
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prion protein. There was no difference in toxicity between the recombinant Null PrP 
and the manganese bound Null PrP, which is probably due to the fact that there are 
no metal ions bound to either protein. 
4.3.2 Octarepeat Region 
Studies have shown that amino acids 23-90 are not required for prion propagation 
(Fischer et al., 1996; Muramoto et al., 1997; Muramoto et al., 1996) suggesting that 
the octarepeat region is not required for infectivity. Work using a fragment of PrP 
termed PrP106 or mini prion, which is 106 amino acids long and contains the 
deletions ∆23-88 and ∆141-176, has also suggested that the octarepeat region is not 
required for toxicity or infection. The mini prion is a soluble form of PrP that 
demonstrates several properties in common with PrPsc (Muramoto et al., 1996), and 
work using recombinant PrP106 has show that it is was highly toxic to primary 
neuronal cultures (Bonetto et al., 2002).  
 
However the octarepeat region may have a role in prion disease pathogenesis, as an 
increase in the number of octarepeat regions from 5 up to 14 is one of the mutations 
observed in fatal familial insomnia, an inherited form of prion disease (Collinge, 
1997; Krasemann et al., 1995). A model using recombinant protein has shown that 
increasing numbers of octarepeat insertions result in increased aggregation of the 
prion protein (Yu et al., 2007). Mice expressing PrP with nine octarepeats 
accumulate an insoluble and weakly protease-resistant form of the mutant protein 
that is not infectious (Biasini et al., 2008).  
 
In addition, work using mice expressing a prion protein mutant devoid of the 
octarepeat region develop prion disease with a longer incubation time (Flechsig et 
al., 2000) when challenged with infection, compared to normal mice. Further work 
using a cell culture model suggests that the octarepeat region of prion protein is 
required at an early stage for production of abnormal prion protein (Sakudo et al., 
2008), however it may not be required later, PrPsc is cleaved during trafficking and 
the 90-231 fragment is found in patients suffering from CJD (Chen et al., 1995).  
 
There has been some debate on how many manganese atoms bind to the octarepeat 
region of the prion protein, some studies have not been able to detect any binding to 
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the octarepeat region (Garnett and Viles, 2003; Treiber et al., 2007) however more 
recent work suggests a single low affinity binding event in the octarepeat region 
(Brazier et al., 2008). PrP ∆51-90 has been shown to bind metals at the fifth site 
(Jones et al., 2004). 
 
We found that both full and partial removal of the octarepeat region led to a 
significant increase in MnPrP toxicity. This result was confirmed using a mutant 
containing only the fifth site histidines and no octarepeat region histidines which was 
shown to be significantly more toxic than the wild type protein. Work investigating 
the effect of the deletion of the octarepeat region on toxicity has been limited, 
however there is evidence that deletion results in a loss of protective function (Haigh 
and Brown, 2006).  In our model the increase in toxicity observed may be due to a 
loss of stability in the absence of metal binding in the octarepeat region. Studies have 
shown that a deletion mutant, PrP 90-231, which contains only the fifth binding site 
is unstable in the presence of copper and ascorbate due to the oxidation of the 
methionines and histidines in the fifth site region (Nadal et al., 2007). This oxidation 
can be partially prevented by the presence of the octarepeat region. If this oxidation 
were to take place in the fifth site only MnPrP mutant, in the presence of manganese, 
a potential effect could be an increase in aggregation, as oxidation of the prion 
protein has been shown to increase aggregation in vitro (Requena et al., 2001). 
Oxidation-induced aggregation may increase the toxicity of the protein, as fibrils and 
aggregates of recombinant PrP have been shown to be toxic to cells in vitro (Corsaro 
et al., 2006; Novitskaya et al., 2006). Additionally the loss of the octarepeat region 
may also result in a loss of stability, as proteins that do not contain the repeat region 
have been shown to be less stable under pressure (Cordeiro et al., 2005). 
 
Several studies have shown that PrP is susceptible to cleavage in the presence of 
metals and H2O2 (McMahon et al., 2001). Cleavage of PrPc occurs at around amino 
acids 111 and 112. PrPsc cleavage occurs at round amino acid 90, although the 
normal protein can also be cleaved here (Mange et al., 2004).  Further work has 
shown that PrP bound to manganese can be partially cleaved, in the presence of 
H2O2, at amino acid 90 and that this protein can cause WT PrP to aggregate. 
Interestingly PrP missing the octarepeat region was cleaved much more readily in the 
presence of copper and H2O2 resulting in almost complete cleavage at amino acid 90. 
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The increase in cleavage observed may result in an increased polymerisation of 
cellular PrP and therefore increased toxicity (Abdelraheim et al., 2006). This may 
also explain the increase in toxicity of MnPrP in the absence of the octarepeat. 
 
As the presence of fifth site alone has an effect on toxicity it suggests that the 
binding pattern of our refolded protein is like that observed by Brazier et al with two 
manganese atoms binding to the prion protein one to the fifth site and one to the 
octarepeat region, rather than the earlier suggestion that four manganese atoms bind 
to the octarepeat region (Brown et al., 2000). This is also confirmed by the mass 
spectroscopy data, which showed two manganese atoms bind to the prion protein 
(Uppington and Brown, 2008) 
4.3.3 Fifth Site 
 
A small number of researchers have suggested an alternative hypothesis that the fifth 
site has a higher affinity for copper than the octarepeat region (Jones et al., 2005a; 
Treiber et al., 2007). Studies using peptide covering the region 91-115 have shown 
that this region predominately random coil when not bound to copper.  Once bound 
to copper the peptide is more structured, showing an increase in β-sheet, 
accompanied by the loss of some of the irregular structure. This implies the fifth 
binding site may be important in determining structure (Jones et al., 2004). However 
as yet it is not clear whether manganese binding to the fifth alone site can also induce 
changes in structure. 
 
Manganese has been shown to bind to the fifth site in a different manner to copper. 
Work using the 106-126 peptide has shown that the complex with Mn(II), involves 
the carbonyl oxygen’s of Gly-124 and Leu-125, which are close to the metal ion, the 
metal ion interacts with His-110, through a hydrogen bond of metal-bound water 
(Gaggelli et al., 2005). However more recent studies have shown that binding is 
centralised round His-95 and manganese binding still possible even in the presence 
of copper (Brazier et al., 2008). The 5th site is now thought to be the highest affinity 
site for manganese binding (Brazier et al., 2008). However, until now, is there is has 
been no direct work on the effect of metal binding to fifth site and its effect on 
toxicity. We observed no change in toxicity when the fifth site was mutated to 
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prevent metal binding at this site. This suggests that the weaker binding site in the 
octarepeat may be able to maintain the toxicity of the MnPrP without the presence of 
the fifth site but not increase it. 
4.3.4 Hydrophobic Region 
 
The region spanning amino acids 112 to 119 is highly conserved between species 
and has been shown to be the most fibrillogenic motif within the toxic peptide 
(Gasset et al., 1992). 
 
The hydrophobic region is thought to be required for infectivity, antibodies directed 
against hydrophobic region of the prion protein have been shown to prevent prion 
accumulation in infected cells (White et al., 2003). The deletion of the 112-119 
region of PrPc results in resistance to infection in vitro, suggesting that this region is 
required for conversion (Norstrom and Mastrianni, 2005). Studies have shown that 
the hydrophobic region of PrPc interacts with PrPsc or the 106-126 peptide resulting 
in a loss of function of PrPc (Brown, 2000b). 
 
Substitution of the hydrophobic residues in the 106-126 peptide results in a reduction 
in toxicity (Jobling et al., 1999), suggesting that the hydrophobic region has a role in 
toxicity. A study using neuronal cells treated with recombinant prion protein have 
also shown that the hydrophobic region is required for prion toxicity (Simoneau et 
al., 2007). However removal of ∆112-119 does not prevent aggregation of the prion 
protein in yeast (Norstrom and Mastrianni, 2005). The effect of the removal of 
∆112-119 on aggregation in mammalian cells is unclear and need to be investigated 
further. However in vivo the deletion of the 105-125 region results in neonatal 
lethality in mice (Li et al., 2007b) suggesting that the removal of the hydrophobic 
region can also be toxic to cells. Neurodegeneration is also observed when a larger 
fragment is deleted (94-134) (Baumann et al., 2007). Our results demonstrated that 
PrP missing amino acids ∆112-119 was toxic. As deletion of this region results in 
neonatal lethality in mice this it is perhaps unsurprising that PrP ∆112-119 is toxic to 
cells even in the absence of manganese.  We went on to test the toxicity of the 
mutant compared to WT MnPrP as there was a slight increase in toxicity when 
manganese is bound to the protein and the region has been shown to be important in 
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metal metabolism, being required for PrPc internalisation in response to copper 
(Haigh et al., 2005). We did not observe any significant change in toxicity compared 
to WT MnPrP. 
 
It may be interesting to investigate the removal of ∆106-126, this would allow us to 
investigate whether the region often used as an analogue of PrPsc has any effect on 
the toxicity of MnPrP. 
4.3.5 N-terminus 
 
The N-terminal region is an unstructured flexible region of PrP. We have 
investigated two mutants that cover the N-terminal region spanning amino acids 23-
112 and amino acids 23-171. As well as the previously discussed inherited mutations 
in the octarepeat region, the N-terminal region of the prion protein contains several 
other amino acid mutations associated with inherited prion disease (Kitamoto and 
Tateishi, 1994), suggesting the region has a role in the conversion of the prion 
protein. However the reason for the lethality of these mutations remains unclear 
(Jones et al., 2006).  
 
Our studies showed that the N-terminal region of PrP was highly toxic once bound to 
manganese and was significantly more toxic than apoPrP (23-112) suggesting the 
toxicity was due to metal binding. The N-terminus of PrP (23-112) contains all the 
metal binding regions previously discussed, but interestingly was more toxic than 
wild type MnPrP suggesting that manganese binding has a significant effect on the 
N-terminal mutant. As yet there have been there have been no studies investigating 
the structure of this fragment once bound to manganese. Studies investigating the 
structure of the native N-terminus have demonstrated that it is structured at higher 
pH (Zahn, 2003) and flexible at low pH (Donne et al., 1997; O'Sullivan et al., 2007). 
Low pH conditions been shown to cause the protein to adopt a higher β-sheet 
content. 
 
Studies of the metal binding to the N-terminal region have revealed metal binding 
confers structure on the N-terminus (Jones et al., 2004). However in order to fully 
understand the effect of metal binding on the N-terminal fragment further work 
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would need to be done. A fuller understanding of the structure the N-terminal 
fragment, once bound to manganese, may lead to a better understanding of the 
reasons for the toxicity of this protein. 
 
The N-terminus is thought to be important for the formation of higher order 
aggregates such as oligomers and fibrils. Work using N-terminally truncated 
recombinant protein (amino acids 90-231) revealed it formed smaller aggregates 
when compared to the wild type protein (Frankenfield et al., 2005). Work using 
recombinant prion protein missing amino acids 34-133 also showed a significant 
reduction in aggregation, which was associated with a decline in conversion 
efficiency in a cell free assay, although this was dependent upon glycosolation 
(Lawson et al., 2001). More recent work assessing the effect of pathogenic mutations 
on the prion protein structure has found that several mutations expose the N-terminus 
(Yin et al., 2007). The N-terminus has been shown to bind glycosaminoglycans 
(GAGs) (Pan et al., 2002), which have been shown to be required for cellular PrPsc 
incorporation  (Shaked et al., 2001) and are able to reconstitute the infectivity of 
prion rods (Hijazi et al., 2005). The mutations in the N-terminus result in the 
exposure of GAG binding sites and the resultant GAG binding leads to increased 
aggregation of the prion protein (Yin et al., 2007). It may be that as the C-terminus is 
not present in our N-terminal prion protein the regions involved in GAG binding are 
exposed in the manganese bound N-terminus allowing GAG binding and increased 
aggregation. Aggregation of the prion protein may lead to an increase in the toxicity 
of the protein. However further work is required to assess the aggregation of the N-
terminal prion protein when bound to manganese and whether the regions involved 
in binding GAGs are exposed. It may be worth investigating if inhibiting GAG 
binding results in a reduction in toxicity. 
 
We also investigated a longer region of the N-terminus of PrP spanning residues 23-
171, in contrast to 23-112 we found that this region of the protein was toxic to cells 
in the absence of manganese, suggesting that toxicity observed once manganese was 
bound was not due to manganese alone but some other mechanism. It has been 
shown that an N-terminal fragment of human PrP spanning amino acids 23-144 
spontaneously converts from a monomeric unordered state to a fibrillar form. This 
requires the presence of residues 130-148 (Kundu et al., 2003), so offers no 
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explanation for the toxicity of the N-terminal mutant 23-112, however it may offer 
an explanation for the intrinsic toxicity of the fragment 23-171, which contains 
residues 130-148. Further work has suggested that the addition of helix 1 (amino 
acids 144-156) to the N-terminal fragment causes aggregation to occur much more 
rapidly suggesting that this helix is involved in the conversion of the protein (Kundu 
et al., 2003). As the fragment 23-159 is readily able to aggregate (Watzlawik et al., 
2006) it may also be that our slightly longer fragment also retains these properties, 
however further work would need to investigate the aggregation of 23-171. 
4.3.6 C-terminus 
 
The C-terminus region has been shown to contain the only known histidine mutation 
involved in inherited forms of the disease, at amino acid 187 (Cervenakova et al., 
1999) in addition to several other mutations associated with in GSS. Cleaved 
fragments of the C-Terminus have also been found in the brains of people suffering 
with CJD, and these fragments have been shown to be PK resistant (Zou et al., 
2003). The C-Terminus consists of 3 α- helices, one of which was recently been 
shown to be toxic to cells in the presence of copper, although the reason for copper 
requirement was not clear (Thompson et al., 2000). 
 
Mice expressing a C-terminal fragment of the prion protein (amino acids 121-231) 
instead of wild-type prion protein die from massive neuronal degeneration within 
weeks of birth (Shmerling et al., 1998). This region of the protein has been shown to 
form soluble oligomers and amyloid fibrils under denaturing conditions despite the 
absence of the amyloidogenic core of PrP (Martins et al., 2006). Experiments using 
the N-terminally truncated recombinant prion protein have revealed that 121-231 is 
toxic to neuronal cells and that this toxicity is enhanced in PrP null cells. This region 
of the prion protein has been found contain several disease related mutations and 
these mutations also enhance the toxicity of 121-231 to neuronal cells (Daniels et al., 
2001). However the toxicity of the fragment is lost when amino acids 113-120 are 
added to the fragment suggesting this region of the protein has a role in mediating 
the toxicity of the C-terminus (Daniels et al., 2001). Our results also confirmed that 
the 113-231 fragment of PrP was not toxic to neuronal cells when not bound to 
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manganese, and appeared to be one of the least toxic apoPrP fragments we analysed, 
as it caused almost no cell death even at the highest doses. 
 
The C-terminus is a highly structured part of the prion protein, and is not generally 
thought to be involved in metal binding. Our study has shown that this protein is 
significantly less toxic than the WT prion. The decrease in toxicity is expected, as 
there are no metal binding sites known to bind manganese in the construct, however 
the difference in toxicity is not as great as the difference between the null construct 
and the WT protein. The reason for this is not clear it may be that the removal of the 
N-terminus changes the structure of the protein which may allow limited manganese 
binding, which would increase the toxicity of the protein. There is evidence for at 
least one functional binding motif for metals in the C-terminus. It has been shown 
that copper can bind to a histidine residue at 187 at pHs approaching neutrality 
(Brown et al., 2004), this binding site is also be able to bind manganese. As this 
region is highly structured it is possible that metal binding in this region is important 
in structure. This histidine certainly has an important role in vivo, as it is the only 
histidine known to be associated with the inheritable prion disease GSS 
(Cervenakova et al., 1999). 
 
The study of regions of the prion protein involved in toxicity has revealed a complex 
process, and requires further work in order to elucidate the mechanisms that are 
involved, giving a better understanding of the why changes in toxicity occur in the 
mutants. Investigating changes to the mutants once bound to manganese such as 
structural and aggregatory changes and in may be the first step in a fuller 
understanding of the mechanisms underlying the changes in toxicity we observed. 
Whilst many groups use fragments of PrP to research prion toxicity it is often 
unclear whether removal of large parts of the protein may change its structure, 
stability and its ability to bind metals, this means work using fragments does not 
accurately reflect an in vivo situation. However work undertaken with the mutants 
where residues were simply replaced, such as the null mutant, maybe provide a 
model more relevant to the in vivo situation. Using these mutants we demonstrated 
the importance of the presence of both the fifth site and octarepeat as without the 
metal binding sites in the octarepeat region the protein became more toxic to the 
cells, possibly due to destabilisation of the protein. 
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It is clear from our model that manganese binding plays a role in modulating the 
toxicity of the prion protein. As there is some evidence the octarepeat region is not 
involved in modulating prion toxicity (Bonetto et al., 2002), it is not surprising this 
region alone with no fifth site did not increase the toxicity of the protein. However 
the fifth site alone, without the protective effect of the octarepeat region was highly 
toxic, suggesting that whilst the octarepeat alone does not increase toxicity it is 
required to protect the protein. Metal binding domains are unlikely to be the only 
regions involved in prion protein conversion, as regions such as the hydrophobic 
region have been shown to be linked to the conversion and toxicity of the protein 
(Jobling et al., 1999; Norstrom and Mastrianni, 2005). 
 
It is unclear why metal binding changes the toxicity of the protein although the 
presence of metal ions has been shown to result in prion aggregation suggesting 
aggregation may play a role (Giese et al., 2004; Kim et al., 2005; Levin et al., 2005). 
In the absence of the octarepeat region metals have been shown to destabilise the 
protein and it may be that manganese destabilises the protein, especially when 
mutations are present in the protein or the protein has been cleaved. Studies have 
shown that manganese binding alters the structure of full-length PrP increasing the 
amount of β-sheet (Brown et al., 2000), suggesting that manganese alters the 
structure, but does not necessarily destabilise the protein, when no mutations are 
present. The increased level of β- sheet may result in aggregation which is linked to 
toxicity (Novitskaya et al., 2006). The change in structure may also result in regions 
of the protein being revealed such as GAG binding sites, which are required for 
conversion. Structural change may also result in changes to the prion protein’s 
interactions with other proteins, several studies have investigated whether PrPc binds 
to s receptor and PrPc has been shown to bind the laminin receptor resulting in PrPc 
internalisation (Saborio et al., 2001). In infected cells reduction of laminin receptor 
expression using siRNA has been shown to clear infection (Leucht et al., 2003) 
suggesting that PrPsc is still able to bind the receptor despite the structural changes, 
however the downstream effects of the binding are likely to be very different. 
 
In order to take this work forward metal binding, structural and aggregation studies 
should be carried out on the protein. This would allow us to tie together changes in 
toxicity with alterations in the metal binding, structure and aggregation, both known 
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factors in the toxicity of the prion protein. This would give us a more complete 
picture of the effect of manganese on the prion protein and allow us to better 
understand the role of aberrant metal binding in prion toxicity. 
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5. Cell Signalling in Prion Disease 
 
Prion diseases cause massive neuronal cell death in the latter stages of disease 
leading to the brains classical spongiform appearance. This cell death is widely 
agreed to be caused by apoptosis. However, the cell signalling pathway leading to 
apoptosis remains unclear.  
 
Several studies have identified neuronal apoptosis both in vitro (Forloni et al., 1993; 
Thellung et al., 2002) and in vivo (Fairbairn et al., 1994; Giese et al., 1995; Gray et 
al., 1999) using a variety of markers including caspase 3 activation and DNA 
fragmentation. Several studies have suggested that caspase 3 activation may be due 
to p38 activation and inhibition of p38 activation has been shown to prevent 
apoptosis in vitro (Thellung et al., 2002). However, other studies have shown that 
caspase 3 activation is p53 mediated, although inhibition of p53 activation is not 
sufficient to prevent disease progression (Engelstein et al., 2005). 
 
Endoplasmic reticulum stress has also been suggested to play a role in neuronal cell 
death in prion disease. Some studies have shown caspase 12, an ER resident caspase, 
activated by ER stress, is activated in response to PrP in vitro (Hetz et al., 2003b). 
However, more recent studies have suggested that ER stress does not play a crucial 
role in cell death in prion diseases (Unterberger et al., 2006). Other studies have 
suggested that calcium release from the ER activates the mitochondrial apoptotic 
pathway (Ferreiro et al., 2008a; Ferreiro et al., 2008b). 
 
Many studies have used the 106-126 peptide to investigate cell death in prion disease 
(Corsaro et al., 2003; Ferreiro et al., 2008a; Ferreiro et al., 2008b; Forloni et al., 
1996; Saez-Valero et al., 2000; Thellung et al., 2002). In this study we intend to use 
the MnPrP model to investigate cell signalling caused by PrP, as whilst we have 
demonstrated that MnPrP is toxic to neuronal cells, the signalling mechanisms that 
result in cell death have not been investigated.  
 
This study aims to further characterise the model of toxicity established in chapter 1 
by investigating the mechanism of cell death induced by MnPrP. We have used a 
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variety of techniques to confirm that cell death is due to apoptosis and that this may 
be mediated by p38 phosphorylation and caspase 3 cleavage.  
 
We have investigated mechanisms by which SMB cells are able to survive chronic 
infection. We have confirmed that SMB cells are not undergoing apoptotic cell death 
whilst in culture. There is also no evidence of caspase 3 or p38 up-regulation in 
SMB cells. However we have found evidence of high levels of caspase 12 expression 
suggesting there is ER stress in SMB cells. We investigated signalling molecules 
important in neuronal survival in SMB cells and found ERK phosphorylation was 
increased in SMB cells and that this increase was involved in cell survival. An 
increase in ERK phosphorylation was observed in F21 cells treated with MnPrP 
suggesting that ERK may be important in protecting cells from prion toxicity 
5.1 F21 signalling in the presence of MnPrP  
5.1.1 Cell death signalling 
 
 DNA laddering was used to establish whether the toxicity we had observed was due 
to apoptosis. DNA laddering occurs as the DNA is broken down, during apoptosis, 
in the cell in a controlled manner, leading to DNA fragments increasing in size by 
200bp. F21 cells were treated for 48h with increasing concentrations of MnPrP. The 
cellular DNA was extracted and run on a 1.5% agarose gel. DNA laddering could 
clearly be seen in lanes treated with 40 µg/ml and 80 µg/ml MnPrP. This DNA 
laddering mimicked the DNA laddering observed in F21 cells treated for 24h with 
stuarosporine, which is known to induce apoptosis. However, in F21 cells treated 
with MnPrP for 24h DNA laddering was not easily visible (figure 5.1). 
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Figure 5.1: DNA laddering in F21 cells treated with MnPrP. A: F21 cells were treated for 48h 
with increasing concentrations of MnPrP, cellular DNA was then extracted and separated on a 
1.5% agarose gel. Lane 1: 100bp ladder, lane 2: untreated control, lane 3: 20µg/ml MnPrP, lane 
4: 40µg/ml MnPrP, lane 5: 80µg/ml MnPrP, lane 6: Manganese control. B: F21 cells were 
treated for 24h with increasing concentrations of MnPrP and a stuarosporine control. Cellular 
DNA was then extracted and separated on a 1.5% agarose gel. Lane 1: 100bp ladder, lane 2: 
control, lane 3: 80µg/ml MnPrP, lane 4: 160µg/ml MnPrP, lane 5: 200µM staurosporine. 
 
To further confirm that MnPrP causes apoptosis, we investigated whether MnPrP 
causes caspase 3 cleavage. Several previous reports have shown caspase 3 activation 
both in cells treated with the 106-126 peptide and in the brains of mice infected with 
scrapie. Caspase 3 activation is one of the final steps in the induction of apoptosis. 
Cells were treated for 4, 8, 16 and 24h with 80 µg/ml MnPrP and caspase 3 cleavage 
was assessed using Western blotting. Caspase 3 cleavage was seen after 16h of 
treatment with MnPrP and was still visible after 24h (figure 5.2).  
 
 
 
 
 
 
Figure 5.2: Caspase 3 cleavage in F21 cells treated with MnPrP. F21 cells were treated with 
80µg/ml MnPrP for varying lengths of time. Cellular protein was extracted using RIPA buffer 
and proteins were separated on an SDS-PAGE gel. Caspase 3 expression and cleavage was 
assessed using western blotting. Lane 1: 0h, Lane 2: 4h, Lane 3: 8h, Lane 5: 16h, Lane 6: 24h.  
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As both p53 and p38 have been implicated in apoptosis in prion disease, we 
investigated the expression of p53 and p38 phosphorylation in F21 cells treated for 
4, 8, 16, and 24h with 80 µg/ml MnPrP. There was a significant decrease in p53 
expression (figure 5.3). 
p53
Tubulin
4h0h 8h 16h 24h
B
*
A
0
0.5
1
1.5
2
2.5
0h 4h 8h 16h 24h
In
te
n
si
ty
 
o
f p
53
/tu
bu
lin
Length of treatment with MnPrP
*
*
*
 
Figure 5.3: Expression of p53 by F21 cells treated with MnPrP. F21 cells were treated with 
80µg/ml MnPrP for varying lengths of time. Cellular protein was extracted using RIPA buffer 
and proteins were separated on an SDS-PAGE gel. p53 expression  was assessed by western 
blotting. A: Intensity was quantified using Image J and normalised using tubulin intensity N=4 
error bars are SEM *p>0.05 as tested by students T-test. B: Lane 1: 100bp ladder Lane 2: 0h, 
Lane 3: 4h, Lane 4: 8h, Lane 5: 16h, Lane 6: 24h. 
 
There was evidence of p38 phosphorylation in cells treated with MnPrP for 16h 
(figure 5.4) this is in line with toxicity studies in previous reports that have shown 
that p38 activation is required for the activation of caspase 3 in the presence of PrP 
peptides. 
 
 
 
 
Figure 5.4: Expression of pp38 by F21 cells treated with MnPrP.  F21 cells were treated with 
80µg/ml MnPrP for varying lengths of time. Cellular protein was extracted using RIPA buffer 
and proteins were separated on an SDS-PAGE gel. pp38 and p38 expression and activation was 
assessed using western blotting. Lane 1: 0h, Lane 2: 4h, Lane 3: 8h, Lane 5: 16h, Lane 6: 24h. 
 
We also investigated other pathways that could be up-regulated in cells treated with 
MnPrP. In order to assess the role that the ER might play in MnPrP toxicity we 
investigated BiP. BiP has previously been shown to bind abnormal forms of PrP (Jin 
et al., 2000) and is up-regulated in response to ER stress, providing a protective 
pp38
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effect (Rao et al., 2002). BiP has also been shown to be up-regulated in response to 
PrP 106-126 (Ferreiro et al., 2008a). We found that treatment for 24h with MnPrP 
did not lead to an increase in BiP expression in F21 cells (figure 5.5). 
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Figure 5.5: Expression of BiP by F21 cells treated with MnPrP. F21 cells were treated with 
varying concentrations of MnPrP for 24h. Cellular protein was then extracted using RIPA 
buffer and separated on a 12% SDS-PAGE gel. BiP expression was assessed by Western 
blotting and normalised to tubulin. Intensity was assessed using Image J. n=5 no points are 
significant as tested by students T-Test. 
5.1.2 Cell Survival Signalling. 
 
We also investigated several signalling molecules thought to be important in cell 
survival signalling. We investigated AKT and ERK both thought to be involved in 
cell survival signalling in response to neuronal growth factors. AKT has been shown 
to promote neuronal survival via PI3K. PI3K is activated in response neuronal 
growth factors and this signalling leads to a wide variety of responses including 
inhibition of pro-apoptotic molecules such as p53 (Yamaguchi et al., 2001) and 
activation of transcription factors involved in cell survival such as NF-κB. ERK is a 
member of the MAPK group of signalling molecules, and was first found to be 
important in neuronal survival in response to neurotrophins (Xia et al., 1995). It has 
also been shown to be important in cell survival in response to injury in certain 
circumstances. More recent evidence has shown that ERK can also be involved in 
regulation of apoptosis (Murray et al., 1998). 
 
We found no change in the levels of AKT activation in F21 cells treated for 24h with 
MnPrP (figure 5.6). We also found no change in the activation of ERK after 24h 
treatment with MnPrP (figure 5.7). However after 48h we found a significant 
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increase in activation (figure 5.7). This may be due to the small surviving population 
being protected by ERK up-regulation. 
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Figure 5.6: Expression of pAKT by F21 cells treated with MnPrP. A: F21 cells were treated 
with varying concentrations of MnPrP for 24h. Cellular protein was then extracted using RIPA 
buffer and separated on a 12% SDS-PAGE gel. AKT phosphorylation was assessed by Western 
blotting and normalised to AKT. B: Intensity was assessed using Image J. n=5 
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Figure 5.7: Expression of pERK by F21 cells treated with MnPrP.  A: F21 cells were treated 
with varying concentrations of MnPrP for 24h or 48h . Cellular protein was then extracted 
using RIPA buffer and separated on a 12% SDS-PAGE gel. ERK phosphorylation was assessed 
by Western blotting and normalised to ERK. B: Intensity was assessed using Image J. Blue 
bars: cells were treated for 24h with MnPrP n=7 no points are significant students T-Test. Red 
bars: cells were treated for 48h with MnPrP n=5 both 40 and 80µg/ml are significant p<0.05 
compared to control. 
 
As ERK was activated in response to MnPrP we investigated the expression of 14-3-
3 a possible upstream activator of ERK that is found in high concentrations in the 
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cerebrospinal fluid (CSF) of patients suffering from prion disease (Hsich et al., 
1996). There was no increase in 14-3-3 expression at 24h (figure 5.8) however 
further investigations at a later time point maybe more useful in determining whether 
it regulates ERK in response to MnPrP.  
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Figure 5.8: Expression of 14-3-3 by F21 cells treated with MnPrP. A: Expression of 14-3-3 in 
F21 cells treated with varying concentrations of MnPrP for 24h. Cellular protein was extracted 
using RIPA buffer and separated on a 12% SDS-PAGE gel. 14-3-3 expression was assessed by 
Western blotting and normalised to tubulin. B: Intensity was assessed using Image J n=8  no 
points are significant when compared to control as assessed by students T-Test. 
5.2 SMB cells 
5.2.1 Cell Death Signalling 
 
Having earlier established that MnPrP induced apoptosis in SMB cells (chapter 3) 
we went on to investigate the effects of scrapie infection on SMB cells. Initially we 
investigated cell signalling molecules involved in cell death. In order to confirm that 
there was no evidence of low level apoptosis in the SMB cell line we used DNA 
laddering. We found no evidence of laddering in SMB cells (Figure 5.9b). We also 
investigated whether caspase 3 and 9 were activated in SMB and SMB-PS cells and 
found no evidence of activation in either cell line (figure 5.9a). 
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Figure 5.9: Caspase 3 and 9 cleavage and DNA laddering in SMB and SMB-PS cells. A: SMB 
and SMB-PS cells were plated and left to adhere overnight. Cellular protein was extracted using 
RIPA buffer and proteins separated on an SDS-PAGE gel. Caspase 3 and caspase 9 expression 
and activation were assessed using western blotting. Lane 1: SMB, Lane 2: SMB-PS. B: DNA 
laddering Lane 1: F21 untreated, lane 2: F21 80µg/ml MnPrP, lane 3: SMB cells. 
 
We investigated the levels of caspase 3 and 9 expression in both SMB and SMB-PS 
cells there was no evidence of an increase in either caspase 3 or caspase 9 expression 
in SMB cells when compared to SMB-PS cells (Figure 5.10). 
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Figure 5.10: Caspase 3 and 9 expression in SMB and SMB-PS cells. A & C: SMB cells were 
plated out and left overnight to adhere. Cellular protein was extracted using RIPA buffer and 
proteins were separated on an SDS-PAGE gel. Caspase 3 (A) or caspase 9 (C) expression was 
assessed by western blotting. A: Lane 1: SMB, Lane 2: SMB-PS. B & D: Intensity was 
quantified using Image J and normalised using tubulin intensity n= at least 4 error bars are 
SEM *p>0.05 as tested by students T-test.  
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We also assessed other signalling molecules associated with apoptosis in prion 
disease including p38. p38 phosphorylation was investigated by western blotting and 
no difference was observed between SMB and SMB-PS cells (figure 5.11).  
p38
p-p38
A B
SMB-PS SMB
0
20
40
60
80
100
120
140
SMB-PS SMB
%
 
pp
38
/p
38
 
ex
pr
es
si
o
n 
co
m
pa
re
d 
to
 
cu
re
d 
ce
lls
 
 
Figure 5.11: pp38 expression in SMB and SMB-PS cells. A: SMB cells were plated out and left 
overnight to adhere. Cellular protein was extracted using RIPA buffer and proteins were 
separated on a SDS-PAGE gel. pp38 and p38 expression was assessed using western blotting. A: 
Lane 1: SMB, Lane 2: SMB-PS. B: Intensity was quantified using Image J and normalised using 
p38 intensity N=6 error bars are SEM. p>0.05 as tested by students T-test.  
5.2.2 Endoplasmic reticulum stress 
 
As several reports have indicated that ER stress may have an important role in prion 
disease, we investigated the expression of caspase 12, an ER resident caspase. SMB 
cells had very high caspase 12 expression levels, whilst in cured cells caspase 12 
expression was almost undetectable (figure 5.12). 
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Figure 5.12: Caspase 12 expression in SMB and SMB-PS cells. A: SMB cells were plated out 
and left overnight to adhere. Cellular protein was extracted using RIPA buffer and proteins 
were separated on an SDS-PAGE gel. Caspase 12 and tubulin expression was assessed using 
western blotting (upper band is non-specific binding). A: Lane 1: SMB, Lane 2: SMB-PS. B: 
Intensity was quantified using Image J and normalised tubulin intensity N=9 error bars are 
SEM. p<0.05 as tested by students T-test.  
 
We also investigated the expression of BiP. BiP is a chaperone that has been shown 
to bind to abnormal forms of PrP. Interestingly, there was no evidence of increase in 
expression of BiP in SMB cells (figure 5.13).  
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Figure 5.13: BiP expression in SMB and SMB-PS cells. A: SMB cells were plated out and left 
overnight to adhere. Cellular protein was extracted using RIPA buffer and proteins separated 
on a SDS-PAGE gel. BiP expression was assessed using western blotting. A: Lane 1: SMB, Lane 
2: SMB-PS. B: Intensity was quantified using Image J and normalised to tubulin intensity N=11 
error bars are SEM. p>0.05 as tested by students T-test.  
 
 
 
 
5.2.3 Cell Survival Signalling 
 
In order to identify signalling molecules that might enhance survival in SMB cells, 
we investigated molecules ERK and AKT that have a role in neuronal survival in the 
normal brain.  
 
There was no difference in AKT phosphorylation between SMB and SMB-PS cells 
(figure 5.14 a, b), however ERK phosphorylation was significantly higher in SMB 
cells (figure 5.14 c, d) compared to SMB-PS cells. 
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Figure 5.14: pERK and pAKT expression in SMB and SMB-PS cells. A & C: SMB cells were 
plated out and left overnight to adhere. Cellular protein was extracted using RIPA buffer and 
proteins were separated on a SDS-PAGE gel. pAKT (A) or pERK (C) expression was assessed 
using western blotting. A: Lane 1: SMB, Lane 2: SMB-PS. B: Intensity was quantified using 
Image J and normalised using either AKT (B) or ERK (D) intensity. n=3 error bars are SEM 
*p<0.05 as tested by students T-test.  
 
To investigate whether this up-regulation was functional, ERK phosphorylation was 
blocked using a specific MEK inhibitor PD98059 (Figure 5.15a). MEK is the sole 
upstream activator of ERK. SMB cells treated with the inhibitor showed a significant 
loss in viability when compared to the control, this was not observed in SMB-PS 
cells, suggesting this up-regulation is functional (Figure 5.15b). 
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Figure 5.15: The effect the inhibition of ERK activation on SMB and SMB-PS survival. A: SMB 
and SMB-PS cells were treated for 1h with a specific MEK inhibitor PD98059 and the cellular 
protein was extracted using RIPA buffer. Western blotting was used to determine the 
expression of pERK and ERK. B: SMB and SMB-PS cells were plated in media 199 and left to 
adhere overnight. Cells were then treated with a specific MEK inhibitor PD98059 for 16h 
viability was assessed using an MTS assay. n=3. *p= 0.03 (Students T Test). Error bars SEM. 
(DMSO included as it was used to solubilise the inhibitor)  
 
As unpublished work from our lab has shown that SMB cells have increased 
resistance to certain types of oxidative stress, we postulated that ERK may be 
important in protecting cells from oxidative stress caused by infection, however, 
treatment with PD980959 had no effect on basal levels of ROS in SMB or SMB-PS 
cells (figure 5.16).  
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Figure 5.16: The effect the inhibition of ERK activation on SMB and SMB-PS cellular ROS 
expression. SMB (red) and SMB-PS (green) cells were plated in serum free media and left to 
* 
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adhere overnight. Cells were then treated with a specific MEK inhibitor PD98059 and ROS 
were assessed using DCDFDA, a probe that is cleaved and creates a fluorescent signal in 
response to ROS. n=4. No points are significant (Students T Test). Error bars SEM. (DMSO 
included as it was used to solubilise the inhibitor) 
 
In order to investigate the upstream signalling mechanisms that may lead to up-
regulation of ERK, we decided to examine the expression of 14-3-3. 14-3-3 has been 
found in the CSF of patients with CJD and is thought to be early marker of disease 
(Hsich et al., 1996). It is also one of the potential activators of ERK. Previous 
research has shown inhibition of certain homolog’s of 14-3-3 can lead to ERK 
suppression and an increase in activation of apoptotic pathways (Xing et al., 2000). 
Our work, using a pan 14-3-3 antibody has found that 14-3-3 is up-regulated in SMB 
cells, this up-regulation may play a role in ERK activation (figure 5.17).  
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Figure 5.17: Expression of 14-3-3 in SMB cells or SMB-PS cells. A: Cellular protein was 
extracted using RIPA buffer and separated on a 12% SDS-PAGE gel. 14-3-3 expression was 
assessed by Western blotting and normalised to tubulin. B: Intensity was assessed using Image 
J. n=4  p<0.05 as assessed by students T-Test. 
 
As PKA is also a known activator of ERK, we also investigated its ability to regulate 
ERK. SMB cells were treated for 16h with a PKA inhibitor prior to viability analysis 
using a MTS assay. There was a slight but significant increase in viability in SMB 
cells treated with the PKA inhibitor for 24h (figure 5.18). However, there was no 
evidence of inhibition of ERK by western blotting, indicating that PKA is not 
involved in pERK activation but maybe involved in another pathway that is 
responsible for SMB survival (Figure 5.19). 
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Figure 5.18: Effect of PKA inhibition on SMB and SMB-PS survival. SMB (Red) and SMB-PS 
(blue) cells were treated for 24h with varying concentrations of H89 a specific PKA inhibitor, 
cell viability was assessed using an MTS assay. n=4. There was a significant increase in cell 
viability in SMB cells treated with 50µM H89 compared to untreated control, as assessed by 
students T-test p<0.05. 
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Figure 5.19: A: Expression of ERK in SMB and SMB-PS cells treated with a PKA inhibitor. 
Expression of pERK in either SMB cells (top) or SMB-PS cells (bottom) treated with H89 for 
4h. Cellular protein was extracted using RIPA buffer and separated on a 12% SDS-PAGE gel. 
pERK expression was assessed by Western blotting and normalised to ERK. Intensity was 
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assessed using Image J. n=3. No points are significant when compared to control as assessed by 
students T-Test. B: Sample blots 
5.3 Overview of Results 
 
The table below provides an overview of the results, perhaps most striking of all the 
results is the up-regulation of ERK activation in both infected cells and surviving 
F21 cells. It is also clear that the cell death induced by MnPrP is apoptotic and is 
mediated by caspase 3 cleavage. There was no evidence of cell death in SMB cells 
suggesting that the infection carried by SMB cells is not enough to induce apoptosis. 
However earlier work had shown treatment with MnPrP was sufficient to induce 
apoptosis in similar manner to that observed in SMB cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: A comparative table outlining the changes in expression in signalling molecules as 
assessed by western blotting. The SMB column shows the levels of expression of signalling 
molecules when compared to the cured cell line SMB-PS.  The F21 column shows the expression 
of signalling molecules after treatment for 24h with MnPrP compared to control. 
↓-p53
↑↔p-p38
-↔Caspase 9
Cleaved (16h)↔Caspase 3Cell Death
-↑Caspase 12
↔↔BiP (GRP78)EndoplasmicReticulum
↔↑14-3-3
↔↔AKT
↑ (48h)↑ERKNeuroprotective
F21 Expression
(Compared to untreated control)
SMB Expression
(compared to SMB-PS)
Signalling
molecule
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5.4 Discussion 
5.4.1 Cell signalling and MnPrP 
 
Previous studies have shown that prion diseases cause massive neuronal cell death 
(Fairbairn et al., 1994; Giese et al., 1995). In vitro results have demonstrated caspase 
3 cleavage is at least partially responsible for cell death. Studies have shown that 
primary neuronal cells treated with PrP 106-126 underwent massive neuronal 
apoptosis characterised by DNA fragmentation and activation of caspase 3 (Carimalo 
et al., 2005), caspase 3 activation has also been observed in a neuronal cell line 
treated with PrP 106-126 (Corsaro et al., 2003).  
 
Initial investigations have shown that MnPrP is toxic to several cell lines and to 
primary CGNs. In this chapter it was shown, using a variety of methods, that MnPrP 
causes apoptosis in both F21 and SMB cells. Initially DNA laddering was observed 
48h after treatment with MnPrP. As caspase 3 has been shown to be required for 
DNA fragmentation (Janicke et al., 1998) we investigated whether caspase 3 was 
activated in response to MnPrP. We found that caspase 3 was activated at 16h after 
MnPrP treatment in F21 cells and was still visible at 24h. In SMB cells treated with 
MnPrP active caspase 3 was only seen at 16h. Further work in our laboratory has 
confirmed that caspase 3 is involved in cell death in our model as inhibition of 
caspase 3 using a specific caspase 3 inhibitor leads to an increase in cells viability in 
F21 cells treated with MnPrP (Uppington and Brown, 2008). 
 
We further investigated possible upstream signalling pathways that may activate 
caspase 3. p53 is a signalling molecule involved in the regulation of cell cycle (Diller 
et al., 1990). p53 can activate caspase 3 in CGNs (Cregan et al., 1999). p53 has been 
shown to be involved in apoptosis in a variety of neurodegenerative diseases 
including Alzheimer’s (Tamagno et al., 2003a) and Parkinson’s (Martin et al., 2006). 
p53 has been implicated in apoptosis in prion disease (Engelstein et al., 2005). 
However inhibition of the p53 in hamsters infected with prion disease did not reduce 
incubation time, despite reducing caspase 3 expression (Engelstein et al., 2005). This 
implies that p53 mediated caspase 3 is not the sole mechanism of cell death in prion 
disease. PrPc may have a role in p53 regulation, p53 studies indicate that p53-
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dependent caspase 3 activation triggered is by the C1 fragment of PrPc (Paitel et al., 
2004; Sunyach et al., 2007) and this is dependent on PrPc endocytosis (Sunyach and 
Checler, 2005).   
 
In response to cellular stress p53 is up-regulated and its stability is increased. 
However in our model p53 expression significantly decreased suggesting that it is 
not involved in the activation of caspase 3 in our model. As there is evidence that 
p53-dependant caspase 3 activation can be triggered by PrPc upon its endocytosis 
(Sunyach and Checler, 2005). We postulate that in our model PrPc endocytosis is 
inhibited by MnPrP and therefore caspase 3 cannot be activated, via this pathway.  
 
We investigated p38 activation as another possible mechanism for caspase 3 
activation. Previous research using the 106-126 peptide had implicated p38 in 
caspase 3 activation (Thellung et al., 2002). Further work has shown that p38 is 
involved in caspase 3 activation in cells treated with PrP 90-231 (Corsaro et al., 
2006; Villa et al., 2006). In vivo work has shown p38 is activated in the brains of 
hamsters infected with scrapie (Lee et al., 2005). We demonstrated that in our model 
p38 phosphorylation was visible 16h after treatment with MnPrP. As several 
previous studies have shown that PrP peptides mediate p38 phosphorylation leading 
to caspase 3 activation (Corsaro et al., 2006; Corsaro et al., 2003; Thellung et al., 
2002; Villa et al., 2006), we believe that this pathway is at least one of the pathways 
responsible for cell death in our models. In order confirm its role in caspase 3 
activation in our system, further work should be to inhibit p38 and investigate 
whether this reduced caspase 3 activation. Work using a fibrillar fragment of PrP, 
90-231, has shown that inhibition of p38 activation leads to a reduction in apoptosis 
in cells treated with the fragment (Villa et al., 2006), further suggesting that the p38 
pathway may be important in cell death in prion disease. 
 
Studies of the therapeutic use of p38 inhibitors have shown they can reduce 
behavioural deficits in a mouse model of Alzheimer’s disease (Munoz et al., 2007). 
As inhibition of the cell signalling mechanisms leading to cell death could be of use 
therapeutically, the upstream mechanism leading to p38 activation should be 
investigated to find other possible targets for therapeutic inhibition. As there is 
evidence that prion disease causes an increase in m
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brain, it could be hypothesised that p38 is activated in response to the increase in 
ROS. Previous work has shown that treatment of neurones with PrP 106-126 leads to 
an increase in ROS and activation of p38 (Pietri et al., 2006). This activation of p38 
is most likely triggered by NO production as this has been demonstrated to trigger 
activation of the p38 pathway in neurones (Moriya et al., 2000). This results in the 
translocation of Bax from the mitochondria leading to apoptosis (Ghatan et al., 
2000). p38 can also be activated by hydrogen peroxide, studies using Aβ have shown 
that Aβ treatment leads to an increase in hydrogen peroxide production and 
activation of p38 (Tamagno et al., 2003b). Alpha synuclein and toxic forms of the 
prion protein have been shown to generate hydrogen peroxide in vitro (Tabner et al., 
2005) suggesting that hydrogen peroxide may play a role in cell death in a variety of 
neurodegenerative diseases. 
5.4.2 Cell signalling and infection. 
 
Initial studies led us to believe that SMB cells carry a low level of prion disease, as 
the lysate from SMB cells is not toxic to either SMB cells or to F21 cells. However, 
we were interested in any modification in signalling that may have allowed cells to 
survive even a low level infection for such a long period of time, as previous 
research has shown changes in apoptotic signalling in cells treated with sub-lethal 
levels of 106-126 (White et al., 2001). Initially we wanted to confirm that there was 
no low level apoptosis in SMB cells. No DNA laddering in was observed in SMB 
cells, we also looked for caspase activation in both SMB and SMB-PS cells and 
found no evidence of activation in either cell line. Finally, as we have shown p38 
activation in F21 cells treated with MnPrP, we investigated p38 activation in SMB 
and SMB-PS cells and found no evidence of activation or up-regulation in either cell 
line. 
 
As SMB cells maybe under stress due to the infection they carry, we investigated the 
expression levels of several un-cleaved caspases in SMB and SMB-PS cells. We 
found no evidence of an increase in expression of caspase 3 and 9. However there 
was a large increase in caspase 12 expression in SMB cells, when compared to 
SMB-PS cells in which caspase 12 was almost undetectable. Interestingly, caspase 
12 is an ER resident caspase, and as SMB cells have a large amount of misfolded 
- 123 - 
 
protein in the ER it may be an increase in caspase 12 expression in response to this 
accumulation. This is most likely a stress response and not protective to the cells. 
Further work would need to be undertaken to investigate whether the caspase 12 
present in SMB cells is cleaved and if so, what downstream effects, occur including 
whether cleavage of caspase 12 leads to apoptosis. We also investigated whether BiP 
was up-regulated. BiP is an ER chaperone that has been shown to bind to misfolded 
PrP and mediate its degradation (Jin et al., 2000). However, no evidence of up-
regulation could be found in SMB cells. Previous work on ER stress in prion disease 
has been contradictory, as some studies have shown active caspase 12 in N2A cells 
treated with PrPsc (Hetz et al., 2003b), whilst, in vivo studies have shown that ER 
stress has a limited role in prion disease (Unterberger et al., 2006). More recent work 
has investigated the possibility that the ER releases calcium in response to PrP 
leading to mitochondrial mediated cell death (Ferreiro et al., 2008b), as scrapie 
infected cells appear to be under ER stress calcium release should be investigated in 
these cells. 
 
In order to better understand survival pathways that may be activated in chronically 
infected cells we investigated ERK and AKT, two signalling molecules that have 
been shown to play an important role in neuronal survival. Both molecules respond 
to neurotrophins, which normally leads to survival. AKT signals via PI3K. ERK is a 
member of the MAPK family, and its sole upstream activator is MEK. Microarray 
studies have identified PrPc as having a significant relationship with AKT, and 
MAPK signalling pathways (Satoh et al., 2008). There is evidence that AKT 
activation can be modulated by PrPc, PrP knockout mice have reduced AKT 
activation and enhanced caspase-3 activation in response to cerebral ischemia (Weise 
et al., 2006). ERK activation is up-regulated in brains of hamsters infected with 
scrapie  (Lee et al., 2005), ERK has also been shown to be involved in the neurotoxic 
response to PrP 106-126 mediated by glial cells (Combs et al., 1999).  
 
Whilst there was no change in AKT activation in infected cells compared to 
uninfected, ERK activation was up-regulated in infected cells. In order to investigate 
this further we inhibited ERK activation in cured and infected cells and examined 
cell viability. Infected cells treated with the MEK inhibitor showed a decrease in cell 
viability, suggesting that ERK up-regulation is important in SMB survival as this 
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was not seen in cured cells. The precise reasons for the protective effect of ERK are 
not clear. ERK has been demonstrated to be important in protection of cells in 
response to oxidative stress  (Han and Holtzman, 2000). As our laboratory has 
shown that SMB cells are more resistant to oxidative stress, we hypothesised that 
ERK activation was protecting against oxidative stress induced by infection, 
however we found no evidence of this. Studies have shown that ERK up-regulation 
can be protective against other neurodegenerative diseases, treatment of neurones 
with Aβ oligomers leads to apoptosis, which can be prevented by Docosahexaenoic 
acid, in part due to an up-regulation of ERK (Florent et al., 2006), this suggests that 
ERK inhibition might be a useful therapeutic tool against prion toxicity. 
 
We also investigated whether ERK was activated in F21 cells treated with MnPrP 
but did not see any increase in ERK activation in cells treated for 24h with MnPrP. 
Work using tissue from scrapie infected brains has previously shown a down-
regulation of ERK pathway genes (Sorensen et al., 2008), however after MnPrP 
treatment 48h we saw an increase in ERK activation. We hypothesise that, as we 
have shown there is little further cell death after 48h, the remaining cells may up-
regulate ERK as a protective mechanism allowing the cells to survive and that this 
mechanism is similar to the mechanism in SMB cells.  
 
We finally investigated possible upstream activators of ERK. We investigated 14-3-
3, which has been shown to be involved in the regulation of a wide variety of 
proteins including ERK (Xing et al., 2000) and Bad (Datta et al., 2000). We found 
that 14-3-3 expression was increased in infected cells and therefore may be one of 
the upstream proteins involved ERK regulation. 14-3-3 has been hypothesised to 
prevent apoptosis by a variety of mechanisms including by binding Raf leading to 
activation of ERK and this is postulated to protect cells. 14-3-3 has been found in the 
CSF of CJD patients (Hsich et al., 1996) although why it is there remains unclear. It 
may be due to up-regulation of a variety of signalling mechanisms as 14-3-3 
involved in many signalling responses.  
 
Overall our findings have demonstrated that cell death in MnPrP is due to apoptosis, 
and that this is at least partially caspase 3 mediated, probably in response to p38 
activation. We have also demonstrated that there is no evidence of apoptosis in cells 
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infected with scrapie and that these cells have developed a signalling mechanism 
involving ERK, which allows them to survive the infection. This up-regulation of 
ERK activation is also observed in cells that survive MnPrP treatment, suggesting 
that modulating expression of certain survival signalling pathways could be useful 
therapeutically. Much more still need to be done to elucidate the pathways involved 
in the cell death signalling that occurs when cells are treated with MnPrP and the 
pathways that regulate SMB survival. Elucidation of the upstream pathways may 
give us a better understanding of the precise causes of neuronal cell death in prion 
disease and other neurodegenerative diseases. 
 
Further work should look at possible upstream targets of ERK, this could provide a 
therapeutic target. Work has suggested that microglial cells treated with PrP 106-126 
up-regulate ERK via PKC which is activated in response to calcium, although in 
contrast to our study ERK is not protective but results in the production of 
neurotoxic signalling molecules (Combs et al., 1999). However PKC activation 
should be investigated in our model. Work investigating whether MnPrP can activate 
glial signalling may also give us a better understanding of toxicity of the MnPrP. 
Further work should also investigate ERK expression in vivo, as previous work has 
shown it is up-regulated in hamsters infected with scrapie (Lee et al., 2005), however 
the role of ERK over-expression has not been elucidated, investigations using 
transgenic mice over-expressing ERK could determine the role of ERK in prion 
diseases. 
 
As well as investigating protective signalling mechanisms elucidation of the 
pathway(s) involved in MnPrP cell death could provide therapeutic targets. As 
oxidative stress has been implicated in cell death in prion disease further 
investigation into the whether MnPrP treatment results in free radical production 
could provide a clue to the upstream pathways involved in apoptosis. Investigations 
have shown that PrP 106-126 triggers reactive oxygen species overflow in cells 
leading to up-regulation of both ERK and JNK resulting in apoptosis (Pietri et al., 
2006). 
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6. Rescuing cells from MnPrP induced cell death 
 
Although there has been intensive study of prion diseases no suitable therapies have 
been developed that are able to slow or halt disease progression. Having established 
a model of toxicity using MnPrP our aim in this chapter was to find a method of 
preventing the toxicity of MnPrP. 
 
PrPc has been shown to have superoxide dismutase activity, leading to the belief that 
it may be involved in preventing oxidative stress in the brain. Mice lacking the PrP 
protein have been shown to express higher levels of oxidative stress markers (Wong 
et al., 2001c). In the disease state, the brains of scrapie infected mice also exhibit 
oxidative stress even before clinical symptoms develop (Yun et al., 2006). Therefore 
reducing oxidative stress may prevent cell death in prion disease.  
 
The level of PrPc in the cell has also been shown to effect the incubation time of the 
disease (Manson et al., 1994; Prusiner et al., 1993). PrPc is also up-regulated in 
disease (Voigtlander et al., 2001) suggesting that PrPsc may have some effect on the 
promoter. Therefore down regulating PrP may decrease toxicity. In this regard 
regulating the prion promoter activity may be of benefit. 
 
The prion protein is encoded by the prnp gene which has been well characterised in 
several species. In mice it consists of three exons and two introns, with the third 
exon encompassing the entire open reading frame (Westaway et al., 1994). All the 
prion promoters studied so far lack a TATA box. However various binding sites 
have been found that enhance and inhibit promoter activity. These include Sp-1 
binding sites and AP-1 and AP-2 binding sites, which can inhibit and enhance 
promoter activity depending on which transcription factors bind to them (Saeki et al., 
1996b). Heat shock elements have been found in the rat promoter (Shyu et al., 2002), 
and heat shock proteins have been shown up-regulate prion protein expression in 
humans cells (Shyu et al., 2000), there is also an increase in expression of heat shock 
proteins in disease (Tortosa et al., 2007).  
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Whilst mammals are susceptible to prion diseases there is no evidence of these 
diseases in species such as reptiles and birds, although prion protein analogues are 
found in both species. There is much less conservation of the prion protein sequence 
between mammals and non-mammalian species. A notable example of the large 
differences in prion protein structure is the prion protein analogue found in Xenopus. 
This protein is missing the octarepeat region (Calzolai et al., 2005) involved in 
binding metals. If non-mammalian PrP retains the function of mammalian PrP and 
cannot be converted to PrPsc it may provide protection from PrP toxicity. 
 
This part of our study aims to further understand the mechanisms that lead to cell 
death in the model we have developed, and used a variety of methods to try and 
prevent cell the cell death observed. Initially we investigated whether MnPrP 
increased the levels of reactive oxygen species in system, and found that there was a 
significant increase in levels when cells were treated with MnPrP, however 
prevention of the increase in ROS using antioxidants was not enough to prevent cell 
death suggesting that this may not be the main cause of cell death in our system. 
 
We went on to investigate whether over expression of Xenopus or turtle PrP was 
able to prevent cell death induced by MnPrP. Prion disease does not occur naturally 
in these species, leading us to hypothesise the prion protein in these species may be 
resistant to conversion. However over expression of Xenopus PrP was unable to 
protect cells from MnPrP induced cell death, and turtle PrP was only able to slightly 
reduce the levels of cell death caused by MnPrP, suggesting that cell death signalling 
is able to take place regardless of the species of PrP being expressed by the cell. 
 
The prion promoter can be modulated by a variety of factors including neuronal 
growth factor (Zawlik et al., 2006) and copper (Varela-Nallar et al., 2006), we 
wanted to investigate whether PrP could modulate the prion promoter. We found that 
apoPrP, but not MnPrP could modulate the prion promoter. 
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6.1 Generation of Reactive Oxygen Species. 
 
F21 cells were treated with MnPrP or apoPrP and reactive oxygen species were 
assessed using a fluorescent probe. The probe, CM-H2DCFDA, is a cell permeable 
probe. However once oxidised to it fluoresces and is no longer cell permeable so 
remains inside the cell. It can be oxidised by hydrogen peroxide, organic 
hyroperoxides, nitric oxide and peroxynitrite. Cells were treated for 4h prior to the 
addition of the probe. Fluorescence was measured at time 0, 1 and 2h after the 
addition of the probe. The MnPrP treated wells had significantly higher levels of 
ROS when compared to apoPrP (figure 6.1).  
 
Figure 6.1: Cellular ROS production by F21 cells treated with MnPrP.  F21 cells were treated 
for 4h with varying concentrations of MnPrP (red line), apoPrP (green line) or a manganese 
control (yellow line). After 4h the media was removed and replaced with the fluorescent probe 
DCDFDA. Cell fluorescence was then assessed. Error bars are SEM and each point represents 
at least 6 repeats. Significance was assessed using a one way ANOVA p<0.01. 
 
As MnPrP was removed when the probe was added we wanted to investigate 
whether adding both the probe and the MnPrP the same time would make any 
difference to the levels of ROS produced. F21 cells were treated with the probe and 
MnPrP at the same time, this time the cells were not pre-incubated but ROS 
production was immediately assessed and then assessed again after 2h. An increase 
in cell ROS production was still observed in cells treated in this manner (data not 
shown). 
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The increase in ROS observed in F21 cells treated with MnPrP was also observed in 
SMB cells treated with MnPrP (figure 6.2), although this required higher 
concentrations of MnPrP than in the F21 cells. This may be due to the fact that SMB 
cells cannot be plated as densely however it may be due to SMBs producing less 
ROS in response to MnPrP. 
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Figure 6.2: Cellular ROS production by SMB cells treated with MnPrP. SMB cells were treated 
for 4h with varying concentrations of MnPrP (red line), apoPrP (blue line). After 4h the media 
was removed and replaced with the fluorescent probe DCDFDA. Cell fluorescence was then 
assessed. Error bars are SEM and each point represents at least 6 repeats. Significance was 
assessed using a one way ANOVA p<0.01. 
 
We went on to investigate whether antioxidants could reduce the levels of ROS 
induced by MnPrP. We first investigated All-Trans-Retinoic-Acid (ATRA), this is a 
powerful antioxidant, which has previously been shown to reduce PrP expression 
(Rybner et al., 2002).  
 
Initial experiments showed that ATRA was able to significantly reduce the levels of 
ROS generated by treatment with MnPrP (figure 6.3). However further work 
revealed that ATRA was toxic at levels high enough to significantly reduce ROS 
expression in MnPrP treated cells, making this an unsuitable antioxidant to use in 
these experiments. We went on to investigate whether low levels of ATRA could 
protect, possibly by another mechanism. F21 cells were treated for 24h with varying 
concentrations of MnPrP and either 0.5µM or 1µM ATRA and viability was assessed 
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by MTS assay (figure 6.4). No difference was observed in survival suggesting that 
ATRA is not able to save cells from MnPrP induced apoptosis. 
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Figure 6.3: The effect of ATRA on cellular ROS expression by F21 cells.  F21 cells were treated 
for 4h with varying concentrations of ATRA and MnPrP. After 4h the media was removed and 
replaced with the fluorescent probe DCDFDA. Cell fluorescence was then assessed at time 0 
(red line) and after 2h (green line). Error bars are SEM and each point represents at least 3 
repeats. 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Survival of F21 cells treated with MnPrP and ATRA. F21 cells were treated for 24h 
with varying concentrations of MnPrP alone (red) MnPrP and 0.5µM ATRA (yellow) or MnPrP 
and 1µM ATRA (green). Cell viability was assessed by MTS assay. Error bars are SEM and 
each point represents at least 3 repeats. 
 
We used the antioxidants vitamin C (ascorbic acid) and E (α-tocopherol) in order to 
further investigate whether antioxidants could be useful in rescuing cells treated with 
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MnPrP. We initially investigated whether either antioxidant was able to reduce basal 
levels of F21 ROS production. Cells were treated with either 40mM ascorbic acid or 
10µM tocopherol and the probe. ROS production was measured after addition of the 
probe and then at 1 and 2h (figure 6.5). 
 
Figure 6.5: The effect of ascorbic acid and α-tocopherol on cellular ROS expression by F21 cells. 
F21 cells were either untreated (red) or treated with ascorbic acid (green) tocopherol (yellow) 
and treated with the fluorescent probe DCDFDA. Cell fluorescence was then assessed at time 0 
after 1h and after 2h. Error bars are SEM and each point represents at least 3 repeats. 
Significance was assessed using a Student’s T-Test p<0.05. 
 
Tocopherol was able to significantly reduce basal levels of ROS production when 
compared to the control. Ascorbic acid was less effective and was only able to 
significantly reduce ROS production at 1h. 
 
We then investigated the ability of both ascorbic acid and tocopherol to reduce the 
levels of ROS produced by MnPrP treatment. Cells were either pretreated with the 
antioxidants for 4h and then the probe and MnPrP were added or cells were treated 
with probe, antioxidant and MnPrP at the same time. Both ascorbic acid and 
tocopherol were able to significantly reduce the level of ROS produced by MnPrP 
treated cells. The reduction greater if the cells were not pretreated, but added with 
the MnPrP (figure 6.6). We ensured the levels of both antioxidants did not affect cell 
viability after 24h of treatment (figure 6.7). 
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Figure 6.6: Effect of ascorbic acid and tocopherol on ROS production by F21 cells treated with 
MnPrP. A: F21 cells were pretreated with either ascorbic acid (green) or tocopherol (yellow) or 
untreated (red). Cells were incubated for 4h prior to the addition of the probe and 40µg/ml 
MnPrP. Fluorescence was then assessed. B: F21 cells were treated with either ascorbic acid 
(green) or tocopherol (yellow) or untreated (red), prior to the addition of the probe and 40µg/ml 
MnPrP. Fluorescence was then assessed. Error bars are SEM and each bar represents at least 3 
repeats. Significance was assessed using a Student’s T-Test *<0.05. 
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Figure 6.7: Effect of ascorbic acid and tocopherol on F21 cell survival. F21 cells were treated for 
24h with either 40mM ascorbic acid or 10µM tocopherol for 24h and viability was assessed 
using an MTS assay. Error bars are SEM n=3. There was no significant difference between the 
control and either ascorbic acid or α-tocopherol as assessed by students T-test. 
 
F21 cells were treated with both MnPrP and the antioxidants and cells were 
incubated for 24h. Cell viability was assessed using an MTS assay. No difference 
was seen in viability whether cells had been treated with the antioxidant or not 
(figure 6.8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Effect of ascorbic acid and tocopherol on MnPrP treated F21 cell survival. F21 cells 
were treated with either MnPrP alone (red), ascorbic acid and MnPrP (green) or tocopherol 
and MnPrP (yellow) for 24h. Viability was assessed using a MTS assay, no points were 
significant as assessed by Students T-test. 
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We hypothesised that the antioxidants used might not survive for long periods of 
time at 37oC and so we investigated whether there was any difference in viability of 
cells treated with antioxidants and MnPrP for a shorter time period of 8h (figure 6.9). 
There was no difference in viability, indicating that despite being able to 
significantly reduce the levels of ROS produced by cells treated with MnPrP 
antioxidants are not sufficient to reduce MnPrP toxicity. 
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Figure 6.9: Effect of ascorbic acid and tocopherol on MnPrP treated F21 cell survival. F21 cells 
were treated with either MnPrP alone (red), ascorbic acid and MnPrP (green) or tocopherol 
and MnPrP (yellow) for 8h. Viability was assessed using a MTS assay, no points were significant 
as assessed by Students T-test. 
6.2 The Prion Promoter 
 
Cellular PrP expression is required for disease pathogenesis and the level of PrPc 
expression has been shown effect disease incubation (Manson et al., 1994; Prusiner 
et al., 1993). Therefore the modulation of expression of PrP by the promoter may 
alter disease progression. 
 
F14 cells, lacking PrPc expression, were transiently transfected with either the full-
length mouse promoter which had been tagged with GFP or with a GFP tagged 
CMV promoter both were in the pd2-EGFP vector and had been created as 
previously described (Haigh et al., 2007). The CMV (Cytomegalovirus) promoter is 
constitutively expressed and acts as a control (figure 6.10). 
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Figure 6.10: F14 cells transfected with the mouse PrP promoter or CMV promoter. Cells were 
transiently transfected with A: A WT mouse prion promoter tagged with GFP B: A CMV 
promoter tagged with GFP. Expression was assessed using confocal microscopy. 
 
Previous work has shown that GFP expression was up-regulated by DMSO in F14 
cells expressing the full length promoter suggesting DMSO was able to modulate the 
promoter. In order ensure that the promoter could be modulated transfected cells 
were treated for 1h with 1% DMSO and there was a visible increase in GFP 
expression (figure 6.11). 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: The effect of DMSO on promoter expression. Incubation of WT and CMV cells 
with 1% DMSO for 1h. Images were captured using a confocal microscope at 63x 
magnification.  
 
To investigate the ability of MnPrP and apoPrP to modulate the expression of the 
promoter we treated cells for 4h with 80 µg/ml PrP or with a manganese control and 
GFP intensity was assessed. Interestingly the apoPrP was able to significantly down-
regulate PrP promoter expression, whilst MnPrP had lost this ability (figure 6.12). 
Therefore the binding of manganese to the prion protein inhibits its ability to 
A B
WT cells after 1hr incubation with 1% DMSO
CMV cells after 1hr incubation with 1% 
DMSO
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regulate the promoter. There was no difference in intensity in CMV promoter 
expression with any treatment. 
 
Figure 6.12: The effect of MnPrP on promoter expression. Cells were transfected with WT 
promoter and treated for 4h with either apoPrP, MnPrP or a Manganese control. Cellular GFP 
intensity was assessed using Zeiss LSM software. Each bar represents at least 25 cells. Error 
bars are SEM. Significant points were assessed using students T-test *p<0.05. 
6.3 Non Mammalian Prion Proteins 
 
The prion protein is highly conserved between mammals; however PrP analogues 
found in non-mammalian species are less well conserved. Evolutionary speaking 
Xenopus PrP is one of the most distant prion proteins to be fully characterised and is 
completely missing the octarepeat region (Calzolai et al., 2005) (figure 6.13). We 
wanted investigate if Xenopus prion protein could protect cells from MnPrP toxicity 
as prion expression has been shown to be required for toxicity. We hypothesised as 
Xenopus do not naturally develop prion disease the PrP they express may not be 
susceptible to conversion and therefore could protect against prion toxicity. Cells 
were stably transfected with either GFP tagged mouse PrP or GFP tagged Xenopus 
PrP. Expression was checked visually prior to any experiment. Previous work using 
confocal microscopy had shown that constructs were expressed at the cell surface, as 
would be expected (figure 6.13), In order to express turtle and Xenopus in a 
mammalian cells parts of the mouse PrP sequence were used, meaning the protein 
was correctly processed to the cell surface. The mouse construct contained the GFP 
sequence inserted at amino acid 42, the full mouse sequence is included in it. The 
Xenopus and turtle constructs contained the mouse sequence from amino acid 1 to 
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42, then the GFP and then the turtle or Xenopus sequence, the mouse sequence was 
also included at the C-terminus end of the protein from amino acid 231, again to 
allow correct processing of the protein. The construct was inserted into pEGFP-C1 
vector (figure 6.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: Expression of non-mammalian prion proteins. A: Confocal microscopy of F14 cells 
transfected with mouse, turtle or Xenopus PrP tagged with GFP (Pictures kindly donated by Dr 
Cathryn Haigh). B: A schematic diagram of Xenopus mouse and turtle PrP. C: A schematic 
diagram showing the GFP construct used, mouse regions were used to ensure the protein was 
correctly expressed. 
 
Cells were plated and treated for 24h with varying concentrations of PrP and cell 
viability was assessed using an MTS assay. There was no difference in the viability 
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of cells transfected with Xenopus PrP or mouse PrP suggesting that Xenopus PrP is 
not able to protect cells from MnPrP induced toxicity (figure 6.14). 
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Figure 6.14: Effect of Xenopus PrP expression on cell survival in response to MnPrP. Cells were 
transfected with a GFP tagged mouse PrP construct (red) or a GFP tagged Xenopus PrP 
construct (green). Transfected cells were then treated for 24h with varying concentrations of 
MnPrP. Viability was assessed by MTS assay. Error bars are SEM, n=9. No points were 
significant as assessed by students T-Test.  
 
We also investigated the ability of the expression of turtle PrP to protect the cells 
from MnPrP toxicity. Turtles do not develop prion disease naturally like Xenopus, 
but unlike Xenopus they retain a repeat region although it is a hexarepeat rather than 
an octarepeat. F14 cells were transfected with either a GFP tagged mouse PrP 
construct or a GFP tagged turtle PrP construct, which was expressed at the cell 
surface (figure 3.13). Cells were then treated for 24h with MnPrP for 24h. 
Interestingly cells expressing turtle PrP showed a slight but significant increase in 
cell viability when compared to cells expressing mouse PrP suggesting that turtle 
PrP may be able to protect cells from MnPrP toxicity (figure 3.15). 
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Figure 6.15: Effect of turtle PrP expression on cell survival in response to MnPrP. Cells were 
transfected with a GFP tagged mouse PrP construct (red) or a GFP tagged turtle PrP construct 
(green). Transfected cells were then treated for 24h with varying concentrations of MnPrP. 
Viability was assessed by MTS assay. Error bars are SEM, n=3. *<0.05 as assessed by students 
T-Test.  
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6.4 Discussion 
 
A large body of work has suggested a link between prion disease and oxidative 
stress. In the normal state the prion protein has been demonstrated to be important in 
preventing oxidative stress (Brown et al., 1997b; Watt et al., 2007; Wong et al., 
2001c). In the disease state there is evidence of markers of oxidative damage 
(Freixes et al., 2006; Guentchev et al., 2000; Yun et al., 2006), although it is not 
clear whether this is due to the loss of the normal prion protein or the disease 
process.  
 
Our study has revealed that MnPrP increases the amount of ROS produced by F21 
cells whilst apoPrP does not increase ROS production. Previous studies using other 
models of prion toxicity, have also shown an increase in oxidative stress. Cells 
treated with toxic levels of PrP 106-126 have increased heme-oxygenase (HO-1) 
expression, a marker of oxidative stress (Rizzardini et al., 1997). Microglial cells 
have been shown to release nitric oxide in response to PrP 90-231 (Thellung et al., 
2007). As in our model studies have suggested the importance of metals in the 
generation of ROS by the prion protein. A C-terminal fragment of PrP containing 
several known disease related mutations was found to generate hydrogen peroxide in 
the presence of iron and this was hypothesised to result in enhanced toxicity of the 
protein (Turnbull et al., 2003b).  
 
We hypothesise that MnPrP, like PrPsc, is able to induce oxidative-stress and this 
requires the presence of metals. In order to inhibit the production of ROS by cells 
treated with MnPrP we treated the cells with the antioxidants tocopherol or ascorbic 
acid. Tocopherol has been shown to protect neural tissue form damage by oxidative 
stress in vitro. Studies showed that rat neurons subjected to hypoxia could be saved 
by tocopherol treatment (Tagami et al., 1998). Ascorbic acid has been shown to 
reduce neuronal apoptosis observed in the developing brains of rats exposed to 
arsenic, which causes oxidative stress (Tagami et al., 1998). However there has been 
little research into specific antioxidant therapies in CJD, although α--tocopherol has 
also been shown to reduce the toxicity of PrP 106-126 in cerebellar cultures (Brown 
et al., 1996) and a single case of treatment with antioxidants has been reported, with 
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an increase in life expectancy (Drisko, 2002). There has been much more research 
into the use of antioxidants in Alzheimer’s disease as a possible therapy, although α-
-tocopherol, has been shown to be fairly ineffective (Boothby and Doering, 2005). 
  
In our model whilst antioxidant treatment was able to reduce the levels of ROS 
produced by MnPrP, this did not rescue the cells from MnPrP induced apoptosis. 
This may be due to the fact that we did not use high enough concentrations of 
antioxidants. Previous studies using tocopherol to inhibit prion induced cell death 
have used much higher concentrations (Brown et al., 1996). However in our system 
concentrations higher than used resulted in an increased in cellular proliferation so 
could not be used in conjunction with the cellular proliferation assay used to assess 
cell death. As the levels used resulted in a significant reduction in ROS levels it 
could be suggested that ROS may not be the major component in cell death in our 
system. However in vivo oxidative stress may be relevant especially as prion 
diseases are more prevalent in the elderly who are more susceptible to oxidative 
stress (Urano et al., 1998). 
 
One of the limitations of the work is the use of a general probe for ROS rather than 
using more specific probes. Further investigation of the reactive oxygen species 
produced when cells are treated with MnPrP may provide more insight whether there 
is a specific reactive oxygen species produced, and allow us to elucidate the 
signalling pathway that leads to it production. Previous studies have highlighted 
some pathways that maybe involved in ROS production in prion disease. The 106-
126 peptide can increase ROS production in a neuronal cell line and it is suggested 
this is due to an interaction with PrPc on the cell surface involving the signalling 
molecule fyn-kinase, a molecule widely thought to be involved in PrPc signalling, 
and this ROS production could be reduced using a fyn-kinase inhibitor (Pietri et al., 
2006). Other studies have suggested other pathways that maybe involved in ROS 
production in prion disease, treatment with 106-126 has been shown to increase 
cystolic Ca2+ levels leading to an increase in the production of ROS which could be 
reduced by preventing Ca2+ release from the ER (Ferreiro et al., 2008b; Ferreiro et 
al., 2006). Future work should concentrate on investigating the types of ROS 
produced in our model and the signalling mechanisms involved, this would provide a 
better understanding of the role of ROS in our model. 
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The increase in ROS observed in F21 cells treated with MnPrP was also observed in 
SMB cells treated with MnPrP. This is perhaps unsurprising as MnPrP is also toxic 
to SMB cells.  However the dose of MnPrP required to induce ROS production was 
higher than in the F21 cells. This may be due to the fact that SMB cells cannot be 
plated as densely. This would need to be investigated, either by ensuring that 
identical numbers of cells were plated or using a different method such as flow 
cytometry which can count individual cells. If the difference is not due to a disparity 
in plating, the differences observed could also be due to changes in the signalling 
pathways involved in ROS induction. These signalling pathways may not being 
activated in response to low levels MnPrP in SMB cells as readily as F21 cells. This 
could be protective response developed by SMB cells to resist PrPsc toxicity. Initial 
observations in our laboratory have shown that SMB cells are more resistant 
oxidative stress than SMB-PS cells. Further work could investigate whether SMB 
and SMB-PS cells require different concentrations of MnPrP to induce ROS 
production.  
 
Prion expression has been shown to be important in disease pathogenesis. Down-
regulation of PrP expression via the prion promoter may be able to increase or 
decrease cell death observed. The promoter can be modulated by several factors, 
including copper. From a therapeutic point of view perhaps the most interesting 
factor is all-Trans retinoic acid (ATRA). ATRA is a vitamin A derivative already 
used in the treatment of promyelocytic leukaemia. It has been shown to down-
regulate PrP expression although the mechanisms by which it does this are unclear 
but could involve the transcription factor AP-2 (Rybner et al., 2002). AP-2 has been 
suggested to exert an effect on the prnp gene (Cabral et al., 2002).  
 
As previous studies had shown that PrP expression was up-regulated in prion disease 
(Voigtlander et al., 2001) we initially hypothesised that PrPsc might be up-regulating 
the expression of PrP by acting on its own promoter. In order to test this in our 
model we investigated whether MnPrP could up-regulate the PrP promoter leading to 
an over-expression of PrPc.  
 
In vivo if PrPsc was able to regulate its own promoter, thereby increasing prion 
protein expression, this would lead to a decrease in incubation time, as over-
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expression of PrP in mice has been shown to lead to a shorter incubation time 
(Bueler et al., 1993; Manson et al., 1994). We found that MnPrP showed a tendency 
to increase promoter activity, although this was not significant. ApoPrP was able to 
down-regulate PrP expression. The ability of PrP to regulate its own promoter would 
be extremely important in PrP toxicity and in vivo in disease progression. We 
hypothesise that the down-regulation observed when cells are treated with apoPrP, 
would lead to a decrease in PrP expression and a correspondent decrease in the 
toxicity, as PrP expression is required for PrP toxicity (Novitskaya et al., 2006). 
Conversely the tendency of MnPrP to up-regulate PrP promoter activity would result 
in an increase in PrP expression and a resulting increase in toxicity. ApoPrP may be 
able to regulate the prion promoter as once in the media it may bind copper giving a 
structure like PrPc, it may then be able to modulate signalling leading to a decrease 
in PrP expression. This self-regulation of PrP keeps the cellular level of PrP low. 
The up-regulation of the promoter by MnPrP may be one of the causes of MnPrP 
toxicity. In order to investigate whether MnPrP does up-regulate PrP expression and 
if apoPrP can down-regulate PrP expression levels of PrP expression should be 
assessed at the protein level using Western blotting. This would allow us to confirm 
that the increase or decrease in promoter activity was functional rather than an 
artefact. This would then allow us to investigate how PrP is able to regulate its own 
promoter. PrP may interact directly with promoter and the change in response may 
be due to the change in protein structure and is ability to directly interact with the 
promoter. If PrP is not able to enter the nucleus and interact directly with the prion 
promoter change in expression may come either from apoPrP interacting directly 
with a cell surface receptor or PrPc on the cell surface or indirect activation of 
signalling pathways.  The prion promoter has been shown to associate with several 
cellular proteins including laminin (Gauczynski et al., 2001) and fyn kinase (Pietri et 
al., 2006), however there is no evidence that PrP binding to receptors can result in a 
change in promoter activity.  
 
As oxidative stress has been shown to be regulate the prion promoter (Shyu et al., 
2004), it maybe the increase in ROS produced by MnPrP that leads to the up-
regulation of the PrP promoter. Studies have also shown that the signalling molecule 
MEK is able to activate the PrP promoter in response to neuronal growth factor 
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(NGF) (Zawlik et al., 2006). As MEK is activated by MnPrP (via ERK) in our 
system this may be the reason for the increase in promoter activation observed.   
 
There has been extensive work investigating the species barrier that generally 
prevents the spread of prion disease between different species. Studies have 
demonstrated that inoculation of mice with hamster scrapie generally does not result 
in disease, unless the mice express HaPrP (hamster PrP) (Prusiner et al., 1990; Scott 
et al., 1989). Further work demonstrated that mice expressing HaPrP specifically in 
astrocytes were susceptible to prion disease. However expression of mouse PrP 
prevented this susceptibility (Raeber et al., 1997). This suggests that expression of 
PrP may have an inhibitory effect on the conversion of PrP from other species. 
Although there are notable exceptions to this barrier, including the proposed spread 
of BSE into the human population as vCJD (Bruce et al., 1997). We hypothesised 
that by expressing non-mammalian prion proteins we could prevent the toxicity of 
MnPrP. We choose to use non-mammalian prion proteins as they show little 
sequence homology to mouse PrP, although they do retain a surprisingly similar 
secondary structure (Ahn and Son, 2007; Calzolai et al., 2005). Xenopus PrP does 
not have the octarepeat region found in most prion proteins (Calzolai et al., 2005) 
and unpublished data from our laboratory has shown that it does not bind metals. A 
chimera of Xenopus and mouse PrP expressed in cells has shown that the N-terminal 
region of Xenopus, despite missing the octarepeat region, is able to direct subcellular 
trafficking of the prion protein properly suggesting that the N-terminus is required as 
targeting signal for subcellular trafficking (Nunziante et al., 2003). This also 
suggests that Xenopus/mouse chimera can be successfully expressed in mammalian 
cells, this confirms our observations that the chimera appeared to be properly 
expressed at the cell surface. Turtle PrP is closer in primary structure to mouse PrP, 
still retaining some of the metal binding motifs (Calzolai et al., 2005). Neither turtle 
PrP nor Xenopus PrP expression was able to completely save cells from MnPrP 
induced cell death, although turtle PrP expression did give a slight protective effect.  
 
In order for the turtle and Xenopus prion protein to be properly processed and 
expressed in mammalian cells the regions involved in the processing of the protein 
however these signalling regions should be cleaved during processing and are 
unlikely to have impact on the ability of the protein to protect the F14 cells from 
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MnPrP toxicity. However a small part of the N-terminus of mouse PrP would still be 
present in the protein after processing and the effect of this on toxicity should be 
investigated. 
 
Previous work using recombinant protein has demonstrated that a human PrPres seed 
is unable to convert recombinant mouse PrP to PrPres in vitro suggesting that the 
species barrier still exists between recombinant proteins (Baskakov, 2004). This led 
us to the conclusion that the non-mammalian proteins expressed by the cells must 
still have the regions required for toxicity, this is perhaps unsurprising given that 
certain regions have been shown to retain structural motifs that may be important in 
function. Recent work has suggested that the octarepeat region may be important for 
conversion (Sakudo et al., 2008), however in our system, expressing Xenopus PrP 
which does not have the octarepeat region we observed no reduction in prion toxicity 
suggesting it is not required for prion toxicity. This is also confirmed by work using 
construct such as the mini-prion which do not contain the octarepeat region but are 
still toxic to cells (Bonetto et al., 2002).  
 
Further investigation of the ability of turtle PrP to protect against MnPrP toxicity is 
required, including investigating the effect of the mouse regions in the protein on the 
ability to protect against toxicity. In order to elucidate whether turtle PrP is able to 
protect against infection as well as toxicity attempts to infect permissible cell lines 
expressing turtle PrP should be undertaken. The ability of other non-mammalian 
prion proteins, such as avian prion proteins, to protect against MnPrP toxicity should 
also be investigated. 
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7. General Discussion 
7.1 Models of Prion Toxicity 
 
Prion diseases have been studied extensively and multiple models of prion toxicity 
have been developed. Mouse models have been used to establish the requirement of 
PrPc expression for both infectivity and toxicity (Brandner et al., 1996; Bueler et al., 
1993; Bueler et al., 1994). Several different animal models have also highlighted the 
role of neuronal apoptosis in the pathogenesis of prion disease (Fairbairn et al., 1994; 
Giese et al., 1995). Work using mouse models has revealed deletion of certain 
regions of the prion protein can result in neurodegeneration in mice suggesting these 
regions of the protein interact to prevent exposure of highly toxic domains. For 
example deletion of amino acids 105-125 of the prion protein has been shown to 
cause neonatal lethality in mice (Li et al., 2007b). A prion protein expressed in the 
cytosol is also toxic mice (Norstrom et al., 2007). Mouse models provide an accurate 
model of prion disease, although some, such as the deletion mutants, do not 
necessarily mimic a situation that would occur naturally in disease but highlight 
regions important for prion protein stability.  
 
Perhaps the most widely used models of PrP toxicity are cells (either primary or cell 
lines) treated with either peptides or recombinant PrP. These models provide 
information on the regions of PrP required for toxicity as well as the mechanism of 
toxicity. Unlike mouse models they provide a low cost, high throughput model. 
However the biological relevance of some of the peptides and PrP fragments has 
been called into question. The most widely used peptide is the 106-126 peptide. This 
peptide has many of the properties of the prion protein (Forloni et al., 1993) and has 
been widely used to investigate the mechanism of toxicity of the prion protein 
(Corsaro et al., 2003; Dupiereux et al., 2006; Ettaiche et al., 2000; Pietri et al., 2006). 
However it is not a fragment of the prion protein that has been found in vivo and as 
such it cannot replicate the situation in vivo. Several other peptides have been found 
that replicate some properties of the prion peptide. A peptide spanning the putative 
transmembrane region of the prion protein (amino acids 118-135) has been shown to 
be toxic to neuronal cells although this was not dependant on cellular PrP 
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expression, so it does not replicate the in vivo situation (Chabry et al., 2003). A 
peptide that corresponds to a fragment of the prion protein found in the brains of 
patients of GSS, the fragment has been shown to be toxic to primary cortical neurons 
and toxicity is dependent on cellular PrP expression (Fioriti et al., 2007). Whilst 
peptides can be used as model of prion disease, they cannot replicate the differing 
fragments of PrP found in vivo and in the disease, and as such represent a limited 
model of toxicity. 
 
Many studies have used recombinant protein to investigate the toxicity of the prion 
protein, however conversion of the protein is often uses chemicals that would not be 
found at the concentrations used in vivo (Post et al., 2000), or thermal denaturation 
(Corsaro et al., 2006) or shaking (Novitskaya et al., 2006). However recombinant 
protein has been shown to be selectively toxic to cells that express PrPc (Novitskaya 
et al., 2006; Post et al., 2000), suggesting that whilst the conversion methods 
currently used may not be relevant in vivo the use of recombinant protein provides a 
useful model of prion disease. Our model of prion disease uses full-length 
recombinant PrP which is bound to manganese unlike the conversions described 
previously there is evidence that manganese is bound to PrPsc in vivo (Wong et al., 
2001b) so it does represent a valid model of PrPsc in vivo.  
 
We showed that MnPrP was significantly more toxic to cell lines than apoPrP and 
that toxicity of the protein was dependant on cellular PrP expression, representing 
the situation in vivo. However the dose of MnPrP required for toxicity was quite 
high, other studies using recombinant protein generally used slightly lower doses, 
0.5µM was sufficient to cause up to 30% cell death in N2a cells treated with 
recombinant PrP fibrils (Novitskaya et al., 2006).  
 
Although apoPrP was significantly less toxic than MnPrP it was toxic to cells, this is 
in contrast to studies using PrP 90-231 which have shown that in its α-helical state is 
not toxic to cells, although in a β-sheet rich conformation it is highly toxic (Corsaro 
et al., 2006). The structure of the prion protein is thought to be important for toxicity 
and previous work using MnPrP has shown that it is partially protease resistant and 
has a higher β-sheet content once aged, this mimics some of the properties of PrPsc 
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(Brown et al., 2000) and therefore it is likely the increased β-sheet structure 
contributed to the toxicity of MnPrP. 
 
In order to investigate the toxicity of MnPrP we choose to use an in vitro model, we 
choose this model for several reasons. Firstly time constraints meant that mouse 
models would have limited our ability to fully research the toxicity of MnPrP. We 
were also aware that whilst animal models provide the best replication of disease, 
cell models can provide greater detail at a cellular level and therefore give us a 
greater understanding of the underlying causes of MnPrP toxicity. However the lack 
of an in vivo study is one of the greatest limitations of the model and, as misfolded 
PrP produced in vitro has been shown to infect mice (Castilla et al., 2005; Weber et 
al., 2007), the ability of MnPrP to infect cells and mice should be investigated.  
 
The use of recombinant protein also means we are unable to replicate the 
glycosylation of PrP. Glycosylation is thought to be important in determining the 
outcome of prion infection. Mice can sustain infection even when expressing an 
unglycosylated prion protein, however disease susceptibility is reduced and some 
strains do require glycosylation for infection suggesting that glycosylation plays an 
important in prion diseases (Tuzi et al., 2008). Work in an in vivo model should 
establish whether glycosylation is important in toxicity in our model. 
 
There are several strong lines of evidence to suggest that manganese binding to PrP 
may have a role in prion disease. Manganese has been shown to bind to PrP, with a 
lower affinity than copper (Brazier et al., 2008; Jackson et al., 2001). The lower 
affinity for manganese led to a hypothesis that manganese binding would not occur 
in vivo. However recent studies have suggested that the dissociation constant of PrP 
for manganese is similar to that of other, known, manganese binding proteins 
(Brazier et al., 2008). They also revealed that manganese binding to PrP did not 
require copper displacement, which had previously been thought to be a requirement 
for manganese binding to PrP (Brazier et al., 2008). This strongly suggests that 
manganese binding to the prion protein could occur in vivo. Previous work had also 
shown that PrP bound to manganese had many of the properties associated with 
PrPsc, including partial protease resistance and an increase in β-sheet structure. 
MnPrP had also been shown to be toxic to neuronal cells and this was dependent on 
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cellular PrP expression (Brown et al., 2000). Increasing evidence has also pointed to 
a role for manganese in the disease in vivo, there is an increase in manganese in the 
CNS of patients suffering from CJD (Hesketh et al., 2008) and in scrapie infected 
mice (Thackray et al., 2002) and sheep (Hesketh et al., 2007). Work has also shown 
that manganese is associated with PrPsc extracted from the brains of patients with 
sCJD, suggesting the increase in manganese observed in the disease may be due to 
manganese binding to the prion protein (Wong et al., 2001b). Whilst there is 
increasing evidence of the relevance of manganese in prion disease the toxicity of 
manganese bound PrP has not been fully studied, this thesis has revealed that 
manganese binding results in increased toxicity. We further investigated the role of 
manganese binding in prion toxicity and demonstrated that if the histidines known to 
bind manganese were mutated the toxicity of the protein was significantly reduced. 
This suggested that binding of manganese, to known metal binding sites, was 
required for toxicity. We have also shown that removal of the octarepeat region 
increases the toxicity of MnPrP, suggesting that this region has a protective effect. In 
contrast removal of the fifth site has no effect on toxicity.  
 
Further work could look at the effect of other metals on PrP toxicity, iron has been 
implicated in the conversion of PrP in vitro (Basu et al., 2007) and therefore may 
have an effect on the toxicity of the prion protein. Work should also investigate the 
effect of copper binding on PrP toxicity. As copper is thought to be bound to PrPc in 
vivo it would be expected to be less toxic than PrP bound to other metals but there is 
evidence that copper can cause toxicity, copper has been shown to increase the 
aggregation of PrP 106-126 and its toxicity (Jobling et al., 2001). This suggests there 
may be a more complex relationship that needs to be investigated. 
 
There is increasing evidence that metal imbalance maybe relevant in other 
neurodegenerative diseases suggesting that our model of neurotoxicity could be 
useful to research into other neurodegenerative diseases. Previous studies have 
shown that Amyloid Beta (AΒ), the main constituent of amyloid plaques in the 
brains of AD patients, can bind copper and zinc (Talmard et al., 2007; Tougu et al., 
2008). Copper binding to AΒ 25-35 has been shown to promote conversion to a 
more β-sheet structured peptide that is more toxic in vitro (Giuffrida et al., 2007). It 
has also been suggested that zinc binding to AΒ can cause aggregation (Tougu et al., 
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2008). Whilst we have developed a limited understanding of the regions involved in 
MnPrP toxicity further structural and aggregation studies of the mutants may reveal 
the reasons for the differing toxicities of mutants and may reveal a similar 
mechanism of aggregation and toxicity to that of Aβ bound to metals, this may mean 
that similar therapies are useful in both diseases. 
 
7.2 Cell signalling in prion disease 
 
Prion diseases result in massive neuronal cell death, several studies have shown this 
is due to apoptosis of the neurones (Fairbairn et al., 1994; Giese et al., 1995; Gray et 
al., 1999). However the signalling mechanisms that initiate apoptosis remain unclear. 
Several studies have shown that caspase 3 cleavage is involved in initiating 
apoptosis in prion disease (Corsaro et al., 2006; Ferreiro et al., 2008a; Jamieson et 
al., 2001). However some studies have concluded that cell death is independent of 
caspase 3 activation (Engelstein et al., 2005; Saez-Valero et al., 2000), as inhibition 
of caspase 3 was unable to prevent cell death. In contrast we have found that 
inhibition of caspase 3 results in cell survival in our model (Uppington and Brown, 
2008) suggesting that cell death in our model is initiated by caspase 3. 
 
Investigations have revealed several signalling mechanisms by which cell death may 
occur in prion disease. It has been suggested that cell death is due to endoplasmic 
reticulum (ER) stress which causes activation of caspase 12, an ER associated 
caspase (Hetz et al., 2003b). Further work has highlighted the role of calcium 
dysregulation in apoptosis; cells treated with PrP 106-126 release calcium through 
ER ryanodine (RyR) and inositol 1,4,5-trisphosphate (IP(3)R) receptors inducing ER 
stress and leading to increased cytosolic calcium and reactive oxygen species (ROS) 
levels leading  to apoptotic death involving the mitochondria (Ferreiro et al., 2008a; 
Ferreiro et al., 2008b). However in vivo investigations has not shown evidence of ER 
stress in the brain’s of mice infected with scrapie (Unterberger et al., 2006).  
 
Other studies have investigated the role of Bax in prion disease. PrPc prevents Bax 
mediated cell death, by preventing the conformational changes that occur upon 
activation of Bax (Roucou et al., 2005). However Bax has also been implicated  in 
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the neurotoxicity of mutant prion proteins (Chiesa et al., 2005; Li et al., 2007a), but 
deletion of Bax does not prevent against prion toxicity in mice infected with scrapie 
(Steele et al., 2007) suggesting that this may not be an obligatory pathway for 
neuronal apoptosis in prion diseases.  
 
Many studies have investigated the role of the MAPKs and SAPKs in neuronal 
apoptosis in prion diseases. Studies have suggested that JNK is activated in response 
to PrP 106-126 (Carimalo et al., 2005; Pietri et al., 2006) and activation may be due 
to increased oxidative stress (Pietri et al., 2006). JNK activation has also been 
observed in vivo (Lee et al., 2005) and inhibition of JNK activation significantly 
reduced cell death in vitro (Carimalo et al., 2005). p38, a member of the MAPK 
family, has also been implicated neuronal apoptosis in prion disease. p38 is activated 
in cells treated with PrP 106-126 and inhibition of p38 prevents PrP 106-126 toxicity 
(Corsaro et al., 2003). Similar results were also observed in cells treated with the 
toxic conformer of PrP 90-231 (Villa et al., 2006). 
 
In common with many other studies investigating prion toxicity we found that 
caspase 3 was activated in response to MnPrP leading to DNA fragmentation (figure 
7.1). Further work has revealed that, unlike some studies, caspase 3 inhibition results 
cell survival, suggesting that caspase 3 activation is required for cell death in 
response to MnPrP. Investigation has revealed that p38 is also activated in response 
to MnPrP and we propose that p38 is responsible for the activation of caspase 3. 
However further work is required to confirm this. Our work is in line with in vivo 
models of prion disease in that cell death is due to apoptosis and this is mediated 
caspase 3. However as with other models of prion diseases the upstream signalling 
events leading to caspase 3 activation remains unclear. Further investigation is 
required to fully understand the upstream signalling that leads to cell death in our 
model. Cell death signalling may be initiated in response to increase ROS we have 
observed in cells treated with MnPrP and this should be investigated further. 
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Figure 7.1: A diagram showing the major signalling pathways induced by MnPrP. The red 
circles represent MnPrP and the green circles represent PrPc, dashed arrows represent assumed 
pathways. 
 
7.3 Chronic scrapie infection and cell survival 
 
One of the hallmarks of prion disease is vacuolation in the brain caused by massive 
neuronal cell death (Fairbairn et al., 1994; Giese et al., 1995; Gray et al., 1999), 
however several cell lines have been shown to be able to maintain scrapie infection 
with no detrimental effect. Perhaps the best studied is the N2a cell line, which can be 
infected with scrapie and mouse adapted CJD without any detrimental effect (Butler 
et al., 1988). SMB cells can also be infected with scrapie and again show no 
detrimental effects (Birkett et al., 2001). However many cell lines cannot be infected 
with scrapie, and other cell lines, such as GT1 cells, undergo low-level apoptosis 
(Schatzl et al., 1997). Interestingly over-expression of Trk4, a receptor for NGF, in 
GT1 cells and treatment with NGF resulted in a reversal of apoptotic signs (Schatzl 
et al., 1997). NGF, a cell survival molecule, can signal through ERK and it may be 
that the up-regulation observed by us in scrapie infected SMB cells, which we 
propose is a survival mechanism, is similar to the cell survival mechanism observed 
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in GT1 cells over-expressing Trk 4. There are examples of ERK playing a role in 
survival in other neurodegenerative diseases. Brain-derived neurotrophic factor 
(BDNF) has been shown to protect neonatal brains from hypoxic-ischemic injury via 
an ERK mediated pathway (Han and Holtzman, 2000). Zwitter mice have been 
suggested to develop neurodegeneration by a decrease in active ERK through 
intracellular signalling via oxidative stress (Muto and Sato, 2003). D-fructose-1,6-
bisphosphate against has been shown to protect against β-amyloid neurotoxicity in 
rat hippocampal organotypic slice cultures, partially due to the up-regulation of ERK 
(Song et al., 2005). Further work in an in vivo model of prion disease should 
investigate whether over-expression of ERK can result in an extension of scrapie 
incubation time. 
7.4 Possible therapies for prion diseases 
 
A variety of treatments have been tested both in vivo and in vitro however, as yet, no 
treatment for prion disease has been used successfully in humans. Compounds that 
interact with PrPsc could be useful in preventing conversion by stopping PrPsc 
interacting with PrPc. Several compounds have been shown to bind PrP and inhibit 
conversion of PrP. These include Congo red and its derivatives. Congo red is dye 
used to stain amyloid protein fibrils in histopathology. It has also been shown to 
delay the onset of prion disease when injected into animals at the time of infection 
(Ingrosso et al., 1995). However Congo red has several shortfalls including a low 
permeability to the BBB. Several derivatives of Congo red have been shown to be 
effective in curing cells in vitro and may be more suitable as a therapy (Sellarajah et 
al., 2004). 
 
Several other compounds have been shown to prevent the conversion of PrPc to 
PrPsc, quinacrine, an anti-malarial, binds to PrPc and, in vitro, was able to inhibit the 
accumulation of PrPsc in scrapie infected cells (Doh-Ura et al., 2000). However in 
tests in vivo has proved to be ineffective either as a prophylactic (Collins et al., 2002) 
or in mice already infected with prion disease (Doh-ura et al., 2004). Several patients 
have also been treated with quinacrine however benefits have been limited (Benito-
Leon, 2004; Nakajima et al., 2004). Pentosan polysulphate (PPS) has also been 
shown to prevent the propagation of PrPsc in vitro
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and prolong the incubation period of infection in vivo (Doh-ura et al., 2004; 
Ladogana et al., 1992). 
 
An emerging therapy may be RNA aptamers, RNA aptamers are structural pieces of 
RNA that can interfere with specific proteins. Several aptamers have been shown to 
specifically bind PrP. And one aptamer, which recognises a peptide comprising 
amino acid residues 90-129 of the human prion protein with high specificity, has 
been shown to significantly reduce the de novo production of PrPsc in vitro (Proske 
et al., 2002). 
 
Down-regulating cellular prion expression has been proposed as a possible therapy 
for prion diseases as prion expression is required for infection (Bueler et al., 1993) 
and down-regulating PrP expression has been shown to lengthen disease incubation 
time (Manson et al., 1994; Prusiner et al., 1993). Research in mouse models has also 
shown that down-regulating prion protein expression in mice infected with prion 
disease halts neuronal cells death and the mouse recovers, showing that even in 
infected animals, down regulation of PrP expression could lead to a halt in disease 
progression (Mallucci et al., 2007). We investigated whether MnPrP was able to alter 
PrP promoter activity, as PrP expression is up-regulated in disease. We found that 
MnPrP was able to up-regulate promoter activity (although this was not statistically 
significant) and apoPrP down-regulated promoter activity. This suggests that PrP can 
regulate its own promoter and further investigation into the mechanisms by which 
PrP can do this may lead to possible therapeutic target. 
 
In the disease state immunohistochemistry of brain slices of mice infected with 
scrapie have revealed several markers of oxidative stress including nitrotyrosine, a 
marker of peroxynitrite generation (Guentchev et al., 2000) and lipid oxidation 
markers (Wong et al., 2001a). In vitro experiments are in agreement with these 
results, oxidative stress was induced in cells treated with the 106-126 fragment of 
PrP (Brown et al., 1997b). It is clear that oxidative stress may have a significant role 
in neurodegeneration in prion disease and prevention of oxidative stress may slow 
disease progression. However there has been little research into specific antioxidant 
therapies in CJD, although a single case of treatment with antioxidants has been 
reported, with an increase in life expectancy (Drisko, 2002). Oxidative stress is also 
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prominent in both Parkinson’s and Alzheimer’s, markers of oxidative stress are also 
found in the brains of Parkinson’s sufferers (Jenner et al., 1992) and Alzheimer’s 
sufferers (Sayre et al., 1997). AΒ and alpha-synuclein have been shown to generate 
hydrogen peroxide during the early stages of aggregation (Tabner et al., 2005), as 
has as a fragment of PrP (Turnbull et al., 2003b). It has been proposed that this 
peroxide generation may mediate toxicity as an antioxidant can reduce the toxicity of 
PrP 106-126 probably by scavenging hydroxyl radicals produced by it (Turnbull et 
al., 2003c). Recent work has suggested that attenuation of oxidative stress and 
mitochondrial dysregulation had therapeutic benefit in an animal model of 
Parkinson’s (Stack et al., 2008). We observed an increase in cellular ROS in cells 
treated with MnPrP, but treatment with antioxidants did not reduce cell death, 
however further work should investigate other antioxidants. The mechanisms 
underlying ROS production by cells treated with MnPrP should also be investigated, 
this may allow inhibition of ROS production and therefore prevent cell death. 
 
There has been extensive work investigating the species barrier that generally 
prevents the spread of prion disease between different species. Studies have 
demonstrated that inoculation of mice with hamster scrapie generally does not result 
in disease, unless the mice express hamster PrP (Prusiner et al., 1990; Scott et al., 
1989). This suggests that expression of PrP may have an inhibitory effect on the 
conversion of PrP from other species. We investigated whether expressing non-
mammalian prion proteins we could prevent the toxicity of MnPrP. We choose to 
use non-mammalian prion proteins as they show little sequence homology to mouse 
PrP, although they do retain a surprisingly similar secondary structure (Ahn and Son, 
2007; Calzolai et al., 2005). Xenopus PrP does not have the octarepeat region 
conserved in most prion proteins (Calzolai et al., 2005) and unpublished data from 
our laboratory has shown that it does not bind metals. Turtle PrP is closer in primary 
structure to mouse PrP, still retaining some of the metal binding motifs (Calzolai et 
al., 2005). Neither turtle PrP nor Xenopus PrP expression was able to completely 
save cells from MnPrP induced cell death, although turtle PrP expression did give a 
slight protective effect which should be investigated further. Previous work using 
recombinant protein has demonstrated that a human PrPres seed is unable to convert 
recombinant mouse PrP to PrPres in vitro suggesting that the species barrier still 
exists between recombinant proteins (Baskakov, 2004). This led us to the conclusion 
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that the non-mammalian proteins expressed by the cells must still have at least some 
of the regions required for toxicity, this is perhaps unsurprising given that certain 
regions have been shown to retain structural motifs that may be important in 
function. Further work should investigate the regions required for PrP toxicity, 
possibly by expressing mutants missing regions of the prion protein in PrP-Null cells 
and treating with MnPrP. Further investigation of the protective effect of turtle PrP 
should also be undertaken. 
 
This study has demonstrated that manganese bound PrP is a sound model of prion 
toxicity. It also provided some insight into the mechanisms that lead to MnPrP cell 
death. However further work is required to produce an animal model of MnPrP 
infection. Further work should also be carried out in the in vitro model to better 
understand the mechanism of toxicity, this may provide possible therapeutic targets. 
- 157 - 
 
References 
 
(1996) From the Centers for Disease Control and Prevention. Surveillance for 
Creutzfeldt-Jakob disease--United States. Jama, 276, 938-939. 
Abdelraheim, S.R., Kralovicova, S. and Brown, D.R. (2006) Hydrogen peroxide 
cleavage of the prion protein generates a fragment able to initiate 
polymerisation of full length prion protein. Int J Biochem Cell Biol, 38, 1429-
1440. 
Aguzzi, A., Raeber, A., Blattler, T., Flechsig, E., Klein, M., Weissmann, C. and 
Brandner, S. (1997) Neurotoxicity and neuroinvasiveness of prions. J 
Neurovirology, 3 Suppl 1, S23-24. 
Ahn, I. and Son, H.S. (2007) Comparative bioinformatics analysis of prion proteins 
isolated from reptile, rodent, ruminant, and human species. Exp Mol Med, 39, 
769-777. 
Ala, A., Walker, A.P., Ashkan, K., Dooley, J.S. and Schilsky, M.L. (2007) Wilson's 
disease. Lancet, 369, 397-408. 
Aronoff-Spencer, E., Burns, C.S., Avdievich, N.I., Gerfen, G.J., Peisach, J., 
Antholine, W.E., Ball, H.L., Cohen, F.E., Prusiner, S.B. and Millhauser, G.L. 
(2000) Identification of the Cu2+ binding sites in the N-terminal domain of 
the prion protein by EPR and CD spectroscopy. Biochemistry, 39, 13760-
13771. 
Baskakov, I.V. (2004) Autocatalytic conversion of recombinant prion proteins 
displays a species barrier. J Biol Chem, 279, 7671-7677. 
Baskakov, I.V., Legname, G., Baldwin, M.A., Prusiner, S.B. and Cohen, F.E. (2002) 
Pathway complexity of prion protein assembly into amyloid. J Biol Chem, 
277, 21140-21148. 
Basu, S., Mohan, M.L., Luo, X., Kundu, B., Kong, Q. and Singh, N. (2007) 
Modulation of proteinase K-resistant prion protein in cells and infectious 
brain homogenate by redox iron: implications for prion replication and 
disease pathogenesis. Mol Biol Cell, 18, 3302-3312. 
Baumann, F., Tolnay, M., Brabeck, C., Pahnke, J., Kloz, U., Niemann, H.H., 
Heikenwalder, M., Rulicke, T., Burkle, A. and Aguzzi, A. (2007) Lethal 
recessive myelin toxicity of prion protein lacking its central domain. Embo J, 
26, 538-547. 
Benito-Leon, J. (2004) Combined quinacrine and chlorpromazine therapy in fatal 
familial insomnia. Clin Neuropharmacol, 27, 201-203. 
Biasini, E., Medrano, A.Z., Thellung, S., Chiesa, R. and Harris, D.A. (2008) 
Multiple biochemical similarities between infectious and non-infectious 
aggregates of a prion protein carrying an octapeptide insertion. J Neurochem, 
104, 1293-1308. 
Binolfi, A., Rasia, R.M., Bertoncini, C.W., Ceolin, M., Zweckstetter, M., Griesinger, 
C., Jovin, T.M. and Fernandez, C.O. (2006) Interaction of alpha-synuclein 
with divalent metal ions reveals key differences: a link between structure, 
binding specificity and fibrillation enhancement. J Am Chem Soc, 128, 9893-
9901. 
Birkett, C.R., Hennion, R.M., Bembridge, D.A., Clarke, M.C., Chree, A., Bruce, 
M.E. and Bostock, C.J. (2001) Scrapie strains maintain biological phenotypes 
on propagation in a cell line in culture. Embo J, 20, 3351-3358. 
- 158 - 
 
Bocharova, O.V., Breydo, L., Salnikov, V.V. and Baskakov, I.V. (2005) Copper(II) 
inhibits in vitro conversion of prion protein into amyloid fibrils. 
Biochemistry, 44, 6776-6787. 
Bonetto, V., Massignan, T., Chiesa, R., Morbin, M., Mazzoleni, G., Diomede, L., 
Angeretti, N., Colombo, L., Forloni, G., Tagliavini, F. and Salmona, M. 
(2002) Synthetic miniprion PrP106. J Biol Chem, 277, 31327-31334. 
Boothby, L.A. and Doering, P.L. (2005) Vitamin C and vitamin E for Alzheimer's 
disease. Ann Pharmacother, 39, 2073-2080. 
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., 
Marino, S., Weissmann, C. and Aguzzi, A. (1996) Normal host prion protein 
necessary for scrapie-induced neurotoxicity. Nature, 379, 339-343. 
Brazier, M.W., Davies, P., Player, E., Marken, F., Viles, J.H. and Brown, D.R. 
(2008) Manganese binding to the prion protein. J Biol Chem. 
Brown, D.R. (1999) Prion protein expression aids cellular uptake and veratridine-
induced release of copper. J Neurosci Res, 58, 717-725. 
Brown, D.R. (2000a) Altered toxicity of the prion protein peptide PrP106-126 
carrying the Ala(117)-->Val mutation. Biochem J, 346 Pt 3, 785-791. 
Brown, D.R. (2000b) PrPSc-like prion protein peptide inhibits the function of 
cellular prion protein. Biochem J, 352 Pt 2, 511-518. 
Brown, D.R. (2001) Copper and prion disease. Brain Res Bull, 55, 165-173. 
Brown, D.R., Guantieri, V., Grasso, G., Impellizzeri, G., Pappalardo, G. and 
Rizzarelli, E. (2004) Copper(II) complexes of peptide fragments of the prion 
protein. Conformation changes induced by copper(II) and the binding motif 
in C-terminal protein region. J Inorg Biochem, 98, 133-143. 
Brown, D.R., Hafiz, F., Glasssmith, L.L., Wong, B.S., Jones, I.M., Clive, C. and 
Haswell, S.J. (2000) Consequences of manganese replacement of copper for 
prion protein function and proteinase resistance. Embo J, 19, 1180-1186. 
Brown, D.R., Herms, J. and Kretzschmar, H.A. (1994) Mouse cortical cells lacking 
cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport, 
5, 2057-2060. 
Brown, D.R., Qin, K., Herms, J.W., Madlung, A., Manson, J., Strome, R., Fraser, 
P.E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W., Giese, A., Westaway, 
D. and Kretzschmar, H. (1997a) The cellular prion protein binds copper in 
vivo. Nature, 390, 684-687. 
Brown, D.R., Schmidt, B. and Kretzschmar, H.A. (1996) Role of microglia and host 
prion protein in neurotoxicity of a prion protein fragment. Nature, 380, 345-
347. 
Brown, D.R., Schmidt, B. and Kretzschmar, H.A. (1997b) Effects of oxidative stress 
on prion protein expression in PC12 cells. Int J Dev Neurosci, 15, 961-972. 
Brown, D.R., Schulz-Schaeffer, W.J., Schmidt, B. and Kretzschmar, H.A. (1997c) 
Prion protein-deficient cells show altered response to oxidative stress due to 
decreased SOD-1 activity. Exp Neurol, 146, 104-112. 
Brown, D.R., Wong, B.S., Hafiz, F., Clive, C., Haswell, S.J. and Jones, I.M. (1999) 
Normal prion protein has an activity like that of superoxide dismutase. 
Biochem J, 344 Pt 1, 1-5. 
Brown, L.R. and Harris, D.A. (2003) Copper and zinc cause delivery of the prion 
protein from the plasma membrane to a subset of early endosomes and the 
Golgi. J Neurochem, 87, 353-363. 
Brown, P. and Bradley, R. (1998) 1755 and all that: a historical primer of 
transmissible spongiform encephalopathy. Bmj, 317, 1688-1692. 
- 159 - 
 
Bruce, M., Chree, A., McConnell, I., Foster, J., Pearson, G. and Fraser, H. (1994) 
Transmission of bovine spongiform encephalopathy and scrapie to mice: 
strain variation and the species barrier. Philos Trans R Soc Lond B Biol Sci, 
343, 405-411. 
Bruce, M.E., Will, R.G., Ironside, J.W., McConnell, I., Drummond, D., Suttie, A., 
McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H. and 
Bostock, C.J. (1997) Transmissions to mice indicate that 'new variant' CJD is 
caused by the BSE agent. Nature, 389, 498-501. 
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, 
N., Ramponi, G., Dobson, C.M. and Stefani, M. (2002) Inherent toxicity of 
aggregates implies a common mechanism for protein misfolding diseases. 
Nature, 416, 507-511. 
Bueler, H., Aguzzi, A., Sailer, A., Greiner, R.A., Autenried, P., Aguet, M. and 
Weissmann, C. (1993) Mice devoid of PrP are resistant to scrapie. Cell, 73, 
1339-1347. 
Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H.P., DeArmond, S.J., 
Prusiner, S.B., Aguet, M. and Weissmann, C. (1992) Normal development 
and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature, 
356, 577-582. 
Bueler, H., Raeber, A., Sailer, A., Fischer, M., Aguzzi, A. and Weissmann, C. (1994) 
High prion and PrPSc levels but delayed onset of disease in scrapie-
inoculated mice heterozygous for a disrupted PrP gene. Mol Med, 1, 19-30. 
Burns, C.S., Aronoff-Spencer, E., Legname, G., Prusiner, S.B., Antholine, W.E., 
Gerfen, G.J., Peisach, J. and Millhauser, G.L. (2003) Copper coordination in 
the full-length, recombinant prion protein. Biochemistry, 42, 6794-6803. 
Butler, D.A., Scott, M.R., Bockman, J.M., Borchelt, D.R., Taraboulos, A., Hsiao, 
K.K., Kingsbury, D.T. and Prusiner, S.B. (1988) Scrapie-infected murine 
neuroblastoma cells produce protease-resistant prion proteins. J Virol, 62, 
1558-1564. 
Cabral, A.L., Lee, K.S. and Martins, V.R. (2002) Regulation of the cellular prion 
protein gene expression depends on chromatin conformation. J Biol Chem, 
277, 5675-5682. 
Calne, D.B., Chu, N.S., Huang, C.C., Lu, C.S. and Olanow, W. (1994) Manganism 
and idiopathic parkinsonism: similarities and differences. Neurology, 44, 
1583-1586. 
Calzolai, L., Lysek, D.A., Perez, D.R., Guntert, P. and Wuthrich, K. (2005) Prion 
protein NMR structures of chickens, turtles, and frogs. Proc Natl Acad Sci U 
S A, 102, 651-655. 
Cardoso, S.M., Rego, A.C., Pereira, C. and Oliveira, C.R. (2005) Protective effect of 
zinc on amyloid-beta 25-35 and 1-40 mediated toxicity. Neurotox Res, 7, 
273-281. 
Carimalo, J., Cronier, S., Petit, G., Peyrin, J.M., Boukhtouche, F., Arbez, N., 
Lemaigre-Dubreuil, Y., Brugg, B. and Miquel, M.C. (2005) Activation of the 
JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by 
PrP106-126 and prion infection. Eur J Neurosci, 21, 2311-2319. 
Castilla, J., Saa, P., Hetz, C. and Soto, C. (2005) In vitro generation of infectious 
scrapie prions. Cell, 121, 195-206. 
Caughey, B. and Raymond, G.J. (1993) Sulfated polyanion inhibition of scrapie-
associated PrP accumulation in cultured cells. J Virol, 67, 643-650. 
- 160 - 
 
Cereghetti, G.M., Schweiger, A., Glockshuber, R. and Van Doorslaer, S. (2001) 
Electron paramagnetic resonance evidence for binding of Cu(2+) to the C-
terminal domain of the murine prion protein. Biophys J, 81, 516-525. 
Cervenakova, L., Buetefisch, C., Lee, H.S., Taller, I., Stone, G., Gibbs, C.J., Jr., 
Brown, P., Hallett, M. and Goldfarb, L.G. (1999) Novel PRNP sequence 
variant associated with familial encephalopathy. Am J Med Genet, 88, 653-
656. 
Chabry, J., Ratsimanohatra, C., Sponne, I., Elena, P.P., Vincent, J.P. and Pillot, T. 
(2003) In vivo and in vitro neurotoxicity of the human prion protein (PrP) 
fragment P118-135 independently of PrP expression. J Neurosci, 23, 462-
469. 
Chattopadhyay, M., Walter, E.D., Newell, D.J., Jackson, P.J., Aronoff-Spencer, E., 
Peisach, J., Gerfen, G.J., Bennett, B., Antholine, W.E. and Millhauser, G.L. 
(2005) The octarepeat domain of the prion protein binds Cu(II) with three 
distinct coordination modes at pH 7.4. J Am Chem Soc, 127, 12647-12656. 
Chen, M., Margittai, M., Chen, J. and Langen, R. (2007) Investigation of alpha-
synuclein fibril structure by site-directed spin labeling. J Biol Chem, 282, 
24970-24979. 
Chen, S.G., Teplow, D.B., Parchi, P., Teller, J.K., Gambetti, P. and Autilio-
Gambetti, L. (1995) Truncated forms of the human prion protein in normal 
brain and in prion diseases. J Biol Chem, 270, 19173-19180. 
Chiarini, L.B., Freitas, A.R., Zanata, S.M., Brentani, R.R., Martins, V.R. and Linden, 
R. (2002) Cellular prion protein transduces neuroprotective signals. Embo J, 
21, 3317-3326. 
Chiesa, R., Piccardo, P., Dossena, S., Nowoslawski, L., Roth, K.A., Ghetti, B. and 
Harris, D.A. (2005) Bax deletion prevents neuronal loss but not neurological 
symptoms in a transgenic model of inherited prion disease. Proc Natl Acad 
Sci U S A, 102, 238-243. 
Chiesa, R., Piccardo, P., Ghetti, B. and Harris, D.A. (1998) Neurological illness in 
transgenic mice expressing a prion protein with an insertional mutation. 
Neuron, 21, 1339-1351. 
Chihota, C.M., Gravenor, M.B. and Baylis, M. (2004) Investigation of trace 
elements in soil as risk factors in the epidemiology of scrapie. Vet Rec, 154, 
809-813. 
Chiovitti, K., Corsaro, A., Thellung, S., Villa, V., Paludi, D., D'Arrigo, C., Russo, 
C., Perico, A., Ianieri, A., Di Cola, D., Vergara, A., Aceto, A. and Florio, T. 
(2007) Intracellular accumulation of a mild-denatured monomer of the 
human PrP fragment 90-231, as possible mechanism of its neurotoxic effects. 
J Neurochem, 103, 2597-2609. 
Choi, C.J., Kanthasamy, A., Anantharam, V. and Kanthasamy, A.G. (2006) 
Interaction of metals with prion protein: possible role of divalent cations in 
the pathogenesis of prion diseases. Neurotoxicology, 27, 777-787. 
Clarke, M.C. and Haig, D.A. (1970) Multiplication of scrapie agent in cell culture. 
Res Vet Sci, 11, 500-501. 
Cobb, N.J., Sonnichsen, F.D., McHaourab, H. and Surewicz, W.K. (2007) Molecular 
architecture of human prion protein amyloid: a parallel, in-register beta-
structure. Proc Natl Acad Sci U S A, 104, 18946-18951. 
Cohen, F.E., Pan, K.M., Huang, Z., Baldwin, M., Fletterick, R.J. and Prusiner, S.B. 
(1994) Structural clues to prion replication. Science, 264, 530-531. 
- 161 - 
 
Cohen, F.E. and Prusiner, S.B. (1998) Pathologic conformations of prion proteins. 
Annu Rev Biochem, 67, 793-819. 
Collinge, J. (1997) Human prion diseases and bovine spongiform encephalopathy 
(BSE). Hum Mol Genet, 6, 1699-1705. 
Collinge, J., Palmer, M.S., Sidle, K.C., Gowland, I., Medori, R., Ironside, J. and 
Lantos, P. (1995a) Transmission of fatal familial insomnia to laboratory 
animals. Lancet, 346, 569-570. 
Collinge, J., Palmer, M.S., Sidle, K.C., Hill, A.F., Gowland, I., Meads, J., Asante, E., 
Bradley, R., Doey, L.J. and Lantos, P.L. (1995b) Unaltered susceptibility to 
BSE in transgenic mice expressing human prion protein. Nature, 378, 779-
783. 
Collins, S., McLean, C.A. and Masters, C.L. (2001) Gerstmann-Straussler-Scheinker 
syndrome,fatal familial insomnia, and kuru: a review of these less common 
human transmissible spongiform encephalopathies. J Clin Neurosci, 8, 387-
397. 
Collins, S.J., Lewis, V., Brazier, M., Hill, A.F., Fletcher, A. and Masters, C.L. 
(2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob 
disease model. Ann Neurol, 52, 503-506. 
Combs, C.K., Johnson, D.E., Cannady, S.B., Lehman, T.M. and Landreth, G.E. 
(1999) Identification of microglial signal transduction pathways mediating a 
neurotoxic response to amyloidogenic fragments of beta-amyloid and prion 
proteins. J Neurosci, 19, 928-939. 
Cordeiro, Y., Kraineva, J., Gomes, M.P., Lopes, M.H., Martins, V.R., Lima, L.M., 
Foguel, D., Winter, R. and Silva, J.L. (2005) The amino-terminal PrP domain 
is crucial to modulate prion misfolding and aggregation. Biophys J, 89, 2667-
2676. 
Corsaro, A., Paludi, D., Villa, V., D'Arrigo, C., Chiovitti, K., Thellung, S., Russo, 
C., Di Cola, D., Ballerini, P., Patrone, E., Schettini, G., Aceto, A. and Florio, 
T. (2006) Conformation dependent pro-apoptotic activity of the recombinant 
human prion protein fragment 90-231. Int J Immunopathol Pharmacol, 19, 
339-356. 
Corsaro, A., Thellung, S., Villa, V., Principe, D.R., Paludi, D., Arena, S., Millo, E., 
Schettini, D., Damonte, G., Aceto, A., Schettini, G. and Florio, T. (2003) 
Prion protein fragment 106-126 induces a p38 MAP kinase-dependent 
apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid 
fibril formation. Ann N Y Acad Sci, 1010, 610-622. 
Cortijo-Arellano, M., Ponce, J., Durany, N. and Cladera, J. (2008) Amyloidogenic 
properties of the prion protein fragment PrP(185-208): comparison with 
Alzheimer's peptide Abeta(1-28), influence of heparin and cell toxicity. 
Biochem Biophys Res Commun, 368, 238-242. 
Cregan, S.P., MacLaurin, J.G., Craig, C.G., Robertson, G.S., Nicholson, D.W., Park, 
D.S. and Slack, R.S. (1999) Bax-dependent caspase-3 activation is a key 
determinant in p53-induced apoptosis in neurons. J Neurosci, 19, 7860-7869. 
Cui, T., Daniels, M., Wong, B.S., Li, R., Sy, M.S., Sassoon, J. and Brown, D.R. 
(2003) Mapping the functional domain of the prion protein. Eur J Biochem, 
270, 3368-3376. 
Daniels, M., Cereghetti, G.M. and Brown, D.R. (2001) Toxicity of novel C-terminal 
prion protein fragments and peptides harbouring disease-related C-terminal 
mutations. Eur J Biochem, 268, 6155-6164. 
- 162 - 
 
Datta, S.R., Katsov, A., Hu, L., Petros, A., Fesik, S.W., Yaffe, M.B. and Greenberg, 
M.E. (2000) 14-3-3 proteins and survival kinases cooperate to inactivate 
BAD by BH3 domain phosphorylation. Mol Cell, 6, 41-51. 
DeArmond, S.J., McKinley, M.P., Barry, R.A., Braunfeld, M.B., McColloch, J.R. 
and Prusiner, S.B. (1985) Identification of prion amyloid filaments in 
scrapie-infected brain. Cell, 41, 221-235. 
DeMarco, M.L. and Daggett, V. (2004) From conversion to aggregation: protofibril 
formation of the prion protein. Proc Natl Acad Sci U S A, 101, 2293-2298. 
Demuro, A., Mina, E., Kayed, R., Milton, S.C., Parker, I. and Glabe, C.G. (2005) 
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic 
mechanism of soluble amyloid oligomers. J Biol Chem, 280, 17294-17300. 
Diller, L., Kassel, J., Nelson, C.E., Gryka, M.A., Litwak, G., Gebhardt, M., Bressac, 
B., Ozturk, M., Baker, S.J., Vogelstein, B. and et al. (1990) p53 functions as 
a cell cycle control protein in osteosarcomas. Mol Cell Biol, 10, 5772-5781. 
Doh-ura, K., Ishikawa, K., Murakami-Kubo, I., Sasaki, K., Mohri, S., Race, R. and 
Iwaki, T. (2004) Treatment of transmissible spongiform encephalopathy by 
intraventricular drug infusion in animal models. J Virol, 78, 4999-5006. 
Doh-Ura, K., Iwaki, T. and Caughey, B. (2000) Lysosomotropic agents and cysteine 
protease inhibitors inhibit scrapie-associated prion protein accumulation. J 
Virol, 74, 4894-4897. 
Donne, D.G., Viles, J.H., Groth, D., Mehlhorn, I., James, T.L., Cohen, F.E., 
Prusiner, S.B., Wright, P.E. and Dyson, H.J. (1997) Structure of the 
recombinant full-length hamster prion protein PrP(29-231): the N terminus is 
highly flexible. Proc Natl Acad Sci U S A, 94, 13452-13457. 
Drisko, J.A. (2002) The use of antioxidants in transmissible spongiform 
encephalopathies: a case report. J Am Coll Nutr, 21, 22-25. 
Dupiereux, I., Zorzi, W., Rachidi, W., Zorzi, D., Pierard, O., Lhereux, B., Heinen, E. 
and Elmoualij, B. (2006) Study on the toxic mechanism of prion protein 
peptide 106-126 in neuronal and non neuronal cells. J Neurosci Res, 84, 637-
646. 
Engelstein, R., Grigoriadis, N., Greig, N.H., Ovadia, H. and Gabizon, R. (2005) 
Inhibition of P53-related apoptosis had no effect on PrP(Sc) accumulation 
and prion disease incubation time. Neurobiol Dis, 18, 282-285. 
Ettaiche, M., Pichot, R., Vincent, J.P. and Chabry, J. (2000) In vivo cytotoxicity of 
the prion protein fragment 106-126. J Biol Chem, 275, 36487-36490. 
Fairbairn, D.W., Carnahan, K.G., Thwaits, R.N., Grigsby, R.V., Holyoak, G.R. and 
O'Neill, K.L. (1994) Detection of apoptosis induced DNA cleavage in 
scrapie-infected sheep brain. FEMS Microbiol Lett, 115, 341-346. 
Ferreiro, E., Costa, R., Marques, S., Cardoso, S.M., Oliveira, C.R. and Pereira, C.M. 
(2008a) Involvement of mitochondria in endoplasmic reticulum stress-
induced apoptotic cell death pathway triggered by the prion peptide PrP(106-
126). J Neurochem, 104, 766-776. 
Ferreiro, E., Eufrasio, A., Pereira, C., Oliveira, C.R. and Rego, A.C. (2007) Bcl-2 
overexpression protects against amyloid-beta and prion toxicity in GT1-7 
neural cells. J Alzheimers Dis, 12, 223-228. 
Ferreiro, E., Oliveira, C.R. and Pereira, C.M. (2008b) The release of calcium from 
the endoplasmic reticulum induced by amyloid-beta and prion peptides 
activates the mitochondrial apoptotic pathway. Neurobiol Dis. 
- 163 - 
 
Ferreiro, E., Resende, R., Costa, R., Oliveira, C.R. and Pereira, C.M. (2006) An 
endoplasmic-reticulum-specific apoptotic pathway is involved in prion and 
amyloid-beta peptides neurotoxicity. Neurobiol Dis, 23, 669-678. 
Fioriti, L., Angeretti, N., Colombo, L., De Luigi, A., Colombo, A., Manzoni, C., 
Morbin, M., Tagliavini, F., Salmona, M., Chiesa, R. and Forloni, G. (2007) 
Neurotoxic and gliotrophic activity of a synthetic peptide homologous to 
Gerstmann-Straussler-Scheinker disease amyloid protein. J Neurosci, 27, 
1576-1583. 
Fioriti, L., Dossena, S., Stewart, L.R., Stewart, R.S., Harris, D.A., Forloni, G. and 
Chiesa, R. (2005) Cytosolic prion protein (PrP) is not toxic in N2a cells and 
primary neurons expressing pathogenic PrP mutations. J Biol Chem, 280, 
11320-11328. 
Fischer, M., Rulicke, T., Raeber, A., Sailer, A., Moser, M., Oesch, B., Brandner, S., 
Aguzzi, A. and Weissmann, C. (1996) Prion protein (PrP) with amino-
proximal deletions restoring susceptibility of PrP knockout mice to scrapie. 
Embo J, 15, 1255-1264. 
Flechsig, E., Shmerling, D., Hegyi, I., Raeber, A.J., Fischer, M., Cozzio, A., von 
Mering, C., Aguzzi, A. and Weissmann, C. (2000) Prion protein devoid of 
the octapeptide repeat region restores susceptibility to scrapie in PrP 
knockout mice. Neuron, 27, 399-408. 
Florent, S., Malaplate-Armand, C., Youssef, I., Kriem, B., Koziel, V., Escanye, 
M.C., Fifre, A., Sponne, I., Leininger-Muller, B., Olivier, J.L., Pillot, T. and 
Oster, T. (2006) Docosahexaenoic acid prevents neuronal apoptosis induced 
by soluble amyloid-beta oligomers. J Neurochem, 96, 385-395. 
Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O. and 
Tagliavini, F. (1993) Neurotoxicity of a prion protein fragment. Nature, 362, 
543-546. 
Forloni, G., Bugiani, O., Tagliavini, F. and Salmona, M. (1996) Apoptosis-mediated 
neurotoxicity induced by beta-amyloid and PrP fragments. Mol Chem 
Neuropathol, 28, 163-171. 
Frankenfield, K.N., Powers, E.T. and Kelly, J.W. (2005) Influence of the N-terminal 
domain on the aggregation properties of the prion protein. Protein Sci, 14, 
2154-2166. 
Freixes, M., Rodriguez, A., Dalfo, E. and Ferrer, I. (2006) Oxidation, glycoxidation, 
lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex 
in Creutzfeldt-Jakob disease. Neurobiol Aging, 27, 1807-1815. 
Gaggelli, E., Bernardi, F., Molteni, E., Pogni, R., Valensin, D., Valensin, G., 
Remelli, M., Luczkowski, M. and Kozlowski, H. (2005) Interaction of the 
human prion PrP(106-126) sequence with copper(II), manganese(II), and 
zinc(II): NMR and EPR studies. J Am Chem Soc, 127, 996-1006. 
Garnett, A.P. and Viles, J.H. (2003) Copper binding to the octarepeats of the prion 
protein. Affinity, specificity, folding, and cooperativity: insights from 
circular dichroism. J Biol Chem, 278, 6795-6802. 
Gasset, M., Baldwin, M.A., Lloyd, D.H., Gabriel, J.M., Holtzman, D.M., Cohen, F., 
Fletterick, R. and Prusiner, S.B. (1992) Predicted alpha-helical regions of the 
prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci 
U S A, 89, 10940-10944. 
Gauczynski, S., Peyrin, J.M., Haik, S., Leucht, C., Hundt, C., Rieger, R., 
Krasemann, S., Deslys, J.P., Dormont, D., Lasmezas, C.I. and Weiss, S. 
- 164 - 
 
(2001) The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor 
for the cellular prion protein. Embo J, 20, 5863-5875. 
Ghatan, S., Larner, S., Kinoshita, Y., Hetman, M., Patel, L., Xia, Z., Youle, R.J. and 
Morrison, R.S. (2000) p38 MAP kinase mediates bax translocation in nitric 
oxide-induced apoptosis in neurons. J Cell Biol, 150, 335-347. 
Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, G., Young, K., Prelli, 
F., Farlow, M.R., Dlouhy, S.R. and Tagliavini, F. (1996) Prion protein 
amyloidosis. Brain Pathol, 6, 127-145. 
Giese, A., Groschup, M.H., Hess, B. and Kretzschmar, H.A. (1995) Neuronal cell 
death in scrapie-infected mice is due to apoptosis. Brain Pathol, 5, 213-221. 
Giese, A., Levin, J., Bertsch, U. and Kretzschmar, H. (2004) Effect of metal ions on 
de novo aggregation of full-length prion protein. Biochem Biophys Res 
Commun, 320, 1240-1246. 
Giuffrida, M.L., Grasso, G., Ruvo, M., Pedone, C., Saporito, A., Marasco, D., 
Pignataro, B., Cascio, C., Copani, A. and Rizzarelli, E. (2007) Abeta(25-35) 
and its C- and/or N-blocked derivatives: copper driven structural features and 
neurotoxicity. J Neurosci Res, 85, 623-633. 
Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P. and Wolozin, B. (2002) 
Magnesium inhibits spontaneous and iron-induced aggregation of alpha-
synuclein. J Biol Chem, 277, 16116-16123. 
Govaerts, C., Wille, H., Prusiner, S.B. and Cohen, F.E. (2004) Evidence for 
assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad 
Sci U S A, 101, 8342-8347. 
Gray, F., Chretien, F., Adle-Biassette, H., Dorandeu, A., Ereau, T., Delisle, M.B., 
Kopp, N., Ironside, J.W. and Vital, C. (1999) Neuronal apoptosis in 
Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol, 58, 321-328. 
Guentchev, M., Voigtlander, T., Haberler, C., Groschup, M.H. and Budka, H. (2000) 
Evidence for oxidative stress in experimental prion disease. Neurobiol Dis, 7, 
270-273. 
Haigh, C.L. and Brown, D.R. (2006) Prion protein reduces both oxidative and non-
oxidative copper toxicity. J Neurochem, 98, 677-689. 
Haigh, C.L., Edwards, K. and Brown, D.R. (2005) Copper binding is the governing 
determinant of prion protein turnover. Mol Cell Neurosci, 30, 186-196. 
Haigh, C.L., Wright, J.A. and Brown, D.R. (2007) Regulation of prion protein 
expression by noncoding regions of the Prnp gene. J Mol Biol, 368, 915-927. 
Han, B.H. and Holtzman, D.M. (2000) BDNF protects the neonatal brain from 
hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci, 20, 5775-
5781. 
Hegde, R.S., Mastrianni, J.A., Scott, M.R., DeFea, K.A., Tremblay, P., Torchia, M., 
DeArmond, S.J., Prusiner, S.B. and Lingappa, V.R. (1998) A transmembrane 
form of the prion protein in neurodegenerative disease. Science, 279, 827-
834. 
Herms, J., Tings, T., Gall, S., Madlung, A., Giese, A., Siebert, H., Schurmann, P., 
Windl, O., Brose, N. and Kretzschmar, H. (1999) Evidence of presynaptic 
location and function of the prion protein. J Neurosci, 19, 8866-8875. 
Hesketh, S., Sassoon, J., Knight, R. and Brown, D.R. (2008) Elevated manganese 
levels in blood and CNS in human prion disease. Mol Cell Neurosci, 37, 590-
598. 
Hesketh, S., Sassoon, J., Knight, R., Hopkins, J. and Brown, D.R. (2007) Elevated 
manganese levels in blood and central nervous system occur before onset of 
- 165 - 
 
clinical signs in scrapie and bovine spongiform encephalopathy. J Anim Sci, 
85, 1596-1609. 
Hetz, C., Maundrell, K. and Soto, C. (2003a) Is loss of function of the prion protein 
the cause of prion disorders? Trends Mol Med, 9, 237-243. 
Hetz, C., Russelakis-Carneiro, M., Maundrell, K., Castilla, J. and Soto, C. (2003b) 
Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of 
pathological prion protein. Embo J, 22, 5435-5445. 
Hetz, C., Russelakis-Carneiro, M., Walchli, S., Carboni, S., Vial-Knecht, E., 
Maundrell, K., Castilla, J. and Soto, C. (2005) The disulfide isomerase Grp58 
is a protective factor against prion neurotoxicity. J Neurosci, 25, 2793-2802. 
Hewitt, P.E., Llewelyn, C.A., Mackenzie, J. and Will, R.G. (2006) Creutzfeldt-Jakob 
disease and blood transfusion: results of the UK Transfusion Medicine 
Epidemiological Review study. Vox Sang, 91, 221-230. 
Hijazi, N., Kariv-Inbal, Z., Gasset, M. and Gabizon, R. (2005) PrPSc incorporation 
to cells requires endogenous glycosaminoglycan expression. J Biol Chem, 
280, 17057-17061. 
Hijazi, N., Shaked, Y., Rosenmann, H., Ben-Hur, T. and Gabizon, R. (2003) Copper 
binding to PrPC may inhibit prion disease propagation. Brain Res, 993, 192-
200. 
Hill, A.F., Desbruslais, M., Joiner, S., Sidle, K.C., Gowland, I., Collinge, J., Doey, 
L.J. and Lantos, P. (1997) The same prion strain causes vCJD and BSE. 
Nature, 389, 448-450, 526. 
Hill, A.F., Joiner, S., Linehan, J., Desbruslais, M., Lantos, P.L. and Collinge, J. 
(2000) Species-barrier-independent prion replication in apparently resistant 
species. Proc Natl Acad Sci U S A, 97, 10248-10253. 
Holme, A., Daniels, M., Sassoon, J. and Brown, D.R. (2003) A novel method of 
generating neuronal cell lines from gene-knockout mice to study prion 
protein membrane orientation. Eur J Neurosci, 18, 571-579. 
Holscher, C., Delius, H. and Burkle, A. (1998) Overexpression of nonconvertible 
PrPc delta114-121 in scrapie-infected mouse neuroblastoma cells leads to 
trans-dominant inhibition of wild-type PrP(Sc) accumulation. J Virol, 72, 
1153-1159. 
Hornemann, S., Korth, C., Oesch, B., Riek, R., Wider, G., Wuthrich, K. and 
Glockshuber, R. (1997) Recombinant full-length murine prion protein, 
mPrP(23-231): purification and spectroscopic characterization. FEBS Lett, 
413, 277-281. 
Hornshaw, M.P., McDermott, J.R. and Candy, J.M. (1995) Copper binding to the N-
terminal tandem repeat regions of mammalian and avian prion protein. 
Biochem Biophys Res Commun, 207, 621-629. 
Hsiao, K., Baker, H.F., Crow, T.J., Poulter, M., Owen, F., Terwilliger, J.D., 
Westaway, D., Ott, J. and Prusiner, S.B. (1989) Linkage of a prion protein 
missense variant to Gerstmann-Straussler syndrome. Nature, 338, 342-345. 
Hsiao, K., Scott, M., Foster, D., DeArmond, S.J., Groth, D., Serban, H. and Prusiner, 
S.B. (1991) Spontaneous neurodegeneration in transgenic mice with prion 
protein codon 101 proline----leucine substitution. Ann N Y Acad Sci, 640, 
166-170. 
Hsiao, K.K., Scott, M., Foster, D., Groth, D.F., DeArmond, S.J. and Prusiner, S.B. 
(1990) Spontaneous neurodegeneration in transgenic mice with mutant prion 
protein. Science, 250, 1587-1590. 
- 166 - 
 
Hsich, G., Kenney, K., Gibbs, C.J., Lee, K.H. and Harrington, M.G. (1996) The 14-
3-3 brain protein in cerebrospinal fluid as a marker for transmissible 
spongiform encephalopathies. N Engl J Med, 335, 924-930. 
Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J. and 
Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute 
promyelocytic leukemia. Blood, 72, 567-572. 
Ingrosso, L., Ladogana, A. and Pocchiari, M. (1995) Congo red prolongs the 
incubation period in scrapie-infected hamsters. J Virol, 69, 506-508. 
Jackson, G.S., Murray, I., Hosszu, L.L., Gibbs, N., Waltho, J.P., Clarke, A.R. and 
Collinge, J. (2001) Location and properties of metal-binding sites on the 
human prion protein. Proc Natl Acad Sci U S A, 98, 8531-8535. 
Jamieson, E., Jeffrey, M., Ironside, J.W. and Fraser, J.R. (2001) Activation of Fas 
and caspase 3 precedes PrP accumulation in 87V scrapie. Neuroreport, 12, 
3567-3572. 
Janicke, R.U., Sprengart, M.L., Wati, M.R. and Porter, A.G. (1998) Caspase-3 is 
required for DNA fragmentation and morphological changes associated with 
apoptosis. J Biol Chem, 273, 9357-9360. 
Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H. and Marsden, C.D. (1992) 
Oxidative stress as a cause of nigral cell death in Parkinson's disease and 
incidental Lewy body disease. The Royal Kings and Queens Parkinson's 
Disease Research Group. Ann Neurol, 32 Suppl, S82-87. 
Jin, T., Gu, Y., Zanusso, G., Sy, M., Kumar, A., Cohen, M., Gambetti, P. and Singh, 
N. (2000) The chaperone protein BiP binds to a mutant prion protein and 
mediates its degradation by the proteasome. J Biol Chem, 275, 38699-38704. 
Jobling, M.F., Huang, X., Stewart, L.R., Barnham, K.J., Curtain, C., Volitakis, I., 
Perugini, M., White, A.R., Cherny, R.A., Masters, C.L., Barrow, C.J., 
Collins, S.J., Bush, A.I. and Cappai, R. (2001) Copper and zinc binding 
modulates the aggregation and neurotoxic properties of the prion peptide 
PrP106-126. Biochemistry, 40, 8073-8084. 
Jobling, M.F., Stewart, L.R., White, A.R., McLean, C., Friedhuber, A., Maher, F., 
Beyreuther, K., Masters, C.L., Barrow, C.J., Collins, S.J. and Cappai, R. 
(1999) The hydrophobic core sequence modulates the neurotoxic and 
secondary structure properties of the prion peptide 106-126. J Neurochem, 
73, 1557-1565. 
Jones, C.E., Abdelraheim, S.R., Brown, D.R. and Viles, J.H. (2004) Preferential 
Cu2+ coordination by His96 and His111 induces beta-sheet formation in the 
unstructured amyloidogenic region of the prion protein. J Biol Chem, 279, 
32018-32027. 
Jones, C.E., Klewpatinond, M., Abdelraheim, S.R., Brown, D.R. and Viles, J.H. 
(2005a) Probing copper2+ binding to the prion protein using diamagnetic 
nickel2+ and 1H NMR: the unstructured N terminus facilitates the 
coordination of six copper2+ ions at physiological concentrations. J Mol 
Biol, 346, 1393-1407. 
Jones, E.M., Surewicz, K. and Surewicz, W.K. (2006) Role of N-terminal familial 
mutations in prion protein fibrillization and prion amyloid propagation in 
vitro. J Biol Chem, 281, 8190-8196. 
Jones, E.M. and Surewicz, W.K. (2005) Fibril conformation as the basis of species- 
and strain-dependent seeding specificity of mammalian prion amyloids. Cell, 
121, 63-72. 
- 167 - 
 
Jones, S., Batchelor, M., Bhelt, D., Clarke, A.R., Collinge, J. and Jackson, G.S. 
(2005b) Recombinant prion protein does not possess SOD-1 activity. 
Biochem J, 392, 309-312. 
Kaneko, K., Zulianello, L., Scott, M., Cooper, C.M., Wallace, A.C., James, T.L., 
Cohen, F.E. and Prusiner, S.B. (1997) Evidence for protein X binding to a 
discontinuous epitope on the cellular prion protein during scrapie prion 
propagation. Proc Natl Acad Sci U S A, 94, 10069-10074. 
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. 
and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers 
implies common mechanism of pathogenesis. Science, 300, 486-489. 
Kazlauskaite, J., Young, A., Gardner, C.E., Macpherson, J.V., Venien-Bryan, C. and 
Pinheiro, T.J. (2005) An unusual soluble beta-turn-rich conformation of prion 
is involved in fibril formation and toxic to neuronal cells. Biochem Biophys 
Res Commun, 328, 292-305. 
Kim, N.H., Choi, J.K., Jeong, B.H., Kim, J.I., Kwon, M.S., Carp, R.I. and Kim, Y.S. 
(2005) Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on 
the conversion of PrPC to PrPres. Faseb J, 19, 783-785. 
Kim, N.H., Park, S.J., Jin, J.K., Kwon, M.S., Choi, E.K., Carp, R.I. and Kim, Y.S. 
(2000) Increased ferric iron content and iron-induced oxidative stress in the 
brains of scrapie-infected mice. Brain Res, 884, 98-103. 
Kitamoto, T. and Tateishi, J. (1994) Human prion diseases with variant prion 
protein. Philos Trans R Soc Lond B Biol Sci, 343, 391-398. 
Klajnert, B., Cortijo-Arellano, M., Bryszewska, M. and Cladera, J. (2006) Influence 
of heparin and dendrimers on the aggregation of two amyloid peptides related 
to Alzheimer's and prion diseases. Biochem Biophys Res Commun, 339, 577-
582. 
Klamt, F., Dal-Pizzol, F., Conte da Frota, M.J., Walz, R., Andrades, M.E., da Silva, 
E.G., Brentani, R.R., Izquierdo, I. and Fonseca Moreira, J.C. (2001) 
Imbalance of antioxidant defense in mice lacking cellular prion protein. Free 
Radic Biol Med, 30, 1137-1144. 
Klebe, R.J., Chen, T. and Ruddle, F.H. (1970) Controlled production of proliferating 
somatic cell hybrids. J Cell Biol, 45, 74-82. 
Klewpatinond, M., Davies, P., Bowen, S., Brown, D.R. and Viles, J.H. (2008) 
Deconvoluting the Cu2+ binding modes of full-length prion protein. J Biol 
Chem, 283, 1870-1881. 
Klewpatinond, M. and Viles, J.H. (2007) Fragment length influences affinity for 
Cu2+ and Ni2+ binding to His96 or His111 of the prion protein and 
spectroscopic evidence for a multiple histidine binding only at low pH. 
Biochem J, 404, 393-402. 
Krasemann, S., Zerr, I., Weber, T., Poser, S., Kretzschmar, H., Hunsmann, G. and 
Bodemer, W. (1995) Prion disease associated with a novel nine octapeptide 
repeat insertion in the PRNP gene. Brain Res Mol Brain Res, 34, 173-176. 
Kundu, B., Maiti, N.R., Jones, E.M., Surewicz, K.A., Vanik, D.L. and Surewicz, 
W.K. (2003) Nucleation-dependent conformational conversion of the 
Y145Stop variant of human prion protein: structural clues for prion 
propagation. Proc Natl Acad Sci U S A, 100, 12069-12074. 
Ladogana, A., Casaccia, P., Ingrosso, L., Cibati, M., Salvatore, M., Xi, Y.G., 
Masullo, C. and Pocchiari, M. (1992) Sulphate polyanions prolong the 
incubation period of scrapie-infected hamsters. J Gen Virol, 73 ( Pt 3), 661-
665. 
- 168 - 
 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature, 227, 680-685. 
Laws, D.D., Bitter, H.M., Liu, K., Ball, H.L., Kaneko, K., Wille, H., Cohen, F.E., 
Prusiner, S.B., Pines, A. and Wemmer, D.E. (2001) Solid-state NMR studies 
of the secondary structure of a mutant prion protein fragment of 55 residues 
that induces neurodegeneration. Proc Natl Acad Sci U S A, 98, 11686-11690. 
Lawson, V.A., Priola, S.A., Wehrly, K. and Chesebro, B. (2001) N-terminal 
truncation of prion protein affects both formation and conformation of 
abnormal protease-resistant prion protein generated in vitro. J Biol Chem, 
276, 35265-35271. 
Lee, H.P., Jun, Y.C., Choi, J.K., Kim, J.I., Carp, R.I. and Kim, Y.S. (2005) 
Activation of mitogen-activated protein kinases in hamster brains infected 
with 263K scrapie agent. J Neurochem, 95, 584-593. 
Lee, I.Y., Westaway, D., Smit, A.F., Wang, K., Seto, J., Chen, L., Acharya, C., 
Ankener, M., Baskin, D., Cooper, C., Yao, H., Prusiner, S.B. and Hood, L.E. 
(1998) Complete genomic sequence and analysis of the prion protein gene 
region from three mammalian species. Genome Res, 8, 1022-1037. 
Legleiter, L.R., Ahola, J.K., Engle, T.E. and Spears, J.W. (2007a) Decreased brain 
copper due to copper deficiency has no effect on bovine prion proteins. 
Biochem Biophys Res Commun, 352, 884-888. 
Legleiter, L.R., Liu, H.C., Lloyd, K.E., Hansen, S.L., Fry, R.S. and Spears, J.W. 
(2007b) Exposure to low dietary copper or low copper coupled with high 
dietary manganese for one year does not alter brain prion protein 
characteristics in the mature cow. J Anim Sci, 85, 2895-2903. 
Leucht, C., Simoneau, S., Rey, C., Vana, K., Rieger, R., Lasmezas, C.I. and Weiss, 
S. (2003) The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) 
propagation in scrapie-infected neuronal cells. EMBO Rep, 4, 290-295. 
Levin, J., Bertsch, U., Kretzschmar, H. and Giese, A. (2005) Single particle analysis 
of manganese-induced prion protein aggregates. Biochem Biophys Res 
Commun, 329, 1200-1207. 
Li, A., Barmada, S.J., Roth, K.A. and Harris, D.A. (2007a) N-terminally deleted 
forms of the prion protein activate both Bax-dependent and Bax-independent 
neurotoxic pathways. J Neurosci, 27, 852-859. 
Li, A., Christensen, H.M., Stewart, L.R., Roth, K.A., Chiesa, R. and Harris, D.A. 
(2007b) Neonatal lethality in transgenic mice expressing prion protein with a 
deletion of residues 105-125. Embo J, 26, 548-558. 
Li, G. and Bolton, D.C. (1997) A novel hamster prion protein mRNA contains an 
extra exon: increased expression in scrapie. Brain Res, 751, 265-274. 
Lopez Garcia, F., Zahn, R., Riek, R. and Wuthrich, K. (2000) NMR structure of the 
bovine prion protein. Proc Natl Acad Sci U S A, 97, 8334-8339. 
Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L. and Markesbery, W.R. 
(1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol 
Sci, 158, 47-52. 
Lu, X., Wintrode, P.L. and Surewicz, W.K. (2007) Beta-sheet core of human prion 
protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc 
Natl Acad Sci U S A, 104, 1510-1515. 
Makarava, N., Lee, C.I., Ostapchenko, V.G. and Baskakov, I.V. (2007) Highly 
promiscuous nature of prion polymerization. J Biol Chem, 282, 36704-36713. 
Mallucci, G.R., White, M.D., Farmer, M., Dickinson, A., Khatun, H., Powell, A.D., 
Brandner, S., Jefferys, J.G. and Collinge, J. (2007) Targeting cellular prion 
- 169 - 
 
protein reverses early cognitive deficits and neurophysiological dysfunction 
in prion-infected mice. Neuron, 53, 325-335. 
Manetto, V., Medori, R., Cortelli, P., Montagna, P., Tinuper, P., Baruzzi, A., 
Rancurel, G., Hauw, J.J., Vanderhaeghen, J.J., Mailleux, P. and et al. (1992) 
Fatal familial insomnia: clinical and pathologic study of five new cases. 
Neurology, 42, 312-319. 
Mange, A., Beranger, F., Peoc'h, K., Onodera, T., Frobert, Y. and Lehmann, S. 
(2004) Alpha- and beta- cleavages of the amino-terminus of the cellular prion 
protein. Biol Cell, 96, 125-132. 
Manson, J.C., Clarke, A.R., McBride, P.A., McConnell, I. and Hope, J. (1994) PrP 
gene dosage determines the timing but not the final intensity or distribution 
of lesions in scrapie pathology. Neurodegeneration, 3, 331-340. 
Manuelidis, L., Fritch, W. and Xi, Y.G. (1997) Evolution of a strain of CJD that 
induces BSE-like plaques. Science, 277, 94-98. 
Martin, B.D., Schoenhard, J.A. and Sugden, K.D. (1998) Hypervalent chromium 
mimics reactive oxygen species as measured by the oxidant-sensitive dyes 
2',7'-dichlorofluorescin and dihydrorhodamine. Chem Res Toxicol, 11, 1402-
1410. 
Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., Price, 
D.L. and Lee, M.K. (2006) Parkinson's disease alpha-synuclein transgenic 
mice develop neuronal mitochondrial degeneration and cell death. J 
Neurosci, 26, 41-50. 
Martins, S.M., Frosoni, D.J., Martinez, A.M., De Felice, F.G. and Ferreira, S.T. 
(2006) Formation of soluble oligomers and amyloid fibrils with physical 
properties of the scrapie isoform of the prion protein from the C-terminal 
domain of recombinant murine prion protein mPrP-(121-231). J Biol Chem, 
281, 26121-26128. 
McLennan, N.F., Brennan, P.M., McNeill, A., Davies, I., Fotheringham, A., 
Rennison, K.A., Ritchie, D., Brannan, F., Head, M.W., Ironside, J.W., 
Williams, A. and Bell, J.E. (2004) Prion protein accumulation and 
neuroprotection in hypoxic brain damage. Am J Pathol, 165, 227-235. 
McMahon, H.E., Mange, A., Nishida, N., Creminon, C., Casanova, D. and Lehmann, 
S. (2001) Cleavage of the amino terminus of the prion protein by reactive 
oxygen species. J Biol Chem, 276, 2286-2291. 
Menkes, J.H., Alter, M., Steigleder, G.K., Weakley, D.R. and Sung, J.H. (1962) A 
sex-linked recessive disorder with retardation of growth, peculiar hair, and 
focal cerebral and cerebellar degeneration. Pediatrics, 29, 764-779. 
Miura, T., Hori-i, A. and Takeuchi, H. (1996) Metal-dependent alpha-helix 
formation promoted by the glycine-rich octapeptide region of prion protein. 
FEBS Lett, 396, 248-252. 
Moriya, R., Uehara, T. and Nomura, Y. (2000) Mechanism of nitric oxide-induced 
apoptosis in human neuroblastoma SH-SY5Y cells. FEBS Lett, 484, 253-260. 
Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J.L., Lehmann, S., 
Launay, J.M. and Kellermann, O. (2000) Signal transduction through prion 
protein. Science, 289, 1925-1928. 
Munoz, L., Ranaivo, H.R., Roy, S.M., Hu, W., Craft, J.M., McNamara, L.K., Chico, 
L.W., Van Eldik, L.J. and Watterson, D.M. (2007) A novel p38 alpha MAPK 
inhibitor suppresses brain proinflammatory cytokine up-regulation and 
attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's 
disease mouse model. J Neuroinflammation, 4, 21. 
- 170 - 
 
Muramoto, T., DeArmond, S.J., Scott, M., Telling, G.C., Cohen, F.E. and Prusiner, 
S.B. (1997) Heritable disorder resembling neuronal storage disease in mice 
expressing prion protein with deletion of an alpha-helix. Nat Med, 3, 750-
755. 
Muramoto, T., Scott, M., Cohen, F.E. and Prusiner, S.B. (1996) Recombinant 
scrapie-like prion protein of 106 amino acids is soluble. Proc Natl Acad Sci 
U S A, 93, 15457-15462. 
Murray, B., Alessandrini, A., Cole, A.J., Yee, A.G. and Furshpan, E.J. (1998) 
Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons 
in a cell-culture model of seizure activity. Proc Natl Acad Sci U S A, 95, 
11975-11980. 
Muto, Y. and Sato, K. (2003) Pivotal role of attractin in cell survival under oxidative 
stress in the zitter rat brain with genetic spongiform encephalopathy. Brain 
Res Mol Brain Res, 111, 111-122. 
Nadal, R.C., Abdelraheim, S.R., Brazier, M.W., Rigby, S.E., Brown, D.R. and Viles, 
J.H. (2007) Prion protein does not redox-silence Cu2+, but is a sacrificial 
quencher of hydroxyl radicals. Free Radic Biol Med, 42, 79-89. 
Nakajima, M., Yamada, T., Kusuhara, T., Furukawa, H., Takahashi, M., Yamauchi, 
A. and Kataoka, Y. (2004) Results of quinacrine administration to patients 
with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord, 17, 158-163. 
Nicolas, O., Gavin, R., Braun, N., Urena, J.M., Fontana, X., Soriano, E., Aguzzi, A. 
and del Rio, J.A. (2007) Bcl-2 overexpression delays caspase-3 activation 
and rescues cerebellar degeneration in prion-deficient mice that overexpress 
amino-terminally truncated prion. Faseb J, 21, 3107-3117. 
Nishida, N., Harris, D.A., Vilette, D., Laude, H., Frobert, Y., Grassi, J., Casanova, 
D., Milhavet, O. and Lehmann, S. (2000) Successful transmission of three 
mouse-adapted scrapie strains to murine neuroblastoma cell lines 
overexpressing wild-type mouse prion protein. J Virol, 74, 320-325. 
Norstrom, E.M., Ciaccio, M.F., Rassbach, B., Wollmann, R. and Mastrianni, J.A. 
(2007) Cytosolic prion protein toxicity is independent of cellular prion 
protein expression and prion propagation. J Virol, 81, 2831-2837. 
Norstrom, E.M. and Mastrianni, J.A. (2005) The AGAAAAGA palindrome in PrP is 
required to generate a productive PrPSc-PrPC complex that leads to prion 
propagation. J Biol Chem, 280, 27236-27243. 
Novitskaya, V., Bocharova, O.V., Bronstein, I. and Baskakov, I.V. (2006) Amyloid 
fibrils of mammalian prion protein are highly toxic to cultured cells and 
primary neurons. J Biol Chem, 281, 13828-13836. 
Novitskaya, V., Makarava, N., Sylvester, I., Bronstein, I.B. and Baskakov, I.V. 
(2007) Amyloid fibrils of mammalian prion protein induce axonal 
degeneration in NTERA2-derived terminally differentiated neurons. J 
Neurochem, 102, 398-407. 
Nunziante, M., Gilch, S. and Schatzl, H.M. (2003) Essential role of the prion protein 
N terminus in subcellular trafficking and half-life of cellular prion protein. J 
Biol Chem, 278, 3726-3734. 
Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M. and Wolozin, B. 
(2000) The A53T alpha-synuclein mutation increases iron-dependent 
aggregation and toxicity. J Neurosci, 20, 6048-6054. 
O'Sullivan, D.B., Jones, C.E., Abdelraheim, S.R., Thompsett, A.R., Brazier, M.W., 
Toms, H., Brown, D.R. and Viles, J.H. (2007) NMR characterization of the 
pH 4 beta-intermediate of the prion protein: the N-terminal half of the protein 
- 171 - 
 
remains unstructured and retains a high degree of flexibility. Biochem J, 401, 
533-540. 
Paitel, E., Sunyach, C., Alves da Costa, C., Bourdon, J.C., Vincent, B. and Checler, 
F. (2004) Primary cultured neurons devoid of cellular prion display lower 
responsiveness to staurosporine through the control of p53 at both 
transcriptional and post-transcriptional levels. J Biol Chem, 279, 612-618. 
Palmer, M.S., Dryden, A.J., Hughes, J.T. and Collinge, J. (1991) Homozygous prion 
protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature, 
352, 340-342. 
Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., 
Huang, Z., Fletterick, R.J., Cohen, F.E. and et al. (1993) Conversion of 
alpha-helices into beta-sheets features in the formation of the scrapie prion 
proteins. Proc Natl Acad Sci U S A, 90, 10962-10966. 
Pan, T., Wong, B.S., Liu, T., Li, R., Petersen, R.B. and Sy, M.S. (2002) Cell-surface 
prion protein interacts with glycosaminoglycans. Biochem J, 368, 81-90. 
Pankiewicz, J., Prelli, F., Sy, M.S., Kascsak, R.J., Kascsak, R.B., Spinner, D.S., 
Carp, R.I., Meeker, H.C., Sadowski, M. and Wisniewski, T. (2006) Clearance 
and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J 
Neurosci, 23, 2635-2647. 
Pauly, P.C. and Harris, D.A. (1998) Copper stimulates endocytosis of the prion 
protein. J Biol Chem, 273, 33107-33110. 
Pietri, M., Caprini, A., Mouillet-Richard, S., Pradines, E., Ermonval, M., Grassi, J., 
Kellermann, O. and Schneider, B. (2006) Overstimulation of PrPC signaling 
pathways by prion peptide 106-126 causes oxidative injury of bioaminergic 
neuronal cells. J Biol Chem, 281, 28470-28479. 
Post, K., Brown, D.R., Groschup, M., Kretzschmar, H.A. and Riesner, D. (2000) 
Neurotoxicity but not infectivity of prion proteins can be induced reversibly 
in vitro. Arch Virol Suppl, 265-273. 
Proske, D., Gilch, S., Wopfner, F., Schatzl, H.M., Winnacker, E.L. and Famulok, M. 
(2002) Prion-protein-specific aptamer reduces PrPSc formation. 
Chembiochem, 3, 717-725. 
Prusiner, S.B. (1982) Novel proteinaceous infectious particles cause scrapie. Science, 
216, 136-144. 
Prusiner, S.B., Groth, D., Serban, A., Koehler, R., Foster, D., Torchia, M., Burton, 
D., Yang, S.L. and DeArmond, S.J. (1993) Ablation of the prion protein 
(PrP) gene in mice prevents scrapie and facilitates production of anti-PrP 
antibodies. Proc Natl Acad Sci U S A, 90, 10608-10612. 
Prusiner, S.B., McKinley, M.P., Bowman, K.A., Bolton, D.C., Bendheim, P.E., 
Groth, D.F. and Glenner, G.G. (1983) Scrapie prions aggregate to form 
amyloid-like birefringent rods. Cell, 35, 349-358. 
Prusiner, S.B., Scott, M., Foster, D., Pan, K.M., Groth, D., Mirenda, C., Torchia, M., 
Yang, S.L., Serban, D., Carlson, G.A. and et al. (1990) Transgenetic studies 
implicate interactions between homologous PrP isoforms in scrapie prion 
replication. Cell, 63, 673-686. 
Qin, K., Yang, D.S., Yang, Y., Chishti, M.A., Meng, L.J., Kretzschmar, H.A., Yip, 
C.M., Fraser, P.E. and Westaway, D. (2000) Copper(II)-induced 
conformational changes and protease resistance in recombinant and cellular 
PrP. Effect of protein age and deamidation. J Biol Chem, 275, 19121-19131. 
- 172 - 
 
Quaglio, E., Chiesa, R. and Harris, D.A. (2001) Copper converts the cellular prion 
protein into a protease-resistant species that is distinct from the scrapie 
isoform. J Biol Chem, 276, 11432-11438. 
Race, R.E., Fadness, L.H. and Chesebro, B. (1987) Characterization of scrapie 
infection in mouse neuroblastoma cells. J Gen Virol, 68 ( Pt 5), 1391-1399. 
Rachidi, W., Vilette, D., Guiraud, P., Arlotto, M., Riondel, J., Laude, H., Lehmann, 
S. and Favier, A. (2003) Expression of prion protein increases cellular copper 
binding and antioxidant enzyme activities but not copper delivery. J Biol 
Chem, 278, 9064-9072. 
Raeber, A.J., Race, R.E., Brandner, S., Priola, S.A., Sailer, A., Bessen, R.A., Mucke, 
L., Manson, J., Aguzzi, A., Oldstone, M.B., Weissmann, C. and Chesebro, B. 
(1997) Astrocyte-specific expression of hamster prion protein (PrP) renders 
PrP knockout mice susceptible to hamster scrapie. Embo J, 16, 6057-6065. 
Rao, R.V., Peel, A., Logvinova, A., del Rio, G., Hermel, E., Yokota, T., Goldsmith, 
P.C., Ellerby, L.M., Ellerby, H.M. and Bredesen, D.E. (2002) Coupling 
endoplasmic reticulum stress to the cell death program: role of the ER 
chaperone GRP78. FEBS Lett, 514, 122-128. 
Rasia, R.M., Bertoncini, C.W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., 
Griesinger, C., Jovin, T.M. and Fernandez, C.O. (2005) Structural 
characterization of copper(II) binding to alpha-synuclein: Insights into the 
bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A, 
102, 4294-4299. 
Requena, J.R., Groth, D., Legname, G., Stadtman, E.R., Prusiner, S.B. and Levine, 
R.L. (2001) Copper-catalyzed oxidation of the recombinant SHa(29-231) 
prion protein. Proc Natl Acad Sci U S A, 98, 7170-7175. 
Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R. and Wuthrich, K. 
(1996) NMR structure of the mouse prion protein domain PrP(121-321). 
Nature, 382, 180-182. 
Rizzardini, M., Chiesa, R., Angeretti, N., Lucca, E., Salmona, M., Forloni, G. and 
Cantoni, L. (1997) Prion protein fragment 106-126 differentially induces 
heme oxygenase-1 mRNA in cultured neurons and astroglial cells. J 
Neurochem, 68, 715-720. 
Roth, J.A., Feng, L., Walowitz, J. and Browne, R.W. (2000) Manganese-induced rat 
pheochromocytoma (PC12) cell death is independent of caspase activation. J 
Neurosci Res, 61, 162-171. 
Roucou, X., Giannopoulos, P.N., Zhang, Y., Jodoin, J., Goodyer, C.G. and LeBlanc, 
A. (2005) Cellular prion protein inhibits proapoptotic Bax conformational 
change in human neurons and in breast carcinoma MCF-7 cells. Cell Death 
Differ, 12, 783-795. 
Rybner, C., Hillion, J., Sahraoui, T., Lanotte, M. and Botti, J. (2002) All-trans 
retinoic acid down-regulates prion protein expression independently of 
granulocyte maturation. Leukemia, 16, 940-948. 
Saborio, G.P., Permanne, B. and Soto, C. (2001) Sensitive detection of pathological 
prion protein by cyclic amplification of protein misfolding. Nature, 411, 810-
813. 
Saeki, K., Matsumoto, Y., Hirota, Y. and Onodera, T. (1996a) Three-exon structure 
of the gene encoding the rat prion protein and its expression in tissues. Virus 
Genes, 12, 15-20. 
- 173 - 
 
Saeki, K., Matsumoto, Y. and Onodera, T. (1996b) Identification of a promoter 
region in the rat prion protein gene. Biochem Biophys Res Commun, 219, 47-
52. 
Saez-Valero, J., Angeretti, N. and Forloni, G. (2000) Caspase-3 activation by beta-
amyloid and prion protein peptides is independent from their neurotoxic 
effect. Neurosci Lett, 293, 207-210. 
Sakudo, A., Wu, G., Onodera, T. and Ikuta, K. (2008) Octapeptide repeat region of 
prion protein (PrP) is required at an early stage for production of abnormal 
prion protein in PrP-deficient neuronal cell line. Biochem Biophys Res 
Commun, 365, 164-169. 
Salmona, M., Morbin, M., Massignan, T., Colombo, L., Mazzoleni, G., Capobianco, 
R., Diomede, L., Thaler, F., Mollica, L., Musco, G., Kourie, J.J., Bugiani, O., 
Sharma, D., Inouye, H., Kirschner, D.A., Forloni, G. and Tagliavini, F. 
(2003) Structural properties of Gerstmann-Straussler-Scheinker disease 
amyloid protein. J Biol Chem, 278, 48146-48153. 
Sanchez-Alavez, M., Conti, B., Moroncini, G. and Criado, J.R. (2007) Contributions 
of neuronal prion protein on sleep recovery and stress response following 
sleep deprivation. Brain Res, 1158, 71-80. 
Satoh, J., Obayashi, S., Misawa, T., Sumiyoshi, K., Oosumi, K. and Tabunoki, H. 
(2008) Protein microarray analysis identifies human cellular prion protein 
interactors. Neuropathol Appl Neurobiol. 
Sayre, L.M., Zelasko, D.A., Harris, P.L., Perry, G., Salomon, R.G. and Smith, M.A. 
(1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products 
are increased in Alzheimer's disease. J Neurochem, 68, 2092-2097. 
Schatzl, H.M., Laszlo, L., Holtzman, D.M., Tatzelt, J., DeArmond, S.J., Weiner, 
R.I., Mobley, W.C. and Prusiner, S.B. (1997) A hypothalamic neuronal cell 
line persistently infected with scrapie prions exhibits apoptosis. J Virol, 71, 
8821-8831. 
Scott, M., Foster, D., Mirenda, C., Serban, D., Coufal, F., Walchli, M., Torchia, M., 
Groth, D., Carlson, G., DeArmond, S.J. and et al. (1989) Transgenic mice 
expressing hamster prion protein produce species-specific scrapie infectivity 
and amyloid plaques. Cell, 59, 847-857. 
Sellarajah, S., Lekishvili, T., Bowring, C., Thompsett, A.R., Rudyk, H., Birkett, 
C.R., Brown, D.R. and Gilbert, I.H. (2004) Synthesis of analogues of Congo 
red and evaluation of their anti-prion activity. J Med Chem, 47, 5515-5534. 
Selvaggini, C., De Gioia, L., Cantu, L., Ghibaudi, E., Diomede, L., Passerini, F., 
Forloni, G., Bugiani, O., Tagliavini, F. and Salmona, M. (1993) Molecular 
characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide 
homologous to residues 106-126 of the prion protein. Biochem Biophys Res 
Commun, 194, 1380-1386. 
Shaked, G.M., Meiner, Z., Avraham, I., Taraboulos, A. and Gabizon, R. (2001) 
Reconstitution of prion infectivity from solubilized protease-resistant PrP and 
nonprotein components of prion rods. J Biol Chem, 276, 14324-14328. 
Shmerling, D., Hegyi, I., Fischer, M., Blattler, T., Brandner, S., Gotz, J., Rulicke, T., 
Flechsig, E., Cozzio, A., von Mering, C., Hangartner, C., Aguzzi, A. and 
Weissmann, C. (1998) Expression of amino-terminally truncated PrP in the 
mouse leading to ataxia and specific cerebellar lesions. Cell, 93, 203-214. 
Shyu, W.C., Harn, H.J., Saeki, K., Kubosaki, A., Matsumoto, Y., Onodera, T., Chen, 
C.J., Hsu, Y.D. and Chiang, Y.H. (2002) Molecular modulation of expression 
of prion protein by heat shock. Mol Neurobiol, 26, 1-12. 
- 174 - 
 
Shyu, W.C., Kao, M.C., Chou, W.Y., Hsu, Y.D. and Soong, B.W. (2000) Heat shock 
modulates prion protein expression in human NT-2 cells. Neuroreport, 11, 
771-774. 
Shyu, W.C., Lin, S.Z., Saeki, K., Kubosaki, A., Matsumoto, Y., Onodera, T., 
Chiang, M.F., Thajeb, P. and Li, H. (2004) Hyperbaric oxygen enhances the 
expression of prion protein and heat shock protein 70 in a mouse 
neuroblastoma cell line. Cell Mol Neurobiol, 24, 257-268. 
Sigurdsson, E.M., Brown, D.R., Alim, M.A., Scholtzova, H., Carp, R., Meeker, 
H.C., Prelli, F., Frangione, B. and Wisniewski, T. (2003) Copper chelation 
delays the onset of prion disease. J Biol Chem, 278, 46199-46202. 
Simoneau, S., Rezaei, H., Sales, N., Kaiser-Schulz, G., Lefebvre-Roque, M., Vidal, 
C., Fournier, J.G., Comte, J., Wopfner, F., Grosclaude, J., Schatzl, H. and 
Lasmezas, C.I. (2007) In vitro and in vivo neurotoxicity of prion protein 
oligomers. PLoS Pathog, 3, e125. 
Solforosi, L., Criado, J.R., McGavern, D.B., Wirz, S., Sanchez-Alavez, M., Sugama, 
S., DeGiorgio, L.A., Volpe, B.T., Wiseman, E., Abalos, G., Masliah, E., 
Gilden, D., Oldstone, M.B., Conti, B. and Williamson, R.A. (2004) Cross-
linking cellular prion protein triggers neuronal apoptosis in vivo. Science, 
303, 1514-1516. 
Song, X., Wu, B., Takata, T., Wang, X., Oizumi, X.S., Akisaki, T., Yokono, K. and 
Sakurai, T. (2005) Neuroprotective effect of D-fructose-1,6-bisphosphate 
against beta-amyloid induced neurotoxicity in rat hippocampal organotypic 
slice culture: involvement of PLC and MEK/ERK signaling pathways. Kobe 
J Med Sci, 51, 73-83. 
Sorensen, G., Medina, S., Parchaliuk, D., Phillipson, C., Robertson, C. and Booth, 
S.A. (2008) Comprehensive transcriptional profiling of prion infection in 
mouse models reveals networks of responsive genes. BMC Genomics, 9, 114. 
Stack, E.C., Ferro, J.L., Kim, J., Del Signore, S.J., Goodrich, S., Matson, S., Hunt, 
B.B., Cormier, K., Smith, K., Matson, W.R., Ryu, H. and Ferrante, R.J. 
(2008) Therapeutic attenuation of mitochondrial dysfunction and oxidative 
stress in neurotoxin models of Parkinson's disease. Biochim Biophys Acta, 
1782, 151-162. 
Stahl, N., Borchelt, D.R., Hsiao, K. and Prusiner, S.B. (1987) Scrapie prion protein 
contains a phosphatidylinositol glycolipid. Cell, 51, 229-240. 
Steele, A.D., King, O.D., Jackson, W.S., Hetz, C.A., Borkowski, A.W., Thielen, P., 
Wollmann, R. and Lindquist, S. (2007) Diminishing apoptosis by deletion of 
Bax or overexpression of Bcl-2 does not protect against infectious prion 
toxicity in vivo. J Neurosci, 27, 13022-13027. 
Stockel, J., Safar, J., Wallace, A.C., Cohen, F.E. and Prusiner, S.B. (1998) Prion 
protein selectively binds copper(II) ions. Biochemistry, 37, 7185-7193. 
Stohr, J., Weinmann, N., Wille, H., Kaimann, T., Nagel-Steger, L., Birkmann, E., 
Panza, G., Prusiner, S.B., Eigen, M. and Riesner, D. (2008) Mechanisms of 
prion protein assembly into amyloid. Proc Natl Acad Sci U S A, 105, 2409-
2414. 
Stuermer, C.A., Langhorst, M.F., Wiechers, M.F., Legler, D.F., Von Hanwehr, S.H., 
Guse, A.H. and Plattner, H. (2004) PrPc capping in T cells promotes its 
association with the lipid raft proteins reggie-1 and reggie-2 and leads to 
signal transduction. Faseb J, 18, 1731-1733. 
Sunyach, C. and Checler, F. (2005) Combined pharmacological, mutational and cell 
biology approaches indicate that p53-dependent caspase 3 activation 
- 175 - 
 
triggered by cellular prion is dependent on its endocytosis. J Neurochem, 92, 
1399-1407. 
Sunyach, C., Cisse, M.A., da Costa, C.A., Vincent, B. and Checler, F. (2007) The C-
terminal products of cellular prion protein processing, C1 and C2, exert 
distinct influence on p53-dependent staurosporine-induced caspase-3 
activation. J Biol Chem, 282, 1956-1963. 
Supattapone, S., Bosque, P., Muramoto, T., Wille, H., Aagaard, C., Peretz, D., 
Nguyen, H.O., Heinrich, C., Torchia, M., Safar, J., Cohen, F.E., DeArmond, 
S.J., Prusiner, S.B. and Scott, M. (1999) Prion protein of 106 residues creates 
an artifical transmission barrier for prion replication in transgenic mice. Cell, 
96, 869-878. 
Tabner, B.J., Turnbull, S., El-Agnaf, O. and Allsop, D. (2001) Production of reactive 
oxygen species from aggregating proteins implicated in Alzheimer's disease, 
Parkinson's disease and other neurodegenerative diseases. Curr Top Med 
Chem, 1, 507-517. 
Tabner, B.J., Turnbull, S., Fullwood, N.J., German, M. and Allsop, D. (2005) The 
production of hydrogen peroxide during early-stage protein aggregation: a 
common pathological mechanism in different neurodegenerative diseases? 
Biochem Soc Trans, 33, 548-550. 
Tagami, M., Yamagata, K., Ikeda, K., Nara, Y., Fujino, H., Kubota, A., Numano, F. 
and Yamori, Y. (1998) Vitamin E prevents apoptosis in cortical neurons 
during hypoxia and oxygen reperfusion. Lab Invest, 78, 1415-1429. 
Talmard, C., Bouzan, A. and Faller, P. (2007) Zinc binding to amyloid-beta: 
isothermal titration calorimetry and Zn competition experiments with Zn 
sensors. Biochemistry, 46, 13658-13666. 
Tamagno, E., Parola, M., Guglielmotto, M., Santoro, G., Bardini, P., Marra, L., 
Tabaton, M. and Danni, O. (2003a) Multiple signaling events in amyloid 
beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic Biol 
Med, 35, 45-58. 
Tamagno, E., Robino, G., Obbili, A., Bardini, P., Aragno, M., Parola, M. and Danni, 
O. (2003b) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced 
neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol, 180, 
144-155. 
Telling, G.C., Scott, M., Hsiao, K.K., Foster, D., Yang, S.L., Torchia, M., Sidle, 
K.C., Collinge, J., DeArmond, S.J. and Prusiner, S.B. (1994) Transmission of 
Creutzfeldt-Jakob disease from humans to transgenic mice expressing 
chimeric human-mouse prion protein. Proc Natl Acad Sci U S A, 91, 9936-
9940. 
Telling, G.C., Scott, M., Mastrianni, J., Gabizon, R., Torchia, M., Cohen, F.E., 
DeArmond, S.J. and Prusiner, S.B. (1995) Prion propagation in mice 
expressing human and chimeric PrP transgenes implicates the interaction of 
cellular PrP with another protein. Cell, 83, 79-90. 
Thackray, A.M., Knight, R., Haswell, S.J., Bujdoso, R. and Brown, D.R. (2002) 
Metal imbalance and compromised antioxidant function are early changes in 
prion disease. Biochem J, 362, 253-258. 
Thellung, S., Corsaro, A., Villa, V., Venezia, V., Nizzari, M., Bisaglia, M., Russo, 
C., Schettini, G., Aceto, A. and Florio, T. (2007) Amino-terminally truncated 
prion protein PrP90-231 induces microglial activation in vitro. Ann N Y Acad 
Sci, 1096, 258-270. 
- 176 - 
 
Thellung, S., Villa, V., Corsaro, A., Arena, S., Millo, E., Damonte, G., Benatti, U., 
Tagliavini, F., Florio, T. and Schettini, G. (2002) p38 MAP kinase mediates 
the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells. 
Neurobiol Dis, 9, 69-81. 
Thompsett, A.R., Abdelraheim, S.R., Daniels, M. and Brown, D.R. (2005) High 
affinity binding between copper and full-length prion protein identified by 
two different techniques. J Biol Chem, 280, 42750-42758. 
Thompson, A., White, A.R., McLean, C., Masters, C.L., Cappai, R. and Barrow, C.J. 
(2000) Amyloidogenicity and neurotoxicity of peptides corresponding to the 
helical regions of PrP(C). J Neurosci Res, 62, 293-301. 
Tobler, I., Deboer, T. and Fischer, M. (1997) Sleep and sleep regulation in normal 
and prion protein-deficient mice. J Neurosci, 17, 1869-1879. 
Tobler, I., Gaus, S.E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, 
M., Oesch, B., McBride, P.A. and Manson, J.C. (1996) Altered circadian 
activity rhythms and sleep in mice devoid of prion protein. Nature, 380, 639-
642. 
Toni, M., Massimino, M.L., Griffoni, C., Salvato, B., Tomasi, V. and Spisni, E. 
(2005) Extracellular copper ions regulate cellular prion protein (PrPC) 
expression and metabolism in neuronal cells. FEBS Lett, 579, 741-744. 
Torok, M., Milton, S., Kayed, R., Wu, P., McIntire, T., Glabe, C.G. and Langen, R. 
(2002) Structural and dynamic features of Alzheimer's Abeta peptide in 
amyloid fibrils studied by site-directed spin labeling. J Biol Chem, 277, 
40810-40815. 
Tortosa, R., Vidal, E., Costa, C., Alamillo, E., Torres, J.M., Ferrer, I. and Pumarola, 
M. (2007) Stress response in the central nervous system of a transgenic 
mouse model of bovine spongiform encephalopathy. Vet J. 
Tougu, V., Karafin, A. and Palumaa, P. (2008) Binding of zinc(II) and copper(II) to 
the full-length Alzheimer's amyloid-beta peptide. J Neurochem, 104, 1249-
1259. 
Treiber, C., Simons, A. and Multhaup, G. (2006) Effect of copper and manganese on 
the de novo generation of protease-resistant prion protein in yeast cells. 
Biochemistry, 45, 6674-6680. 
Treiber, C., Thompsett, A.R., Pipkorn, R., Brown, D.R. and Multhaup, G. (2007) 
Real-time kinetics of discontinuous and highly conformational metal-ion 
binding sites of prion protein. J Biol Inorg Chem, 12, 711-720. 
Tsenkova, R.N., Iordanova, I.K., Toyoda, K. and Brown, D.R. (2004) Prion protein 
fate governed by metal binding. Biochem Biophys Res Commun, 325, 1005-
1012. 
Turnbull, S., Tabner, B.J., Brown, D.R. and Allsop, D. (2003a) Copper-dependent 
generation of hydrogen peroxide from the toxic prion protein fragment 
PrP106-126. Neurosci Lett, 336, 159-162. 
Turnbull, S., Tabner, B.J., Brown, D.R. and Allsop, D. (2003b) Generation of 
hydrogen peroxide from mutant forms of the prion protein fragment PrP121-
231. Biochemistry, 42, 7675-7681. 
Turnbull, S., Tabner, B.J., Brown, D.R. and Allsop, D. (2003c) Quinacrine acts as an 
antioxidant and reduces the toxicity of the prion peptide PrP106-126. 
Neuroreport, 14, 1743-1745. 
Tuzi, N.L., Cancellotti, E., Baybutt, H., Blackford, L., Bradford, B., Plinston, C., 
Coghill, A., Hart, P., Piccardo, P., Barron, R.M. and Manson, J.C. (2008) 
- 177 - 
 
Host PrP glycosylation: a major factor determining the outcome of prion 
infection. PLoS Biol, 6, e100. 
Unterberger, U., Hoftberger, R., Gelpi, E., Flicker, H., Budka, H. and Voigtlander, T. 
(2006) Endoplasmic reticulum stress features are prominent in Alzheimer 
disease but not in prion diseases in vivo. J Neuropathol Exp Neurol, 65, 348-
357. 
Uppington, K.M. and Brown, D.R. (2008) Resistance of cell lines to prion toxicity 
aided by phospho-ERK expression. J Neurochem. 
Urano, S., Sato, Y., Otonari, T., Makabe, S., Suzuki, S., Ogata, M. and Endo, T. 
(1998) Aging and oxidative stress in neurodegeneration. Biofactors, 7, 103-
112. 
Vanik, D.L., Surewicz, K.A. and Surewicz, W.K. (2004) Molecular basis of barriers 
for interspecies transmissibility of mammalian prions. Mol Cell, 14, 139-145. 
Varela-Nallar, L., Toledo, E.M., Larrondo, L.F., Cabral, A.L., Martins, V.R. and 
Inestrosa, N.C. (2006) Induction of cellular prion protein gene expression by 
copper in neurons. Am J Physiol Cell Physiol, 290, C271-281. 
Villa, V., Corsaro, A., Thellung, S., Paludi, D., Chiovitti, K., Venezia, V., Nizzari, 
M., Russo, C., Schettini, G., Aceto, A. and Florio, T. (2006) Characterization 
of the proapoptotic intracellular mechanisms induced by a toxic conformer of 
the recombinant human prion protein fragment 90-231. Ann N Y Acad Sci, 
1090, 276-291. 
Voigtlander, T., Kloppel, S., Birner, P., Jarius, C., Flicker, H., Verghese-Nikolakaki, 
S., Sklaviadis, T., Guentchev, M. and Budka, H. (2001) Marked increase of 
neuronal prion protein immunoreactivity in Alzheimer's disease and human 
prion diseases. Acta Neuropathol, 101, 417-423. 
Walter, E.D., Chattopadhyay, M. and Millhauser, G.L. (2006) The affinity of copper 
binding to the prion protein octarepeat domain: evidence for negative 
cooperativity. Biochemistry, 45, 13083-13092. 
Watt, N.T., Routledge, M.N., Wild, C.P. and Hooper, N.M. (2007) Cellular prion 
protein protects against reactive-oxygen-species-induced DNA damage. Free 
Radic Biol Med, 43, 959-967. 
Watzlawik, J., Skora, L., Frense, D., Griesinger, C., Zweckstetter, M., Schulz-
Schaeffer, W.J. and Kramer, M.L. (2006) Prion protein helix1 promotes 
aggregation but is not converted into beta-sheet. J Biol Chem, 281, 30242-
30250. 
Webb, S., Lekishvili, T., Loeschner, C., Sellarajah, S., Prelli, F., Wisniewski, T., 
Gilbert, I.H. and Brown, D.R. (2007) Mechanistic insights into the cure of 
prion disease by novel antiprion compounds. J Virol, 81, 10729-10741. 
Weber, P., Giese, A., Piening, N., Mitteregger, G., Thomzig, A., Beekes, M. and 
Kretzschmar, H.A. (2007) Generation of genuine prion infectivity by serial 
PMCA. Vet Microbiol, 123, 346-357. 
Weise, J., Sandau, R., Schwarting, S., Crome, O., Wrede, A., Schulz-Schaeffer, W., 
Zerr, I. and Bahr, M. (2006) Deletion of cellular prion protein results in 
reduced Akt activation, enhanced postischemic caspase-3 activation, and 
exacerbation of ischemic brain injury. Stroke, 37, 1296-1300. 
Weissmann, C., Bueler, H., Fischer, M., Sailer, A., Aguzzi, A. and Aguet, M. (1994) 
PrP-deficient mice are resistant to scrapie. Ann N Y Acad Sci, 724, 235-240. 
Westaway, D., Cooper, C., Turner, S., Da Costa, M., Carlson, G.A. and Prusiner, 
S.B. (1994) Structure and polymorphism of the mouse prion protein gene. 
Proc Natl Acad Sci U S A, 91, 6418-6422. 
- 178 - 
 
Westergard, L., Christensen, H.M. and Harris, D.A. (2007) The cellular prion protein 
(PrP(C)): its physiological function and role in disease. Biochim Biophys 
Acta, 1772, 629-644. 
White, A.R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, 
D., Collinge, J. and Hawke, S. (2003) Monoclonal antibodies inhibit prion 
replication and delay the development of prion disease. Nature, 422, 80-83. 
White, A.R., Guirguis, R., Brazier, M.W., Jobling, M.F., Hill, A.F., Beyreuther, K., 
Barrow, C.J., Masters, C.L., Collins, S.J. and Cappai, R. (2001) Sublethal 
concentrations of prion peptide PrP106-126 or the amyloid beta peptide of 
Alzheimer's disease activates expression of proapoptotic markers in primary 
cortical neurons. Neurobiol Dis, 8, 299-316. 
Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., Alperovitch, A., 
Poser, S., Pocchiari, M., Hofman, A. and Smith, P.G. (1996) A new variant 
of Creutzfeldt-Jakob disease in the UK. Lancet, 347, 921-925. 
Will, R.G. and Ward, H.J. (2004) Clinical features of variant Creutzfeldt-Jakob 
disease. Curr Top Microbiol Immunol, 284, 121-132. 
Wong, B.S., Brown, D.R., Pan, T., Whiteman, M., Liu, T., Bu, X., Li, R., Gambetti, 
P., Olesik, J., Rubenstein, R. and Sy, M.S. (2001a) Oxidative impairment in 
scrapie-infected mice is associated with brain metals perturbations and 
altered antioxidant activities. J Neurochem, 79, 689-698. 
Wong, B.S., Chen, S.G., Colucci, M., Xie, Z., Pan, T., Liu, T., Li, R., Gambetti, P., 
Sy, M.S. and Brown, D.R. (2001b) Aberrant metal binding by prion protein 
in human prion disease. J Neurochem, 78, 1400-1408. 
Wong, B.S., Liu, T., Li, R., Pan, T., Petersen, R.B., Smith, M.A., Gambetti, P., 
Perry, G., Manson, J.C., Brown, D.R. and Sy, M.S. (2001c) Increased levels 
of oxidative stress markers detected in the brains of mice devoid of prion 
protein. J Neurochem, 76, 565-572. 
Wopfner, F., Weidenhofer, G., Schneider, R., von Brunn, A., Gilch, S., Schwarz, 
T.F., Werner, T. and Schatzl, H.M. (1999) Analysis of 27 mammalian and 9 
avian PrPs reveals high conservation of flexible regions of the prion protein. 
J Mol Biol, 289, 1163-1178. 
Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. and Greenberg, M.E. (1995) 
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 
270, 1326-1331. 
Xing, H., Zhang, S., Weinheimer, C., Kovacs, A. and Muslin, A.J. (2000) 14-3-3 
proteins block apoptosis and differentially regulate MAPK cascades. Embo J, 
19, 349-358. 
Xiong, L.W., Raymond, L.D., Hayes, S.F., Raymond, G.J. and Caughey, B. (2001) 
Conformational change, aggregation and fibril formation induced by 
detergent treatments of cellular prion protein. J Neurochem, 79, 669-678. 
Yamaguchi, A., Tamatani, M., Matsuzaki, H., Namikawa, K., Kiyama, H., Vitek, 
M.P., Mitsuda, N. and Tohyama, M. (2001) Akt activation protects 
hippocampal neurons from apoptosis by inhibiting transcriptional activity of 
p53. J Biol Chem, 276, 5256-5264. 
Yin, S., Pham, N., Yu, S., Li, C., Wong, P., Chang, B., Kang, S.C., Biasini, E., Tien, 
P., Harris, D.A. and Sy, M.S. (2007) Human prion proteins with pathogenic 
mutations share common conformational changes resulting in enhanced 
binding to glycosaminoglycans. Proc Natl Acad Sci U S A, 104, 7546-7551. 
- 179 - 
 
Yu, S., Yin, S., Li, C., Wong, P., Chang, B., Xiao, F., Kang, S.C., Yan, H., Xiao, G., 
Tien, P. and Sy, M.S. (2007) Aggregation of prion protein with insertion 
mutations is proportional to the number of inserts. Biochem J, 403, 343-351. 
Yun, S.W., Gerlach, M., Riederer, P. and Klein, M.A. (2006) Oxidative stress in the 
brain at early preclinical stages of mouse scrapie. Exp Neurol, 201, 90-98. 
Zahn, R. (2003) The octapeptide repeats in mammalian prion protein constitute a 
pH-dependent folding and aggregation site. J Mol Biol, 334, 477-488. 
Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., Lopez Garcia, F., Billeter, 
M., Calzolai, L., Wider, G. and Wuthrich, K. (2000) NMR solution structure 
of the human prion protein. Proc Natl Acad Sci U S A, 97, 145-150. 
Zanuy, D., Gunasekaran, K., Ma, B., Tsai, H.H., Tsai, C.J. and Nussinov, R. (2004) 
Insights into amyloid structural formation and assembly through 
computational approaches. Amyloid, 11, 143-161. 
Zawlik, I., Witusik, M., Hulas-Bigoszewska, K., Piaskowski, S., Szybka, M., 
Golanska, E., Liberski, P.P. and Rieske, P. (2006) Regulation of PrPC 
expression: nerve growth factor (NGF) activates the prion gene promoter 
through the MEK1 pathway in PC12 cells. Neurosci Lett, 400, 58-62. 
Zhu, F., Davies, P., Thompsett, A.R., Kelly, S.M., Tranter, G.E., Hecht, L., Isaacs, 
N.W., Brown, D.R. and Barron, L.D. (2008) Raman optical activity and 
circular dichroism reveal dramatic differences in the influence of divalent 
copper and manganese ions on prion protein folding. Biochemistry, 47, 2510-
2517. 
Zou, W.Q., Capellari, S., Parchi, P., Sy, M.S., Gambetti, P. and Chen, S.G. (2003) 
Identification of novel proteinase K-resistant C-terminal fragments of PrP in 
Creutzfeldt-Jakob disease. J Biol Chem, 278, 40429-40436. 
 
- 180 - 
 
Appendices 
 
 
Schematic diagram of the pd2-EGFP-N1 plasmid used for the promoter constructs. 
 
 
Schematic diagram of the pd2-EGFP-N1 plasmid used for the mouse, Xenopus and 
turtle PrP constructs. 
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Mass spectroscopy of full-length his-tagged mouse PrP. 
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23-171WT PrP ∆51-90 ∆135-150
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25kDa
16kDa
25kDa
16kDa
 
 
 
Gels of manganese bound  proteins, first band shows manganese bound protein 
second band shows metal free protein. Bottom marker represents 16kDa, excluding 
23-112. 
 
